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Malaria is a potentially fatal parasitic disease that is endemic in 109 countries and threatens 
over 2.4 billion people, representing 40% of the global population. While there has been a 
gradual decrease in the number of fatalities resulting from the disease in recent decades, this 
progress is now under serious risk of being reversed as a result of the parasite developing 
resistance to the currently available chemotherapies. This has led to a new impetus to look for 
new antimalarial drugs that have different modes of action to the ones that are currently 
available. 
This thesis contains the following areas of research;  
1) The design and synthesis of various compounds of the classes substituted benzyl-α-
hydroxy phosphonates, substituted benzyl-α-methylene phosphonates, substituted 
benzyl-α-hydroxy phosphonic acids and substituted benzyl-α-amino phosphonic 
acids.  
These compounds are intended to target one of the recently hypothesised antimalarial drug 
development targets, Pf-glutamate dehydrogenase (PfGDH).  
2) The synthesised compounds were then tested for their antimalarial activity against the 
P. falciparum strains 3D7 and Dd2. Furthermore, the synthesised compounds were 
tested against other parasitic organisms, Trypanosoma brucei, Trypanosoma cruzi and 
Leishmania major.  
Chapter One describes the rationale for the research, why there is a need for new 
antimalarials, the pathogenesis of the disease and the current constraints to the development 
of new antimalarials. The chapter discusses why Pf-glutamate dehydrogenase (PfGDH) would 
be a viable antimalarial target, from a biological point of view; the compounds designed to 
target this enzyme (PfGDH), the rationale behind the design of such compounds and the novel 
synthetic targets that this project was interested in. This chapter also has a brief summary of 
current malaria chemotherapies that are in use and are currently being researched; the results 
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of the effectiveness of first generation LMU synthesised GDH inhibitors.  The compounds that 
this research project synthesised became second generation or second series LMU GDH 
inhibitors. 
Chapter two describes the detailed reaction mechanisms that drove the synthesis of the target 
compounds and detailed analyses of the analytical data of the synthesised compounds. Most 
of the data that was discussed in this chapter was the NMR and mass spectrometry data. Any 
anomalies in the synthetic procedures were discussed in this chapter, for example, the 
synthesis of the 1,2-benzyl-γ-lactone- diethyl phosphonate and the 1,2-Brook intramolecular 
phosphonate-phosphate rearrangement. 
Chapter three describes how the synthesised compounds were tested against the P. 
falciparum 3D7 and Dd2 strains. Two antimalarial tests were performed, the fluorescence test 
and the growth inhibition test. The differences in the merits of the two tests were discussed in 
this chapter as well. The activity of the synthesised compounds was compared to that of the 
existing malaria chemotherapies, Chloroquine (CQ) and Dihydroartemisinin (DHA). 
Furthermore, the chapter describes how the synthesised compounds were tested against other 
parasitic organisms, Trypanosomiasis brucei, Trypanosomiasis cruzi, Leishmania major and 
HeLa cells. The activity of the compounds against these various parasites was discussed and 
compared to current chemotherapies that are in use against these parasites. 
Chapter four describes alternate synthetic methods that could be utilised to generate 
substituted benzyl-α-methylene phosphonates, substituted benzyl-α-amino phosphonic acids 
thereby improving the yields of these compounds and minimising side reactions. Alternate 
methods of producing phosphonic acids from their precursors which could improve the purity 
and yields of these phosphonic acids were discussed in this chapter as well. This chapter also 
discussed the challenges of monophosphate and monophosphonate drug development and 
some of the prodrug strategies that are currently being utilised to improve the efficacy of the 
monophosphate and monophosphonate therapeutics. The different phosphate and phosphonate 
masking strategies were considered and the merits and demerits that arise from their uses.  Of 
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particular interest was the ProTide prodrug strategy, this chapter discussed how ProTide 
prodrug strategy was developed, how it has been used to improve the efficacy of the 
compounds that the strategy was applied to. This chapter also considered how the ProTide 
prodrug strategy could be applied to the phosphonate esters synthesised in this project to 
improve their efficacy 
Chapter five describes the methods (experimental) utilised for the synthesis of all the 
synthetic targets and their relevant analytical data. The protocols and procedures for the 
antimalarial evaluations and the evaluations for the other parasitic organisms, T. brucei, T. 
cruzi, L. major are described in this chapter as well.  A total of twenty- seven (27) compounds 
were synthesised across five classes. The diethyl phosphonates and the dibenzyl phosphonates 
were considered to be precursors for the final target compounds, their respective phosphonic 
acids. The precursors were to be tested as well to determine if they would have any antimalarial 
activity. 
The compounds that were produced in this study that showed significant antimalarial activity 
would provide the basis for lead compounds, that would be further studied and optimised for 
a new generation of antimalarial compounds. These compounds would then be utilised 
independently or alongside current chemotherapies as part of combination therapy in the fight 
against malaria. The research developed a new simpler method to substitute the hydroxyl 
functional group of the substituted benzyl-α-hydroxy phosphonates with hydrogen to generate 
the substituted benzyl-α-methylene phosphonates which worked on two compounds, 24 and 
25. This substitution method also resulted in the 1,2-Brook intramolecular phosphonate-
phosphate rearrangement under basic conditions occurring, therefore, careful optimisation of 






Ǻ   Angstrom (10-10 m) 
AcOH Acetic Acid 
BF3.OEt2 Boron trifloride etherate 
CD3CN   Deuterated acetonitrile 
CDCl3 Deuterated chloroform   
COSY Correlation spectroscopy 
d Doublet 
D2O Deuterated water 
DMSO Dimethyl Sulfate 
EC50 Concentration of a drug that produces half maximal response. 
(Effective Concentration) 
 
ED50 Dose that produces the desired effect in 50 per cent of a population. 
(Effective Dose/median Effective Dose) 
EI Electron Impact 
EtOAc Ethyl Acetate 
FTIR Fourier transform infrared spectroscopy 
GDH Glutamate Dehydrogenase 
He La   Henrietta Lacks  
Hex Hexane 
Hz Hertz 
IC50 Concentration of inhibitor that produces half maximal inhibitory 
response. (Inhibitory Concentration) 
 
L. major Leishmania Major 
LMU London Metropolitan University 
m Multiplet   
M.Wt Molecular weight 
m/z Mass to charge ratio   
MeOD Deuterated methanol 
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MHz Megahertz   
MMV Medicines for Malaria Venture 
mp melting point 
NaH Sodium Hydride 
NaI Sodium Iodide 
P. falciparum (Pf)   Plasmodium falciparum 
ppm Parts per million   
Rf   Retention factor       
s Singlet 
SAR Structure Activity Relationship 
t Triplet 
T. brucei Trypanosoma brucei 
T. cruzi Trypanosoma cruzi 
TMSiBr Trimethylsilyl bromide  
TMSiCl Trimethylsilyl chloride 
TOF Time Of Flight 
δ Chemical shift   
νmax cm-1   Wavenumber 
Ala (A) Alanine 
Arg (R) Arginine 
Asn (N) Asparagine 
Asp (D) Aspartic acid 
Cys (C) Cysteine 
Glu (E) Glutamic acid 
Gln (Q) Glutamine 
Gly (G) Glycine 
His (H) Histidine 
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Ile (I) Isoleucine 
Leu (L) Leucine 
Lys (K) Lysine 
Met (M) Methionine 
Phe (F) Phenylalanine 
Pro (P) Proline 
Ser (S) Serine 
Thr (T) Threonine 
Tyr (Y) Tyrosine 
Trp (W) Tryptophan 
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1.1 Rationale of the research project 
Malaria is a potentially fatal parasitic disease that is endemic in 109 countries and threatens 
over 2.4 billion people, representing 40% of the global population (WHO malaria reports 
2008, 2009, and 2010). Malaria transmission occurs in regions of Africa, Latin and South 
America, Asia, the Middle East, the South Pacific and the Caribbean. Current statistics show 
that in the years from 2000-2013 the global death rates have decreased from around 1 million, 
(mostly in children under the age of 5) to somewhere between 584,000-660,000 deaths in 
2013. The number of global malaria deaths has been steadily declining with 416,000 estimated 
deaths in 2017 and 405,000 estimated deaths in 2018 (WHO malaria reports 2019). The 
incidence rate of malaria has also been declining globally between 2010 and 2018, from 71 to 
57 cases per 1000 population at risk. However, from 2014 to 2018, the rate of change has 
slowed dramatically, reducing to 57 cases per 1000 in 2014 and remaining at similar levels 
through to 2018 (WHO malaria reports 2019). Although it is believed that the number of 
deaths could still be as high as 1.1 million when undiagnosed or untreated malaria cases are 
considered (Miller. H. L, et al 2013), Diagana. T. T, 2015). Malaria remains among the top 5 
causes of death of children under the age of 5, these make up between 67%-78% of the total 
annual deaths (WHO malaria reports 2019). Malaria has 231-278 million reported clinical 
cases each year with 1% of those cases progressing to severe malaria (WHO malaria reports 
2019). About 125 million pregnancies are at risk each year from malaria and as a result, an 
estimated 10,000 pregnant women and 200,000 babies die from the disease (Biamonte. M. A, 
et al 2013).   
Malaria poses a major global health threat because of environmental changes, particularly 
climate change, population movements and biological changes to the parasite and the mosquito 
vector. Health systems in most countries to which malaria is endemic have weak drug 
management and supply systems. This results in a growing problem of resistance to the 
available antimalarial drugs as a result of mutations in the parasites or as a result of irrational 
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use of antimalarial drugs. This increase in the parasite’s resistance to the available antimalarial 
drugs has led to an increase in the morbidity and mortality of the group at the highest risk 
which is African children (Snow. R. W, et al 2001), thus the need to develop new antimalarial 
agents. Antimalarial drug development can follow several different strategies, which range 
from minor modifications to existing compounds to design of novel agents that act on new 
targets, and combining available agents to improve antimalarial regimens (Rosenthal. P, 
2003).  
Antimalarial drug development is affected by the same constraints that affect any other drug 
development program. In addition to the general considerations such as the new agent being 
safe and demonstrate high efficacy, additional important properties specific to the disease must 
be accounted for. In the case of malaria, the drug development process must consider that the 
drug be available for major widespread use in developing countries. Due to the limited 
resources in these areas the drug should be dosed orally and be effective with single daily 
dosing with a full treatment regimen lasting between 1-3 days in length. However, the most 
important consideration in antimalarial drug development is economical. Financial 
considerations are important in two crucial areas. First, for antimalarial drugs to be widely 
used, they have to be cheaply priced for the populations that need them in developing 
countries, as such, a cost of $1 USD per treatment regimen may be too expensive and 
unacceptable given the degree of poverty in malaria infested areas.  
To this end, any new anti-malaria agents must have a similar cost to that of currently available 
drugs such as chloroquine which cost $0.1 USD per treatment regimen. The second financial 
consideration is that since malaria is prevalent in poor countries, there are limited funding 
opportunities, and investment in antimalarial drug research, discovery and development is 
small. With the estimated funds available for malaria control from international sources 
peaking at US$2 billion in 2011, this remains well short of US$5 billion that is required to 
meet global malaria targets between 2010-2015 (WHO world malaria report 2011). This has 
resulted in research in antimalarial drug discovery to rely on simple synthetic routes and 
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shortcuts to minimize excess costs (Rosenthal. P, 2003). As a result, anti-malaria drug 
discovery is dependent on financial support outside large pharmaceutical companies. This 
financial support comes mainly from grants to academics and industry groups from 
philanthropic organisations such as the Wellcome Trust and the Bill and Melinda Gates 
Foundation, research agencies and new public-private partnerships such as the Medicines for 
Malaria Venture (MMV) formed to address the imbalance in funding between developed and 
developing world diseases (Rosenthal. P, 2003), Diagana. T. T, 2015).  
The current challenge is whether malaria can be completely eliminated on a global scale. 
Several countries have put forward and or begun implementing malaria elimination 
programmes, but it is clear that the targets for these programmes will neither be achieved nor 
successful with the currently available drugs. From 1950 to 2011, Paraguay systematically 
developed policies and programmes to control and eliminate malaria, a significant public 
health challenge for a country that reported more than 80,000 cases of the disease in the 1940s. 
As a result, Paraguay registered its last case of P. falciparum malaria in 1995, and P. vivax 
malaria in 2011. This was followed by a five-year plan to consolidate the gains, prevent re-
establishment of transmission and preparation for elimination certification. The plan involved 
robust case management, engagement with communities, and education to make people more 
aware of ways to prevent malaria transmission, and about diagnosis and treatment options. 
Paraguay was certified malaria free by WHO in 2016 (WHO newsletter June 2018).  
Whilst the current artemisinin based combination therapies are still viable, they require 
multiple daily doses and there is a looming threat of the parasite becoming resistant to them, 
this makes the currently available artemisinin based combination therapies unsuitable for 
malaria elimination programmes (Diagana. T. T, 2015). Sequencing of the parasite’s genome 
and a greater understanding of the parasite’s biology has resulted in the identification of new 
targets for drug development which could be used to defeat the disease (Sahu. N, et al 2008). 
The sequencing of the plasmodium genome and the application of modern genetic tools has 
also led to the identification of numerous potential targets, which include glutathione disulfide 
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reductase and glutamate dehydrogenase, that could be useful in the development of novel 
antimalarials. However, only a few of these targets have been adequately validated chemically 
and even fewer of those fully validated have proved to be viable targets (Biamonte. M. A, et al 
2013). A major part of the problem is that no antimalarial with a novel mechanism of action 
has entered phase 2 clinical trials since hydroxy-1,4-naphthoquinone atovaquone in 1992 
(Diagana. T. T, 2015).  
Most of the available antimalarial drugs target the blood stages of the parasite’s lifecycle, at 
present, the only antimalarials present that are effective against the liver stages of the parasite 
are the combination therapy atovaquone/proguanil and primaquine. Although 
atovaquone/proguanil affects the blood stages of the parasite, it is also effective at clearing 
parasites from the liver. The main obstacle in the search for liver stage drugs is the 
unavailability of efficient and effective culture techniques and models. This means that trials 
for liver stage antimalarials have to utilise primate animal models that are cumbrous and 
unreliable. Current theories suggest an effective antimalarial prophylactic will have to target 
the liver stage and not the blood stage of the life cycle. As of 2015, there are no known 
antimalarials that successfully target the transmission stage of the parasite’s lifecycle 
(Biamonte. M. A et al (2013). Enzymes such as glutathione disulfide reductase and glutamate 
dehydrogenase (GDH), among others, are important to the survival and development of the 
plasmodium inside the host. Synthesis of novel compounds that mimic the structures of these 
enzymes’ substrates could potentially have antimalarial properties. This Ph.D. project focused 
on the development of potentially new antimalarials based on substrates of the parasite’s 
glutamate dehydrogenase (GDH), which would then act as inhibitors to the enzyme. 
1.2 Malaria pathogenesis 
The malaria parasite is a small single-celled protozoan micro-organism that lives as a parasite 
in man and in the female anopheles’ mosquito. There are five different types of plasmodium 
parasites P. vivax, P. ovale, P. falciparum, P. malariae and P. knowlesi. Plasmodiums ovale, 
vivax and malariae cause more benign forms of malaria, P. falciparum being the most severely 
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malignant and can be potentially fatal. P. vivax and P. falciparum cause most of the infections 
worldwide. P. falciparum accounts for much of the burden in sub-Saharan Africa, whilst P. 
vivax accounts for half of the burden in South and East Asia and up to 80 % of the burden in 
the Americas. P. knowlesi was a species that was previously thought to just infect non-human 
primates but has now emerged as a zoonotic malaria parasite and is now an important, 
sometimes, lethal cause of human malaria in parts of South East Asia, in particular Malaysia, 
Indonesia, Thailand, Singapore and the Philippines. P. knowlesi is now a potential cause of 
malaria among travellers returning from this region. There is a limited understanding of the 
pathogenesis of malaria. The knowledge that is available has been provided by studying animal 
models and human malaria. The pathogenicity that is provided by animal models, as valuable 
as it is, does not give an accurate pathogenic process of P. falciparum, therefore, observations 
made in humans are of central importance (Miler. H. L, et al 1994).  
The plasmodium lifecycle consists of two stages, the first stage is in the mosquito and the 
second stage of the lifecycle is in humans. In the human stage of the plasmodium lifecycle, 
the plasmodium sporozoites develop, mature and multiply in the liver hepatocytes for about a 
week. Tens to hundreds of hepatocytes are targeted by the sporozoites and this stage of the 
infection is not responsible for the disease. (Miler. H. L, et al 1994).  The mature sporozoites, 
known as merozoites, rupture the hepatocytes, migrate to, and complete the remainder of their 
lifecycles in the red blood cells. This erythrocytic cycle of the infection is when 
parthenogenesis begins. The parasite remodels the erythrocyte within 12 hours of invasion to 
facilitate a large periodic amplification of the size of the parasite population to increase the 
probability of the merozoites developing into gametocytes (Miler. H. L, et al 1994). Infected 
erythrocytes bind to the endothelium through P. falciparum Erythrocyte Membrane Protein-1 
(PfEMP-1) to avoid clearance in the spleen. Attachment of the infected erythrocytes to the 
endothelium damages the endothelial cells and disrupts blood flow which leads to tissue 
hypoxia and lactic acidosis. This is the same mechanism that contributes to organ specific 
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syndromes such as cerebral malaria and placental malaria when the attachment of the infected 
erythrocytes happens in the brain and/or the placenta.  
The rupture of the infected red blood cells (haemolysis) and near-by bystander red blood cells 
causes anaemia which is worsened by impaired erythropoiesis. Haemolysis also worsens the 
endothelial damage and dysfunction due to the free haemoglobin (Hb) catalysing oxidative 
damage and consumes nitric oxide (NO) a key regulator of endothelial cells. The rupture of 
infected erythrocytes also causes fevers and rigours (Miller. H. L, et al 2013). Merozoites often 
invade uninfected erythrocytes and circulate as ring stage parasites but a few develop into 
schizonts, trophozoites and finally into male and female gametocytes. The gametocytes 
continue to circulate in the bloodstream without being treated by the current antimalarials at 
the asexual blood stages. The male and female gametocytes are then transported by the 
mosquito Anopheles gambiae when it bites and draws blood from the human host. Discovering 
effective, safe therapies to kill gametocytes will go a long way to combat P. falciparum 
(Miller. H. L, et al 2013). The clinical manifestations of the disease are as a result of the 
multiplication and differentiation of the protozoan parasites in the erythrocytes (Wagner. J. T, 
et al (1998). In the erythrocytes, the parasite digests the host’s haemoglobin freeing the 
reactive haem groups. The release of haem groups from the rupture of erythrocytes leads to 





Figure 1.2.1: Malaria life-cycle in human beings and in the parasite. www.CDC.gov 
All aerobic life requires the maintenance of a homeostatic intracellular redox environment that 
minimizes the production of reactive oxygen species and allows for the essential metabolic 
functions to progress. (Muller. S, et al 2004). These aerobic organisms are exposed to reactive 
oxygen species (ROS) such as superoxide anions (O2-), hydrogen peroxide (H2O2) and 
hydroxyl radicals (OH˙) that are generated by their metabolism. These ROS, if left to 
accumulate, can lead to the damage of nucleic acids, proteins, lipids and cell membrane which 
leads to the loss of cellular structure and function. The plasmodium merozoites do not only 
have to contend with, and be able to effectively remove their endogenous toxic metabolites, 
but have to be able to cope with the oxidative or respiratory burst from the host’s immune 
system. The host’s respiratory burst is the sum of the ROS that are produced during the host’s 
defence against pathogens. This includes the optimal anti-microbial action of the neutrophils 
and other phagocytes which involves the rapid production of more reactive oxygen species 
leading to the production of superoxide anions (O2-) by activated NADPH oxidases. The 
superoxide anions (O2-) are then processed to produce hydrogen peroxide (H2O2), hydroxyl 
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radical (OH˙), hypochlorous acid (ClO-) and oxidising derivatives of nitric oxide (NO-) such 
as peroxynitrite (ONOO-) (Muller. S, et al 2003). In addition to this, during the erythrocytic 
cycle of the infection, the parasite digests haemoglobin resulting in the formation of more ROS 
and the toxic ferriprotoporphyrin (IX) through Fenton like reactions. The parasite is sensitive 
to the reactive oxygen species that are produced by the Fenton like reactions so its survival in 
the erythrocyte is dependent on the parasite having good defences against these oxidising 
entities. 
To combat these stresses, the plasmodium has to have powerful and efficient antioxidant and 
detoxification systems that are based on superoxide dismutases and thioredoxin-dependent 
peroxidases but lack catalase and glutathione peroxidases that function alongside its other 
systems which maintain the homeostatic redox conditions (Muller. S, et al 2004). The first line 
of defences of the parasites against these ROS involves several of these superoxide dismutases, 
peroxidases and thiol-dependant reductases (Werner. C, et al 2005). Critical to the 
maintenance of a stable cellular redox state are the ratios of reduced and oxidised pyridine 
nucleotide NADP+ and NADPH and thiols such as glutathione/glutathione disulfide and 
thioredoxin/thioredoxin disulfide. The amounts of ROS present in a cell at any given time can 
be directly monitored by the amounts of the NADP+ and NADPH pools that will be present in 
the cells at that given time. The thioredoxin and glutathione redox cycles both use NADPH as 
a reducing agent that is used as an electron source for the anti-oxidative enzymes glutathione 
reductase and thioredoxin reductase resulting in the transfer of electrons through a series of 
peroxidases to an acceptor molecule. This occurs through a number of redox active enzymes 
and cofactors which neutralise the harmful ROS to less harmful products; for example, 
hydrogen peroxide is converted to water and oxygen, thereby protecting the parasite from 
oxidative damage (Werner. C, et al 2005). These NADPH dependent enzymes such as 
thioredoxin reductase glutathione reductase are critical to the survival of the intraerythrocytic 
P. falciparum (Muller. S, et al 2004). The plasmodium uses some enzymatic reactions absent 
in the red blood cells. These defences are driven by NADPH and the production of NADPH 
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is catalysed by the enzyme glutamate dehydrogenase (GDH), an enzyme that is abundantly 
expressed by the parasite but not by the host erythrocytes (Chodhury. R, et al 2007). Research 
has identified glutamate dehydrogenase is the main source for NADPH that is used by the 
parasite’s antioxidant defence systems (Werner. C, et al 2005). This makes such enzymes and 
disruption of these redox cycles excellent drug targets to combat the disease. Additionally, 
inhibiting the enzyme glutamate dehydrogenase will deprive the parasite of a source of 
NADPH which will render it vulnerable to oxidative damage. The combination of such new 
inhibitors with either the artemisinin based therapies or even older quinoline-based alcohol 
therapies as prodrugs could lead to the successful cost effective management of the disease. 
The enzymes that are present in the red blood cells for the production of antioxidants to mop 
up excess reactive oxygen species ROS are glucose-6-phosphate dehydrogenase and 




Figure 1.2.2: The biosynthesis of glutathione, essential for combating reactive oxygen species (ROS), is 
catalysed by glutathione disulfide reductase 
Glutathione disulfide reductase is involved in the growth and differentiation of the P. 
falciparum parasite. Glutamate dehydrogenase (GDH) is an important enzyme that occupies 
an important junction between carbon and nitrogen metabolism. GDH catalyses the reversible 
oxidative deamination of L-glutamate, which yields 2-oxoglutarate and ammonia (Wagner. J. 
T, et al 1998).  
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1.3 Sources of NADPH in erythrocytes and P. falciparum 
During the intra-erythrocytic stages of the lifecycle, the P.  falciparum, like the host 
erythrocytes obtains its ATP from glycolysis. Unlike the erythrocytes, the P. falciparum does 
not have its own a source of NADPH which it requires for its biosynthetic processes and 
provides an electron source for its defence mechanism. Research has not shown evidence that 
the erythrocytes’ NADPH is available for the parasite and thus, the parasite will need its own 
source of NADPH (Vander. D. L, et al 1989). The major source of NADP in the erythrocytes 
is the pentose phosphate pathway (PPP). This pathway mostly uses the enzyme glucose-6-
phosphate dehydrogenase (G6PD) for the production of its NADPH. Research has shown that 
the P. falciparum has different sources of NADPH. These sources include the presence of 
NADP-specific GDH, which happens to be a key marker for the malarial parasite in the 
erythrocytes (Vander. D. L, et al 1989). The activity associated with this enzyme is only 
limited to the parasite, the erythrocytes do not exhibit any GDH activity.  
It is for this reason that P. falciparum GDH presents itself as a viable target for novel 
antimalarial drugs or prodrugs. Genome sequencing has provided evidence that shows that the 
parasite encodes the homologs of the enzymes that are necessary for a complete citric acid 
cycle, these enzymes are expressed during the intra-erythrocytic stage of the plasmodium life 
cycle. The citric acid cycle plays a crucial role in cellular respiration which results in the 
production of the co-factors NADH and FADH2. In eukaryotic cells there are mostly 
mitochondrial NAD-dependent, some mitochondrial NADP-dependent and some cytosolic 
NAD-dependent isocitrate dehydrogenase (IDH) enzymes which are utilised by the citric acid 
cycle for the production of these co-factors. The P. falciparum encodes for mostly 
mitochondrial NADP- dependent enzymes which means that the citric acid cycle in the P. 
falciparum will mostly produce NADPH, however, some NAD-dependent isocitrate 
dehydrogenase (IDH) has been identified in parasite extracts (Olszewski. K. L, et al 2011).  
Due to the P. falciparum mostly undergoing anaerobic respiration in the earlier stages of its 
carbohydrate metabolism instead of glycolysis, there are not enough substrates to sufficiently 
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contribute to its citric acid cycle, therefore, alternate sources of substrates are required. The P. 
falciparum has been shown to be able to undergo carbon dioxide fixing in the cytoplasm 
through the enzyme PEP carboxylase leading to the production of two of the citric acid cycle 
intermediates oxaloacetate and malate. Another source of the citric acid cycle intermediate 2-
oxoglutarate is obtained by converting glutamine to glutamate by the enzyme glutamate 
synthetase; glutamate is then converted to 2-oxoglutarate by the enzyme glutamate 
dehydrogenase, and this stage results in the production of NADPH (Olszewski. K. L, et al 
2011). P. falciparum encodes for three distinct GDH enzymes, all of the three enzymes that 
are produced have been shown to be NADP-dependant. The first one GDHa, is thought to be 
predominantly found in the apicoplast of the parasite and is thought to be responsible for 
supplying NADPH for biosynthetic reactions in that compartment. The second NADP- 
dependant GDHb which lacks a cleavable signal sequence and is thus believed to be a cytosolic 
enzyme that is responsible for the redox control and the parasites defence mechanisms. 
Available theories suggest that cytosolic GDH is the most abundant and is the major source 
NADPH for the parasite but this has not been confirmed. The third is a large fungal type NAD-
dependant GDHc which does not have any signal sequence and whose purpose is really not 
understood at the moment (Olszewski. K. L, et al 2011).  
Presented research has also provided evidence of the presence of a P. falciparum pentose 
phosphate pathway (PPP) which uses the enzyme glucose-6-phosphate dehydrogenase 
(G6PD) for the production of NADPH in the parasite. The erythrocyte’s and the P. falciparum 
glucose-6-phosphate dehydrogenase (G6PD) enzyme have both been sequenced and have been 
noted to be significantly different to each other, making the plasmodium glucose-6-phosphate 
dehydrogenase another viable anti-malaria target. The pentose phosphate pathway (PPP) is an 
essentially conserved pathway that is present in more or less every cell that is capable of 
metabolising carbohydrates (Olszewski. K. L, et al 2011). Its main purpose is the production 
of five-carbon sugars that are used in nucleotide synthesis and the production of NADPH. The 
pentose phosphate pathway (PPP) is the foremost source of NADPH in human erythrocytes 
 
13 
but it is not clear if it is a major source of NADPH in the P. falciparum since the main enzyme 
for this pathway, glucose-6-phosphate dehydrogenase has been observed as having modest 
activity inside the parasite (Wagner. J. T, et al 1998).     
The importance of the effects of the glutamate dehydrogenase (GDH) and glutathione disulfide 
reductase in the defence against reactive oxidative species is evidenced by the fact that 
glucose-6-phosphate dehydrogenase (G6PD) deficiency, an enzyme used in the host 
erythrocytes that undergoes similar reactions as the glutamate dehydrogenase (GDH), had a 
potent antimalarial effect (Werner. C, et al 2005). It has been observed that several 
haemoglobinopathies such as thalassemia, sickle cell disease, glucose-6-phosphate 
dehydrogenase (G6PD) deficiency and other red cell defects provide protection against 
malaria (Katja. B, et al 2003). Sickle cell disease is the haemoglobinopathy that is currently 
known to offer the best protection against malaria (Katja. B, et al 2003). Interestingly, these 
haemoglobinopathies are most prevalent among people inhabiting malaria-infested regions; 
Africa, South Asia and the Middle East, possibly indicating an evolutionary response to 
malarial stress. Understanding how these conditions provide protection against malaria will 
help us better understand how the parasite can be eliminated during the intra-erythrocytic stage 
of the plasmodium life cycle by disruption of the parasite’s redox balance. In these conditions, 
the erythrocytes membrane fluidity is altered due to changes in the erythrocyte’s membrane 
lipid composition and protein cross-linking. These changes to the erythrocyte result in 
enhanced oxidative stress in the erythrocytes and therefore making the erythrocytes defective. 
Existing theories suggest that the underlying mechanisms of these disorders are as a result of 
the enhanced oxidative stress which the defective erythrocytes are under (Shavlev, et al 1995). 
It is believed that the oxidative environments in the defective erythrocyte impair the growth 
rate and multiplication of the parasite. Another theory suggests that the defective erythrocytes 
are recognised by the host’s immune system early due to the early occurrence of band 3 auto-
antibodies and are phagocytized much more efficiently (Muller. S, et al 2004). This is 
especially effective as it means that the parasite is removed from the body at an early stage of 
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the infection before it has the opportunity to cause parasitaemia and the symptomatic phase of 
the infection can take hold. 
The importance of these enzymes, glutathione disulfide reductase and GDH were noted in 
research which showed that the concentration of the antimalarial drugs chloroquine and 
amodiaquine needed to kill the parasites was inversely proportional to the glutathione levels 
in the cells (Ginsburg. H, et al (1998), Becker. K, et al (2004). This correlation was confirmed 
by a research finding, which showed the correlation between the levels of Glutathione in the 
cells and the degree of chloroquine resistance which was exhibited by different P. falciparum 
strains (Meierjohhann. S, et al (2002) ; Muller et al (2002) ; Biot. C, et al (2004). This research 
pointed to the importance of glutathione in the development of chloroquine resistance. The 
current protocols for control of malaria involves preventive measures such as the use of 
insecticides to eliminate the mosquito vectors, and the use of long lasting insecticidal nets, 
early diagnosis, followed by the prompt and effective pharmacological intervention (WHO 
report 2010). The use of a combination of antimalarial drugs, particularly the use of 
artemisinin-based combination therapy is the most important pharmacological tool in use 
today in the fight against malaria (WHO report 2008). However, the emergence of P. 
falciparum strains that are resistant to the pharmacological interventions that are in use today, 
the lack of a vaccine and the threat of malaria spreading to new areas as a result of failure of 
vector elimination and control programs, global warming and human travel patterns has led to 




Figure 1.3.1: The NADP+- dependant GDHs catalyses the reversible interconversion of L-glutamate to 2-
oxoglutarate 
1.4 Sequences and 3D structures of H. sapiens and P. falciparum 
GDH’s compared  
There are two different types of GDH, the NADP+- dependant GDHs which are concerned 
with ammonium fixation, and the NAD+- dependant GDHs associated with glutamate 
catabolism. Higher eukaryotes have a dual- coenzyme specificity GDH which suggests that it 
may be involved in both metabolic pathways, catabolism and anabolism, whereas bacterial 
and fungal GDH is just NADP+ dependant (Wagner. J. T, et al 1998). When NADP-dependant 
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GDH was extracted from a P. falciparum infected erythrocyte, the protein represented a 
marker for the parasite as the enzyme is absent in the host erythrocytes. When the protein was 
cloned it was determined that the gene for NADP - dependant GDH encodes for a protein that 
has 470 residues which was a 50% match for GDHs from lower eukaryotes and eubacteria but, 
was significantly different from mammalian GDH, with a sequence identity of about 23%, 
indicating a long evolutionary distance between the two (Werner. C, et al 2005), (Wagner. J. 
T, et al 1998).  The parasite GDH is inhibited by D-glutamate and glutarate but it is not 
inhibited by chloroquine. Unlike mammalian GDH, the parasite GDH is not affected by either 
GTP or ADP. The parasite GDH is a homohexamer with a subunit Mr of about 49,500 Dalton 
which is similar to the GDH of other NADP dependant bacteria and invertebrates, the subunits 
are linked together by salt bridges whilst in the human GDH, the subunits are linked together 
by hydrophobic interactions (Werner. C, et al 2005).  The GDH of P. falciparum has a unique 
N-terminal extension that is about 20 residues long and is not observed in any other GDHs that 
have been characterised to-date from other protozoa or bacteria (Werner. C, et al 2005). 
1.5 P. falciparum GDH active site  
The active site of the parasite GDH is similar to that of Clostridium symbiosum. The part of 
the active site that is in contact with the substrate is perfectly conserved and the amino acid 
residues occupy the exact same spots. There is an assumption that there are residues within 
the active site that bind to both the α- and γ-carboxylates of the glutamate substrate. Thus, 
amino acid residues Lys112 and Ser401 are believed to bind to the γ-carboxylate of the 
substrate while Gln133 and Lys136 similarly bind to the α-carboxylate. Just two of these 
active-site residues are different in the human GDH: Gln133 is replaced by Met115, and the 
amino group ligand Gly187 is substituted by Pro171. In addition to the differences in the 
primary structure of the amino acids, there may be further differences in the way the substrate 
binds to the active site. Human GDH and liver bovine GDH share a 96% sequence identity but 
bovine GDH has a different binding mode to Clostridium symbiosum GDH (Peterson P. E, et 
al 1999). This close relationship between human and bovine GDH makes bovine GDH a good 
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analogue for human GDH in biological studies. The coenzyme binding site of the P. 
falciparum GDH is similar to that of dual-specific mammalian GDH in that they are both 
NADP dependant. This is different from the coenzyme binding site of the Clostridium 
symbiosum GDH which is NAD dependant and therefore has different amino acid residues. 
The amino acids that are present in the coenzyme binding site of the Clostridium symbiosum 
GDH are Arg285, Asn133 and Pro262, these amino acid residues restrict the access to the 
coenzyme binding site of the Clostridium symbiosum GDH resulting in a theoretically, less 
positively charged coenzyme binding site compared to that of P. falciparum GDH (Werner. 
C, et al 2005). The NADP-specific GDH coenzyme binding site of the plasmodial GDH and 
mammalian GDH have the amino acid residues Ser284, Lys156 and Lys306. These residues 





Figure 1.5.1: The CLUSTALW sequence of H. sapiens, C. symbiosum and P. falciparum GDH. The 
nucleotide-binding fold is indicated in red, the N-terminal domain in blue. The residues highlighted in 
pink reveal those that bind NADP, while those in yellow bind the substrate L-glutamate. The unique N-





Figure 1.5.2: The 3D crystal structure of P. falciparum GDH 
The main difference between the human and P. falciparum GDH subunit contacts is 
structurally significant enough for the difference to be exploited in drug development. In the 
P. falciparum GDH, the Arg10 which adjoins the C-terminal part of the helix 447-465 is 
hydrogen bonded to the Gln94 of the neighbouring subunit, this arrangement causes spatial 
arrest due to the multiple interactions contributing to the overall packing of the terminal 
domain. The N-terminal peptide approaches the C-terminal helix shielding it from solvent. The 
inter-subunit contact formed by the Arg10 and the Gln94 could contribute to the hexameric 
structure of the P. falciparum GDH. Peptides and peptidomimetics have been shown to be able 
to disrupt the different protein sub-units’ interfaces and can be potentially developed as drug 
candidates. Peptidomimetics with negative charges could interact specifically with positively 
charged Arginine residues in the P. falciparum GDH subunit interfaces. This could be 
significant because parasitized red blood cells are known to exhibit permeability to negatively 




Figure 1.5.3: The 3D crystal structure of Human GDH 
1.6 Current malaria chemotherapies, strategies and modern 
developments  
The P. falciparum is incapable of salvaging pyrimidines, which is the conversion of 
pyrimidine bases into nucleotides, unlike its human host and is therefore dependent on the de 
novo biosynthesis pathways to recoup these pyrimidines. This biosynthetic pathway utilises 
the enzyme dihydroorotate dehydrogenase (DHODH). The project that attempted to synthesise 
(pfDHODH) inhibitors was named project of the year (2010) by the Medicines for Malaria 
Venture (MMV) and was carried out in conjunction with GlaxoSmithKline, the University of 
Texas Southwestern, the University of Washington and the University of Monash (Biamonte. 
M. A, et al (2013). A search for a selective inhibitor for the enzyme dihydroorotate 
dehydrogenase (DHODH) has led to the clinical candidate DSM265, which represents the first 
attempt to clinically validate a genetically identified target. DSM265 was very selective for 
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PfDHODH with an IC50 of 33 nM for PfDHODH and an IC50 of 2500 nM for human DHODH 
(Diagana. T. T, 2015). This compound is 57%-68% orally bioavailable in rats and has a t½ of 
12-28 hours. DSM265 was entered into phase 1 trials in 2013; an initial two-part phase 1 trial 
was run, with part one being run between 12/04/2013 and 14/07/2015 involving 73 participants 
(DSM265, n=55; placebo, n=18). Part two of the phase 1 trial was run between 30/09/2013 
and 25/11/2013 involving 9 participants (150 mg DSM265, n=7; 10 mg/kg mefloquine, n=2), 
with the results from the trials being reported in 2017. The first test of the trial reported 117 
adverse effects events, no drug-related serious or severe events were reported. The main drug 
related event that was reported for these trials were headaches. The two phase 1 trials 
concluded that DSM265 had a good safety profile, long elimination half-life and an 
antimalarial effect that supported its further development as a partner drug in a single-dose 
antimalarial combination treatment (McCarthy. J. S, et al 2017).  
A similar pfDHODH inhibitor which was obtained by the Medicines for Malaria Venture 
(MMV) 2010 project is the triazolopyrimidine derivative DSM190, was observed to be less 
potent in vitro with an IC50 of 190 nM and an EC50 of 1.1 μM in mouse but is 100% bioavailable 
in rats. IC50 being a measure of the in vitro potency of a compound and EC50 being a measure 
of the concentration of a compound that gives a quantal dose response curve for a given ligand 
or receptor – (Gleeson. M. P, et al 2011). Genzyme Biotechnology company is investigating 
some benzimidazole derivatives which could potentially be pfDHODH inhibitors, the 
properties of such compounds are being further explored as these benzimidazole derivatives 
have also been observed to inhibit parasite growth. The best candidate benzimidazole 
derivative has been shown to inhibit pfDHODH (IC50 = 40 nM) and it inhibits parasite growth 
(EC50 = 7-10 nM), and has a 49% bioavailability in rats and a 19% bioavailability in dogs. It 
is eliminated with a t½ of 0.85 hours in rats and 0.52 hours in dogs. Genzyme is also 
investigating the compound Genz-668764 a single enantiomer whose configuration has not 
been published. This compound is believed to inhibit P. falciparum in vitro EC50 of 28 nM 
(3D7) and 65 nM (Dd2) (Biamonte. M. A, et al (2013).   
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Figure 1.6.1: Examples of Dihydroorotate dehydrogenase (DHODH) inhibitors that have shown 
antimalarial activity, some of them in phase 1 and 2 clinical trials 
 
P. vivax hypnozoites can remain dormant in the liver of the host for a number of years which 
may result in relapses of the infection later on. This makes the liver residency a very crucial 
stage of the parasite lifecycle. The potential hypnozoiticidal compound tafenoquine (WR-
238905) has successfully completed phase 3 clinical trials and was approved for use in July 
2018. (Diagana. T. T, 2015, MMV, 2020). Tafenoquine is a novel 8-aminoquinoline which is 
an analogue of primaquine and pamaquine. Primaquine is one of the few compounds that target 
the liver stages of the parasite's lifecycle but has the disadvantage of being slow acting and is 
therefore administered in combination with other drugs, most commonly chloroquine. 
Primaquine causes haemolytic anaemia in people with glucose-6-dehydrogenase (G6PD) 
deficiencies. Glucose-6-dehydrogenase (G6PD) deficiencies occur in 10% of the population 
in malaria prevalent populations. Another disadvantage of primaquine is that studies have 
shown that compliance with the 14-day regimen is not followed as rigorously as it should be; 
tafenoquine has the same glucose-6-dehydrogenase (G6PD) deficiency liabilities that 
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primaquine has, but it is a single dose treatment which makes compliance easier. Due to 
tafenoquine’s long elimination half-life, it has the potential to kill all forms of the parasite and 
be utilised as malaria chemoprophylaxis in geographic areas that chloroquine resistant strains 
of the P. falciparum parasite have been identified (Dhanawat. M, et al 2009). Between 
September 19, 2011, and March 25, 2013, 329 patients were randomly assigned to a treatment 
group (chloroquine plus tafenoquine) in phase 2a and 2b clinical trial. The study concluded 
that a single-dose tafenoquine 300 mg co-administered with chloroquine for P vivax malaria 
relapse prevention was more efficacious than chloroquine alone, with a similar safety profile 
as chloroquine. As a result, (chloroquine plus tafenoquine) combination therapy was selected 
for further clinical assessment in phase 3 trials and approved for use in July 2018 (Llanos-
Cuentas. A, et al 2013; MMV, 2020). 
The Scripps Research Institute and Novartis led a drug discovery programme in 2009 that 
intended to identify non-8-aminoquinoline compounds that were effective against the 
asymptomatic stages of the parasite’s lifecycle and will eliminate the sporozoites and/or the 
hypnozoites in the liver stages without any glucose-6-dehydrogenase (G6PD) liabilities. These 
two establishments managed to develop a new high-throughput screening imaging assay 
technique for the determination of live cell parasite (Plasmodium sporozoites) traversal into 
the liver cells. The assay measures fluorescence that occurs, when the hepatocyte plasma 
membrane is disrupted by the traversing dye-labelled sporozoites. The assay was then used to 
screen 4000 compounds that were known to have blood stage activity with the hope of 
obtaining liver stage inhibitors that could prevent sporozoite migration through cells, 
therefore, preventing the invasion of hepatocytes, and inhibiting the development of 
sporozoites in the liver cells (Derbyshire. E. R, et al 2011); (Biamonte. M. A, et al 2013). This 
technique identified a class of compounds called imidazolopiperazines, whose mode of action 
is currently unknown, which had GNF-pf-5069 as the lead compound. This compound was 
optimised to give compounds GNF179 and GNF156. GNF156 also known as KAF156 has 
completed phase 2 clinical trials, GNF156/KAF156 has an EC50 of 6 nM against P. falciparum. 
 
24 
GNF156/KAF156 is orally bioavailable in mouse 72%, t½ =2.2 hours and has a bioavailability 
of 20-57%, t½ =4.7-8.4 hours in rats. GNF156 inhibits the liver stages of the parasite and also 
prevents transmission of the parasite.  The potency figures of GNF156/ KAF156 in 
plasmodium yoelli have not been disclosed. From March to August 2013, a phase 2, 
KAF156/GNF156/lumefantrine open-label two-part study was done to evaluate the efficacy 
and safety of the compound. A total of 21 adults with acute uncomplicated malaria (11 with 
P. vivax malaria (cohort 1) and 10 with P. falciparum malaria (cohort 2) were enrolled in the 
multiple-dose study, and 22 patients with uncomplicated P. falciparum malaria were enrolled 
in the single-dose study (cohort 3). 400 mg of KAF156 was given once daily for 3 days to 
patients with uncomplicated P. vivax malaria (cohort 1) or P. falciparum malaria (cohort 2). 
Patients in cohort 3, which was a separate group of patients with P. falciparum malaria, were 
treated with a single 800-mg dose of KAF156 in order to assess the cure rate at 28 days and 
the potential for a single-dose cure. 1 patient in cohort 1 and another in cohort 2 experienced 
nausea and vomiting. 4 patients in cohort 3 experienced nausea and 6 patients in cohort 3 
experienced vomiting (Nicholas. W. J, 2016). GNF179 is reported to have similar EC50 figures 
as GNF156, it is not known if these compounds are active against the P. vivax and P. ovale 




Figure 1.6.2: Examples of imidazolopiperazines and Tafenoquine that have shown antimalarial activity. 
The malaria parasite is rich in haem-iron that is derived from the proteolysis of the host cell 
haemoglobin which possibly accounts for artemisinin’s selective toxicity to the parasite. 
Haemoglobin is digested within a specialised, acidic, lysosome-like compartment of the 
parasite also known as a food vacuole, resulting in the formation of free haem. As free haem 
is toxic to the parasite, it is rendered inert as it is produced, by combining one of the peripheral 
carboxyl groups with the Fe(III) iron of an adjacent haem to form the insoluble bio-mineral 
haemozoin (Krishna. S, et al 2008). Haemozoin is a parasite specific pigment also known as 
the ‘malaria-pigment’ that is deposited within the food vacuole after digestion of haemoglobin, 
it has long been proposed as a target of artemisinin and artemisinin like compounds (Fong. K. 
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Y, et al 2013). The antimalarial mode of action of artemisinin is believed to involve the 
cleavage of the endoperoxide bridge in the parasite vacuole. The cleavage of the endoperoxide 
bridge of artemisinin is activated by ferrous Fe(II) iron in the haemozoin generating oxygen 
free radicals which are rearranged to produce more stable carbon-centred free radicals. This is 
then followed by the alkylation of certain malaria proteins and lipid peroxidation by the carbon 
free radicals thereby resulting in lethal damage to the malaria parasite (Egan. T. J, et al (2003); 
Dhanawat, M et al 2009). This has led to the idea that there could be alternative synthetic 
peroxides that could be effective with a similar mode of action as artemisinin; these 
compounds are called 1,2,4-trioxolanes or secondary ozonides.  
The first compound of this first-generation of ozonide peroxides is OZ277 arterolane which 
has proven to be effective against chloroquine-resistant and chloroquine-sensitive parasite 
strains (K1) with an IC50 of 1.6-1.8 nM. This compound has been launched by Ranbaxy as a 
3-day combination therapy of arterolane maleate and piperaquine in India 2012. A second 
generation ozonide peroxide OZ439 which has EC50 of 3.4-4.0 nM is now in phase 2a clinical 
trials. The arrangement of the O-O bond in this ozonide makes the compound 50 fold more 
stable towards Fe(II), presumably because of steric reasons, which translates to a longer half-
life and make it possible for the treatment with this compound to have a shorter dosage regimen 
(Biamonte. M. A, et al 2013). OZ439 has also shown to have a prophylactic effect when 
administered in rats 48 hrs before parasite inoculation. From October 2010 to May 2012, a 
phase 2a, OZ439/Artefenomel open-label exploratory study was done to evaluate the efficacy 
and safety of the compound. This study involved a total of 82 adults with acute 
uncomplicated P. falciparum or P. vivax malaria (20 in each of the 200 mg, 400 mg, and 800 
mg cohorts, and 21 in the 1200 mg cohort). One patient withdrew consent before 
administration of artefenomel. All doses were equally effective in both P. falciparum and P. 
vivax malaria, with median parasite clearance half-lives of 4.1 hours to 5.6 hours for P. 
falciparum and 2.3 hours to 3.2 hours for P. vivax. Maximum plasma concentrations for doses 
proportional to 800 mg, occurred at 4 hours (median). The estimated elimination half-life was 
 
27 
46–62 hours. No serious drug-related adverse effects were reported; other adverse effects were 
generally mild and reversible, with the highest number in the 1200 mg cohort (17) patients 
with at least one adverse event. The most frequently reported adverse effect was an 
asymptomatic increase in plasma creatine phosphokinase concentration.  Artefenomel has 
been generally well tolerated in volunteers at doses up to 1600 mg and is being developed as 
a partner drug in an antimalarial combination treatment. (Phyo. A. P, et al (2016). 
Further exploration of the idea of stabilizing the O-O bond has led to a new class of compounds 
called tetraoxanes for which one of the leading candidate is RKA182 which has displayed an 
IC50 of 4.9 nM against the chloroquine-resistant P. falciparum K1 strain and an IC50 of 1.9 nM 
for the chloroquine-sensitive parasite strain 3D7. This compound inhibits parasite growth with 
an ED50 of 1.8mg/kg/day and the tosylate salt of this compound has a bioavailability of 42% 
in mouse and 38% in rats. However, RKA182 has been reported thus far to not be curative in 
a single dose. The central Drug Institute, Lukow, India is investigating the trioxane CDRI-
97/98 which has concluded phase 1 studies, furthermore, the trials that have been conducted 
on other artemisinin derivatives, ozonides and 1,2,4-trioxanes have been reported to have 
similar potencies as the artemisinin derivative artemether but were not shown to possess any 
additional obvious advantage (Biamonte. M. A, et al (2013). CDRI 97/78 has shown efficacy 
in animal models with falciparum malaria. The first in-human phase I trial in healthy 
volunteers were carried out in July 2012. The study was conducted in 50 healthy volunteers in 
a single, ascending dose, randomized, placebo-controlled, double-blind design. The dose 
ranges evaluated were from 80 mg to 700 mg. After evaluation of safety study results, another 
cohort of 16 participants were administered as a single oral dose of 200 mg of the drug and a 
detailed pharmacokinetic analysis was undertaken. The compound was found to be well 
tolerated. The few adverse events noted were of grade 2 severity (Moderate; minimal 
intervention indicated; some limitation of activities), not requiring intervention and not 
showing any dose response relationship. The electrocardiographic parameters showed 
statistically significant differences, but all were within the predefined normal range. The novel 
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1,2,4 trioxane CDRI 97/78 is safe and will be an asset in malarial therapy if results are 
replicated in multiple dose studies and its benefit are shown in confirmatory trials. 
 
Figure 1.6.3: Examples of ozonides, tetraoxanes and trioxanes that have shown antimalarial activity, some 
of them now in Phase 1 and 2 clinical trials 
Modifications are being made to existing antimalarials derived from 4-aminoquinolines with 
the hope that variations of these compounds could be effective against the chloroquine 
resistant malarial strains. Early candidates for such alternatives are Ferroquine which is in 
phase 2 clinical trials and other related compounds in which the ferrocene has been replaced 
by a benzene ring. Both compounds have shown to be effective against chloroquine-resistant 
and chloroquine-sensitive parasite strains (K1 and W2). N-tert-Butyl isoquine (GSK369796) 
is in phase 1 clinical trials, has been shown to be effective against the chloroquine-resistant 
(K1) with an EC50 of 13 nM both in vivo and in vitro, had a similar mode of action to 
amodiaquine but proved to be no safer than chloroquine, and was therefore discontinued.  
Mefloquine is composed of four isomers, which are divided into two groups (diastereomers) 
each consisting of two enantiomers (namely a [+]-enantiomer and a [−]-enantiomer) within 
the groups but not across groups. The first group is called threo-mefloquine (WR177602) 
defined by the R, R and S, S configurations (known as group: R*, R*). The second group is 
called erythro-mefloquine (WR142490) defined by the R, S and S, R configurations (known 
as group: R*, S*) (Bermudez. L. E, et al (2014); Maaswinkel. H, et al (2015). Erythro-
mefloquine as a racemic mixture [(R, S) -(±)-α-2-piperidinyl-2, 8-bis(trifluoromethyl)-4-
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quinolinemethanol hydrochloride] or [(±)-erythro-mefloquine] is the drug that has been 
clinically used as an effective antimalarial since 1985 (Bermudez. L. E, et al (2012). It has now 
been found that the (+)-erythro-mefloquine, [11R, 2S)- (+)-α-2-piperidinyl-2, 8-
bis(trifluoromethyl)-4-quinolinemethanol] enantiomer is effective as an antimalarial and has 
reduced side-effects compared to the racemic [(±)-erythro-mefloquine] (Fletcher. A, et al 
(2003) US0066643971B1).  The (−)-enantiomer of erytho-mefloquine, [(−)-erythro-
mefloquine], [(11S, 2R) -(−)-α-2-piperidinyl-2, 8-bis(trifluoromethyl)-4-quinolinemethanol 
hydrochloride] has a half-life of 430 hours and is believed to cause side effects that include 
depression, psychosis and nightmares. (Schlagenhauf. P, et al (1999); Biamonte. M. A, et al 
(2013).  
A series of second generation quinoline methanol derivatives that have similar potency as 
mefloquine but without the side effects are being investigated. The Walter Reed Army 
Institution has a lead compound in this class that has lower brain penetration, WR621308. 
Cycloguanil and pyrimethamine are Dihydrofolate reductase inhibitors (DHFR) which have 
developed widespread resistance. Structure based drug design has led to the development of 
WR99210 and P218, DHFR inhibitors which have flexibility within their structure’s design 
that allow them to tolerate all existing clinically relevant DHFR mutations, resulting in these 
compounds being effective for longer. Sulfadoxine-prymethamine combinations have long 
been used as intermittent preventative treatment (IPT) for pregnant women, this treatment has 
become less effective in recent years owing to the parasite developing resistance to this drug 
combination. A combination of azithromycin-chloroquine has been used as a combination 
treatment against chloroquine-resistant P. falciparum in clinical trials. Azithromycin on its 
own is a slow acting antimalarial and finding azithromycin analogues that are fast acting and 




Figure 1.6.4: Examples of quinoline analogues that have shown antimalarial activity, some of them in 
Phase 1 and 2 clinical trials  
Novartis has identified the compound NITD-609/KAE609, a spiroindolone, which has 
undergone phase 2 trials and is very potent with a reported EC50 of 0.7 nM; it has a 
bioavailability of 100% in mice and rats and has an oral t½ of 10 hours in mice and 27 hours 
in rats. NITD-609/KAE609 has been shown to be a potent inhibitor of gametocytogenesis and 
blocks the transmission of the gametes to the parasite. The spiroindolones project was named 
project of the year (2009) by the Medicines for Malaria Venture (MMV). Novartis published 
the results of phase 2 clinical trials of the leading compound NITD-609/KAE609 in 2014 for 
this prospective novel antimalarial with a new mode of action and representing a new class of 
antimalarials (Diagana. T. T, 2015). As of February 2018 NITD-609/KAE609, also known as 
cipargamin, is in phase 2 in-patient studies and is also undergoing parenteral GLP safety 
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studies. Novartis is also in the process of developing compounds that are phosphatidylinositol-
4-OH kinase inhibitors [PI(4)K] that are effective in all of the major lifecycle stages of the 
parasite in its host (Biamonte. M. A et al (2013), Diagana. T. T, 2015). 
 
Figure 1.6.5: Examples of DHFR inhibitors and Spiroindolones that have shown antimalarial activity, 
some of them in Phase 1 and 2 clinical trials. 
Albitiazolium also known as T3 or SAR97276(A) is being researched by the University of 
Montpellier/Sanofi and CNRS is in phase 2 clinical trials. Albitiazolium inhibits the transport 
of choline in the parasite which disrupts the synthesis of phosphatidylcholine, the main lipid 
in the cell membranes when it replicates to form new membranes. This compound is very 
potent and has an EC50 of 2 nM. It is efficacious when administered as an oral dose which 
would be preferable as well, but has a very low oral bioavailability. The clinical trials 
conducted in two separate studies between August 2008 and July 2009 and another in October 
2011 and January 2012 have so far been carried out with intravenous and intramuscular 
injections. These studies showed that monotherapy with SAR97276A up to twice daily for 3 
days is not an efficacious treatment for P. falciparum malaria. SAR97276A will not be further 
developed for the treatment of malaria (Held. J, et al 2017). The pro-drug of Albitiazolium, 
TE3 has an improved oral bioavailability of 15% in mice, reported in 2004-2005, any further 
attempt to improve the bioavailability of such bis-cations has not been successful. Actelion, 
ACT-213615 is fast-acting against all asexual erythrocytic stages of the infection. It is also 30 
times more potent against P. falciparum than P. berghei. Against the P. falciparum, ACT-
213615 has a potency comparable to chloroquine with no acute toxicity observed in mouse 
models. Anacor pharmaceuticals has identified benzoxaborole through structure activity 
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relationships (SAR) as a viable starting point for further optimisation (Biamonte. M. A, et al 
2013). Investigating various configurations of these molecules indicated acidic side chains 
were favoured for high potency antimalarials. Several compounds with an EC50<100 nM have 
been identified for further screening and optimisation.  
 
Figure 1.6.6: Examples of Phosphatidylcholine inhibitors that have shown antimalarial activity, some of 
them in Phase 1 and 2 clinical trials. 
The screening network funded by the WHO Special Programme for Research and Training in 
Tropical Diseases (TDR) screened 10000 compounds against pathogenic organisms for 
tropical diseases including intraerythrocytic forms of P. falciparum. The most potent hit was 
TDR84420 with an EC50 of 326 nM against chloroquine-resistant (K1) strain. Several kinase 
inhibitors screened by GlaxoSmithKline (GSK) have been evaluated as weak inhibitors with 
an EC50>100 nM. Continued structure activity relationships (SAR) screening carried out by 
GlaxoSmithKline (GSK) identified 47 high quality screening hits for further investigation and 
modification. This SAR screening process has led to the compound TCMDC-134142. 
GlaxoSmithKline (GSK) is developing a potentially potent new class of compounds called 2-
pyrimidinecarbonitriles that will act as inhibitors for the proteins falcipain-2 and falcipain-3. 
Falcipains are a group of cysteine proteases that hydrolyse the host’s haemoglobin to provide 
amino acids for the parasite’s protein synthesis. Heat shock protein 90 (hsp90) inhibitors have 
traditionally been pursued as anti-cancer drugs. Harmine is a beta-carboline alkaloid that has 
a variety of pharmacological properties such as anti-microbial, anti-fungal, anti-tumor, anti-
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plasmodial, anti-oxidant, anti-mutagenic, anti-genotoxic and is also hallucinogenic. The 
alkaloid Harmine has been found to selectively inhibit plasmodium hsp90 with an EC50 =50 
nM. The Chinese plant Chang Shan (Dichroa febrifuga) has the active component febrifugine 
which is a potent antimalarial that has rapid effect and bioavailability. However, the compound 
was observed to be very hepatotoxic and that has precluded it from clinical use. Modifications 
to the febrifugine have led to the compound SSJ-183 which is as effective against malaria as 
artenusate and has a better hepatotoxicity profile. Several natural products are being 
investigated as some of these natural products have had some potent antimalarial activity. 
These include the natural marine product salinosporamide A, prodiginine, tsitsikammamine 
C, a berberine analogue, quindolone, propafenone, a sulfonamide analogue [Nitrophenyl-(4-
(furanyl-thiocarboxy)-piperazyl-sulfonamide/NP(FTC)-PSA], a diamine 1,1’-[1,6-
Hexanediylbis(imino-3,1-propanediyl)]bis((3-phenylurea) and an iridoid extract obtained 
from the African herb iThemba’s. The O’Neill group at the University of Liverpool are looking 
at alternative antimalarials that target the electron transport chain of the P. falciparum as 
Atovaquone does. The enzyme NADH: ubiquinone reductase (pfNDH2) is believed to be 
involved in the P. falciparum’s electron transport chain. Investigations of (pfNDH2) inhibitors 
have led to the compound CK-2-25 which is specific for (pfNDH2) and has shown potent in 
vivo antimalarial activity in studies carried out in mice with an ED50 of 1.8mg/kg/day 














1.7 GDH inhibitors 
The research project aims to: 
1) Design and synthesise novel and selective P. falciparum GDH inhibitors as potential 
antimalarial agents. 
2) The GDH inhibitors will be based on molecules similar in structure and size to the 
substrate glutamate, hence, will compete for the active site on the GDH, thus 
minimising its activity. 
3) Utilize simple inexpensive synthetic routes to obtain the intermediates and the final 
products. 
4) Find out if any of the synthesised compounds had any activity against other parasitic 
agents. 
Early research done with bovine GDH determined that the best inhibitors were compounds 
containing an analogous glutamate structure, like isophthalic acid, or electronically similar 
molecules, like 3-nitro and 3-halogeno-benzoates, and 5-bromofuroic acid. These compounds 
were selected based on stereochemical considerations such as similar intramolecular distances 





Figure 1.7.1: A, The superimposed structures of isophthalate and glutarate. B, the superimposed 
structures of m-bromobenzoate, 5-bromofuroate and isophthalate (adopted from Caughey. W, et al 1957) 
Studies on competitive inhibitors by the Engel group at University College Dublin (UCD), 
Ireland, showed remarkable differences in affinity constants (Ki) between Clostridium 
symbiosum GDH and bovine liver GDH, which were used as surrogates for P. falciparum and 
human GDHs respectively (Song Y, 2005).  Isophthalic acid and 3-nitrobenzoic acid were 
shown to be 10 and 7 times, more selective, respectively, for Clostridium symbiosum GDH 
over bovine GDH.  
The same group later carried out a comparison of the inhibitory effects of isophthalic acid and 
a series of related compounds (supplied by our group at London Metropolitan University: 
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Milek A and Ubosowu D 2008) on P. falciparum GDH and bovine GDH (Aparicio I. M, 2010). 
Isophthalic acid (IPA) was shown to be the most active compound tested, and was shown to 
be ~70 fold more active against the parasite GDH.  The Engel group confirmed the effect of 
IPA and the related compounds on the native NADP (H)-dependent GDH activity of the 
parasite. Once again, IPA was shown to be the most efficacious, giving ~87% and ~98% 
inhibitions at 0.1 mM and 1.0 mM concentrations, respectively.  Of all the other compounds 
tested, only 2, 6-pyridine dicarboxylic acid (a pyridine analogue of IPA), showed good 
activity, giving ~38% and 90% inhibitions at 0.1 mM and 1.0 mM respectively (Table 1 
below). 
Table 1: Percentage inhibition of P. falciparum GDH by a series of glutamate analogue prepared at London 
Metropolitan University. Key: IPA-isophthalic acid, IBA-3-iodobenzoic acid, (1)- 2,6-pyridine-dicarboxylic 
acid, (2)- 6-methyl pyridine-2-carboxylic acid, (3) -1,5-dimethylpyrrole-2-carboxylic acid, (4)- 1-methyl-2,5-
pyrrole dicarboxylic acid, (5)- 5-methyl-2-furanoic acid. 
Compound Concentration /mM % Inhibition of Pf GDH 
IPA 0.1  87 
IPA 1.0  98 
IBA 0.1  30 
IBA 1.0  49 
1   0.1  38 
1 1.0  90 
2 0.1  27 
2 1.0  50 
3 0.1  33 
3 1.0  50 
4 0.1  28 
4 1.0  40 
5 0.1  33 
5 1.0  45 
 
While the results of these compounds are interesting and show promise it is important to note 
that the compounds are effective in the micromolar range as based on the values of the EC50. 
Any viable anti-malaria drug that will go into wide spread use must have EC50 that are 
comparable to those of well-established antimalarial drugs such as chloroquine and artemisinin 
which have EC50 in the low nanomolar range. This is important due to the fact that the 
emergence of clinically significant resistant parasites occurs when the ED50 for the drug 
 
39 
increases by approximately 10 fold pushing the concentration required for ED50 into the macro 
molar range (Gelb. Michael. H. 2007).               
 
Figure 1.7.2: L-Glutamate analogues synthesised at London Metropolitan University and tested against 
PfGDH by the research group of Paul Engel at UCD (results shown in Table  1.0) 
1.8 Synthetic targets 
In recent decades there has been a decline in the pharmaceutical industry’s drug discovery 
research innovation and productivity as a result of decreased efficiency in pharmaceutical 
research (Lipinski. C. A, et al 2001). As a result, pharmaceutical companies have focussed on 
the development of drug-like property strategies during the drug discovery process to promote 
the drug discovery process and pharmaceutical industry’s productivity in the hope of reducing 
the attrition rates of compounds and projects during the early discovery process. This will 
enable a rapid selection of high quality compounds and also decrease the number of iterations 
it will take to get to the successful compound. The selection, design and chemical optimisation 
of high quality compounds is done by using one or a combination of metrics to aid in the 
decision making process (Mignani. S, et al 2018). The ‘drug-like’ filters and strategies aid 
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with the processing and handling of the large amounts of data that is now available in both 
computational and experimental approaches. The main weaknesses of these filters include: 
1) They act as cut-off point for a cardinal decision on whether or not a drug candidate 
should be developed further. 
2) They are not well related to the many complex efficacy and safety properties of drugs. 
3) It is difficult to choose which approach to use given the differences in the 
mathematical approaches that are used to determine the physiochemical parameter 
evaluation or the in-vivo parameters and that every approach has its own compounds 
that are exceptions.      
Lipinski’s rule or the rule of 5 (RO5) is a set of computational approaches that help determine 
and predict if a compound will have the desired physical and chemical properties that will 
allow it to be taken orally (Lipinski. C. A, et al (2001). The RO5 is one of the many multi-
parametric computational approaches that is now being used to act as a simple and or complex 
filter to increase the probability of rapidly finding and developing high quality compounds. 
Other such filters include the extended RO5 (eRO5), beyond RO5 (bRO5), Quantitative 
Estimated Drug-likeness QED, ligand-binding thermodynamic and kinetic profiles and the 
Ligand-Efficiency indices (LE indices) also known as the (LE matrices) and 2D Maps 
(Mignani. S, et al 2018). Modern approaches such as Quantitative Estimated Drug-likeness 
(QED) outperformed most of the other simpler scoring systems and approaches including the 
RO5 because of the extra parameters that it uses in its calculation, and because it uses a set of 
approved oral drugs as the basis of its methodology (Ritchie. T. J, et al 2014).  
The RO5 predicts with high probability that compounds with good absorption and 
permeability, have a molecular weight less than or equal to 500, not more than 5 hydrogen 
bond donors, not more than 10 hydrogen bond acceptors and a calculated Log P (CLog P) less 
than 5 or a Moriguchi Log P (MLog P) less than 4.15. Lipophilicity is the most important 
physiochemical property that is used in quantitative structure activity relationship (QSAR) 
analysis. Lipophilicity is an important tool that is used to describe the pharmacodynamics, 
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pharmacokinetics and toxic aspects of drug activity. The lipophilic nature of a compound is 
most commonly defined by the partition coefficient, P, or its decimal logarithm, logP (Bakht. 
M. A, et al, 2014). The logP value only applies for neutral, uncharged molecules and provides 
an indication of whether a substance will be absorbed by living tissue (organic phase) or will 
be easily carried away and disseminated by water (aqueous phase). A negative value for logP 
means the compound has a higher affinity for the aqueous phase (hydrophilic). When logP = 
0 the compound is equally partitioned between the lipid and aqueous phases and a positive 
value for logP denotes a higher concentration in the lipid phase (lipophilic). Highly lipophilic 
compounds (logP>5) have low aqueous solubility thereby compromising their bioavailability. 
Such highly lipophilic compounds will be sequestered by the fatty tissue making them difficult 
to excrete, resulting in accumulation of the compound leading to systemic toxicity. However, 
since the majority of compounds investigated in pharmaceutical research contain ionizable 
sites, the logD would be a better descriptor of lipophilicity. The logD is the distribution of the 
various ionized species at any given pH. LogD would be a particularly useful descriptor for 
the lipophilicity of phosphonates and phosphates which are charged at physiological pH (pKa1 
1.1-2.3 and pKa2 4.0-7.2) (Sevrain. M. C, et al, 2017). Compounds with large molecular 
weights have poor blood brain barrier and intestinal wall penetration. Increased compound 
molecular weight also leads to rapid decline in permeation time of the phospholipid bilayer. 
Compounds with a smaller number of hydrogen bond donors have a higher probability of 
having better permeability. Higher number of hydrogen bond acceptors have been shown to 
hinder phospholipid bi-layer permeability (Lipinski. C. A, et al 2001). 
There are orally active compounds that exist outside the RO5, these include antibiotics, 
antifungals, vitamins and cardiac glycosides. This is because members for these classes of 
compounds have features that make them act as substrates for naturally occurring transporters. 
Compounds that fail to meet the RO5 criterion are considered to likely have poor 
bioavailability and as a result, only one violation can be tolerated. The RO5 does not predict 
whether a compound is pharmacologically active, it predicts whether compounds can be orally 
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delivered and be absorbed by passive mechanisms (Lipinski. C. A, et al 2001).  If the 
compounds synthesized meet the criteria as determined by the RO5 or have one violation, that 
means such compounds would have the desired physical and chemical properties that will 
allow them to be taken orally and are therefore acceptable. 
Fluorine containing compounds are very important and are usually at the forefront of new 
developments in the life sciences industries. In 1990, there were approximately 220 fluorine 
containing compounds representing 8% of all synthetic pharmaceutical compounds that came 
to the market. By 1997 they were 1500 fluorine containing compounds under development in 
the pharmaceutical industry. In the agricultural industry, the number of fluorine containing 
compounds has increased from 4% to 17% of all the currently used crop protection agents 
since 1978. This increase in popularity of fluorinated compounds is due to the fact that 
selectively fluorinated compounds have exhibited dramatically improved potency when 
compared to their non-fluorinated analogues. The incorporation of fluorine into a biologically 
active compound alters the electronic, lipophilic, steric parameters and can increase the 
intrinsic activity, the chemical and metabolic stability and the bioavailability of the compound. 
One of the most common bioisosteric replacement is the substitution of a hydrogen atom with 
fluorine. This is possible because fluorinated compounds have a similar size and shape (Van 
der Waals radius; 1.47 Å for F and 1.20 Å for H) to their non-fluorinated analogues allowing 
the fluorinated compounds to fit in the same target site. Replacement of the C-H bond with the 
C-F enhances the lipophilicity of a compound with functional groups such as CF3, CF3O and 
CF3S being amongst the most lipophilic groups currently known. Compounds containing such 
groups having different pharmacokinetic behaviour such as enhanced passive diffusion across 
membranes. This is evidenced by the fact that most compounds that act on the central nervous 
system (CNS) contain a fluoro-phenyl group or a CF3 group which contribute to the 
pharmacological activity by increasing the CNS penetration. The strength of the C-F bond 
(485KJmol-1 compared to 416KJmol-1 for the C-H bond) makes the fluorinated compounds 
resistant to metabolic degradation. The high electronegativity of fluorine (4.0 against 2.1 for 
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H) alters the electronic effects and chemical reactivity of the compound resulting in an 
enhanced intrinsic activity as well as different chemical behaviour (Maienfisch. P, et al 2004). 
Phosphonates and phosphonic acids are organic phosphorus compounds that are common in 
different organisms such as prokaryotes, eubacteria, fungi, molluscs and insects and have been 
shown to have anti-fungal, anti-bacterial and anti-cancer activity. The first naturally occurring 
phosphonate was isolated in 1959 from the ciliated protozoa in the rumen of sheep, which is 
where this β-alanine and taurine analogue derives its name from, ciliatine. Methyl 
phosphonates and 2-hydroxyethylphosphonates have been mainly found in Nitrosopumilus 
maritimus, one of the most abundant organisms on the planet, that is resident in oxygen rich 
environments of the open oceans (Kafarski. B, 2019).  Despite the different structural and 
electronic functionalities in terms of size, shape, acidity and geometry, phosphonates are 
however, considered to be bioisosteres of the carboxylic group (Kamel. A, et al 2015).  
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Figure 1.8.1: Naturally occurring phosphonic acids and phosphonates derived from protozoa, bacteria 
and other microorganisms (Kafarski. B, 2019) 
 
An estimated one-third of all cellular proteins are modified through phosphorylation, making 
it the second most prevalent post translation modification after glycosylation. This makes 
phosphorylation a pivotal modulator of cellular function through its regulation of signal 
transduction pathways. Phosphorylation and dephosphorylation of target molecules are carried 
out by the large numbers of kinases and phosphatases respectively, that are present in large 
numbers within the human cell cytoplasm and nucleus. Phosphorylation pathways on lipid and 
carbohydrate based substrates play a fundamental role in metabolic processing and in protein, 
carbohydrate and lipid recognition. Due to the ubiquitous nature of substrate phosphorylation 
in cell signalling networks, these pathways are important to physiological processes such as 
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cellular differentiation, migration, metabolism, and apoptosis. When these processes go 
errand, this may result in conditions such as cancer, diabetes and Alzheimer’s disease among 
others. As a result of these wide ranges of effects, general strategies for the design of improved 
inhibitors and probes of these classes of inhibitors that have substrates that can be 
phosphorylated or dephosphorylated is of continued interest to medicinal chemists (Downey. 
A, et al 2014). 
As the phosphonates are hydrolysed to the desired phosphonic acids at the target site there is 
a change in the charge state of the compound making a salt bridge and hydrogen bonding more 
favourable. The nature of the enzymes that are involved in the transformation of phosphate 
and phosphonate esters require their natural substrates to have one or more negative charges. 
As a result, the drug molecules that target these enzymes, generally, must be charged as well. 
This creates an interesting dilemma where the phosphate and phosphonate small drug 
molecules are charged and have great difficulties crossing cell membranes by any means other 
than endocytosis. The resulting contradiction has stimulated abundant effort to develop 
effective prodrugs, these are compounds that are uncharged to enable them to transit biological 
membranes but are then able to release the charged parent drug once inside the target cell. For 
example, the Hepdirect prodrug pradefovir achieved better oral bioavailability (42%) 
compared to the parent drug adefovir (31%) (Wiemer. A, et al 2016). Phosphonates and 
phosphate esters may be lipophilic enough to cross cell membranes where they will be 
hydrolysed to the charged molecules that are active compounds. As such, phosphonates and 
phosphate esters have become central in advancing prodrug forms for their application in the 
development and improvements of drugs. 
The principal synthetic targets of this project were novel analogues of glutamic acid that 
contain the same intramolecular arrangement of carboxylic and/or phosphonic acid 
functionalities (Yokomatsu. T, et al 1997). Synthesis of the 1-hydroxyphosphonic acid 
derivatives has been achieved via the well-established Pudovik reaction (Green. D, et al 1996; 
Pudovik. A, N, et al 1950). The synthetic targets for the P. falciparum GDH were the 2- nitro-
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benzyl- and the 2-carboxyl-benzyl analogues These compounds are glutamate analogs as they 
have the same number of carbon atoms between the acid/acid-isostere functional groups. The 
3-nitro-benzyl, 4-nitro benzyl, 3-carboxyl benzyl and 4-carboxy benzyl analogues are not 
expected to be active as they have one or more extra carbons in-between. These compounds 
are not expected to be active against P. falciparum glutamate dehydrogenase. These 
compounds were synthesised as a proof concept, that it is the stereochemical considerations 
of the 2- nitro benzyl phosphonic acids (30) and the 2- carboxyl-benzyl phosphonic acids (27) 
that make the compounds effective inhibitors. The 1-hydroxy phosphonic acids were obtained 
as racemic mixtures as the α-hydroxy carbon is a chiral centre. After testing, any compounds 
that showed significant activity and were considered promising targets for further development 
as lead compounds would have to be resolved to their pure enantiomers. In a research 
environment, chiral compounds can be resolved in a number of ways including chiral 
chromatography, however, for large scale synthesis, the racemic intermediate or phosphonic 
acid mixture would be converted to a diastereoisomer. This is achieved by converting the 
hydroxyl group to an ester with a pure enantiomer of either R/S-lactic acid or mandelic acid 
which will give the a diastereoisomeric mixture. The two diastereoisomers will have different 
chemical and physical properties consequently enabling them to be separated by 
recrystallization or simple chromatography. The diastereoisomers will then be hydrolysed 
yielding the pure 1-hydroxy phosphonate enantiomers.  
The target compounds were obtained by initially using the well-established Pudovik reaction 
to synthesize the substituted benzyl-α-hydroxy diethyl phosphonates and the substituted 




Figure 1.8.2: Substituted benzyl-α-hydroxyl phosphonates reaction scheme  
Substitution of the α-hydroxyl group to the α-methylene was also achieved. This was done to 
determine if the non-chiral compound at this position would have any activity against P. 
falciparum.  
 
Figure 1.8.3: Substituted benzyl-α-methylene phosphonates reaction scheme 
These substituted benzyl-α-hydroxy diethyl phosphonates and the substituted benzyl-α-
hydroxy dibenzyl phosphonates and their respective substituted benzyl-α-methylene diethyl 
phosphonates and the substituted benzyl-α-methylene dibenzyl phosphonates were used as 
precursors to get to their respective phosphonic acid compounds. The substituted benzyl-α-
hydroxy diethyl phosphonates and the substituted benzyl-α-methylene diethyl phosphonates 
were easier to hydrolyse because they required simple acidolysis whereas the substituted 
dibenzyl phosphonates required catalytic hydrogenolysis. The substituted benzyl-α-hydroxy 
diethyl phosphonates and the substituted benzyl-α-methylene diethyl phosphonates were 
converted to their respective phosphonic acids in two main ways: 
1) Acid hydrolysis with 6M hydrochloric acid or concentrated acetic acid 
2) Dealkylation with bromotrimethylsilane (TMSiBr)/chlorotrimethylsilane (TMSiCl) in 
the presence of a metal halide. 
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Two methods were required for hydrolysis because 29 and 30 could not be obtained by acid 
hydrolysis in which case dealkylation with TMSiBr/TMSiCl was used to obtain these 
phosphonic acids. The F- and NO2 functional groups are unaffected by the TMSi-X reagents 
hence, the dealkylation of the 2-fluoro and the 2-nitro derivatives work well with these 
reagents. The compounds 3-carboxybenzyl-α-hydroxyl phosphonic acid 26, 4-carboxybenzyl-
α-hydroxyl phosphonic acid 28 and 2-carboxybenzyl-α-hydroxyl phosphonic acid 27, could 
not be obtained by dealkylation with TMSiBr/TMSiCl as these reagents failed to react with 
the CN groups. Therefore, acid hydrolysis was used to obtain these phosphonic acids as it 
cleaved the alkyl groups and hydrolysed the CN and the lactone to COOH simultaneously. 
 




Figure 1.8.5: Reaction scheme for the dealkylation of the substituted benzyl-α-hydroxy diethyl 
phosphonates by TMSiBr 
The substitution of the α-hydroxyl group to the α-amino was also attempted. This was done to 
synthesise the substituted benzyl-α-amino phosphonic acids. Amino acids are very important 
biochemical compounds that have a plethora of important tasks within the cell. These tasks 
include but are not limited to catalysing chemical reactions, providing substrates for chemical 
reactions, providing structural elements of a cell, transport of vital materials into the cell and 
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controlling gene activity. If the proposed synthesised substituted benzyl-α-amino phosphonic 
acids inhibitors have a closer structural relationship to the amino acid substrate glutamate, they 
are more likely to be better competitive inhibitors for the enzyme as they will have similar 
interactions with the enzyme pf GDH as the substrate has.    
 
Figure 1.8.6: Synthesis of substituted benzyl-α-amino phosphonic acid reaction scheme  
All of the target molecules were tested against assays of P. falciparum (Pf) parasites strains 
3D7 and Dd2 to determine differences in their relative inhibitions of both strains of the parasite 




Figure 1.8.7: The structures of the second series of targeted protected and unprotected glutamate 
analogues synthesised in this research project.  The lactone containing compound 18 was not the desired 





Figure 1.8.8: The structures of the second series of  protected and unprotected non-glutamate analogues 





Figure 1.8.9: The structures of the –α-methylene phosphate and phosphonate esters that were synthesised 










2 RESULTS AND DISCUSSION  
2.1 Substituted benzyl-α-hydroxy dibenzyl/diethyl phosphonates 
2.1.1 Reaction mechanism 
 
Figure 2.1.1: General reaction mechanism for the synthesis of substituted benzyl-α-hydroxy 
dibenzyl/diethyl phosphonates 
The bioactivity of α-hydroxy phosphonates has made their synthesis a topic of continued 
interest in organophosphorus chemistry (Rădai. Z, et al 2018). The bioactivity of α-hydroxy 
phosphonates has been acknowledged in their use as antibacterial agents, herbicides, anti-HIV 
agents and inhibitors of many different enzymes. They have played a significant role as 
precursors for the synthesis of many other biologically significant molecules such as α-keto 
phosphonates, α-acetoxy phosphonates and α-amino phosphonates to name a few (Pandi, M, 
et al 2012). There are several approaches to the synthesis of α-hydroxy phosphonates, the most 
common being the addition of a dialkyl phosphite to an oxo (an oxygen atom linked to a carbon 
or another element by a double bond) compound in the presence of a base catalyst. The high 
efficiency of the reaction, (Good atom economy- the percentage of reactants that are converted 
to useful or desired products resulting in high yields.) makes this the most appealing way to 
synthesise these compounds although a few acid catalysed variations are known. An 
alternative route for the synthesis of these compounds is the condensation of an oxo compound 
and a trialkylphosphite, this method is usually catalysed by acids. In the literature, these 
reactions are called by a variety of names which include the Pudovik and Abramov reactions 
and phospho-aldol reaction. Other methods that can be utilised to get α-hydroxy phosphonates 
include the reaction of α-keto phosphonates with Grignard reagents or other similar 
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organometallic compounds followed by hydrolysis (Rădai. Z, et al 2018). The reaction for 
obtaining α-hydroxy phosphonates from dialkyl phosphonates and oxo compounds which is 
catalysed by alkali alcoholates was first reported by Pudovik, but since then, variations 
involving different catalysts and conditions have been elaborated. Recent methods have 
targeted the production of these α-hydroxy phosphonates using inexpensive and simple 
catalysts and mild reaction conditions in the spirit of green chemistry and sustainable research 
development. In most cases, this approach has targeted the production of α-hydroxy 
phosphonates without any solvent present. It is worth noting that obtaining α-hydroxy 
phosphonates from ketones is much more challenging than obtaining them from aldehydes. 
This is due to ketones being less reactive because of both steric and electronic effects (Rădai. 
Z, et al 2018).   
The reaction begins with the deprotonation of the phosphorus of the dibenzyl phosphite by the 
basic alumina catalyst thereby generating a negative charge and increasing the nucleophilicity 
of the dibenzyl phosphite (Abell. J. P, et al 2008). The nucleophilic dibenzyl phosphite attacks 
the electrophilic carbonyl of the aldehyde (Merino P, et al 2008). This carbonyl transfers its 
electrons to the oxygen of the C=O generating an alkoxide. The alkoxide is then protonated 
by the alumina-hydride to turn it into a hydroxyl group and regenerating the basic alumina. 
The basic alumina acts as a base in the deprotonation of the dibenzyl phosphite and as an acid 
when it is regenerated in the protonation of the alkoxide. This mechanism forms a catalytic 
cycle which results in the formation of the α- amino and α- hydroxy phosphonic esters (Merino 
P, et al 2008). This is the same reaction that occurs for the diethyl phosphonates below. The 
yields for the diethyl phosphonates are higher than that of the dibenzyl phosphonates, this is 
due to the steric hindrances from the dibenzyl groups. The increase in the size of the alkyl 
group in the dibenzyl phosphites may have the effect of reducing the nucleophilicity of the 
phosphite ion that is formed thereby decreasing its reactivity (Abell. J. P, et al 2008).       
These compounds were straight forward to synthesise. The main source of impurity in the 
product was the starting aldehyde which was easily removed by washing the product 
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repeatedly with a 1:1 hexane diethyl ether mixture. The 3-nitrobenzyl-α-hydroxy dibenzyl 
phosphonate and 4-nitrobenzyl-α-hydroxy dibenzyl phosphonate needed recrystallization 
(hexane: ethyl acetate, 1:1) in order to obtain them as pure compounds. 
 
Figure 2.1.2: substituted benzyl-α-hydroxy phosphonates reaction scheme 
Table 2: Synthesized substituted benzyl-α-hydroxy dibenzyl phosphonates and their respective yields 
Compounds Yield % 
2-Fluorobenzyl-α-hydroxy dibenzyl phosphonate (6) 98 
3-Cyanobenzyl-α-hydroxy dibenzyl phosphonate (7) 54 
3-Nitrobenzyl-α-hydroxy dibenzyl phosphonate (8) 64 
2-Nitrobenzyl-α-hydroxy dibenzyl phosphonate (9) 65 
4-Cyanobenzyl-α-hydroxy dibenzyl phosphonate (10) 96 
4-Nitrobenzyl-α-hydroxy dibenzyl phosphonate (11) 58 
 
Since all the synthesised compounds have a similar structure, the data they produce will have 
a similar pattern. The distinct section of the 1H and 13C-NMR for these compounds was the 
asymmetric section [–α-CH(OH)-P-]; (C-7). The peaks in this region experienced deshielding 
from the adjacent electron-withdrawing groups and were observed down field. The (C-7) 
carbon is directly bonded to the phosphorus and as a result, there is splitting that is observed 
with these peaks due to (P-H) and (P-C) phosphorus coupling. Compounds in which the aryl 
group contained fluorine resulted in the asymmetric section experiencing additional splitting 
from long range fluorine coupling, hence the peaks were observed as multiplets. The –α-C-




Table 3: Distinguishing peaks of the substituted benzyl-α-hydroxy diethyl phosphonates 






δP (ppm) 1J 31P-13C 
(Hz) (C-7) 
6 5.52-5.56 5.52-5.56 63.94 22.19 163.5 
7 5.08 5.44 70.02 21.39 160.02 
8 4.78 5.15 70.21 21.17 158.76 
9 6.32 4.63 66.14 21.59 158.76 
10 5.10 4.18 70.49 21.20 157.50 
11 5.15 4.60 70.45 21.03 157.50 
 
2.2 2-Fluorobenzyl-α-hydroxy dibenzyl phosphonate (6) 
 
Figure 2.2.1: 2-Fluorobenzyl-α-hydroxy dibenzyl phosphonates with numbered carbons. 
2.2.1 1H-NMR000001 
The peaks in the region from 4.90-5.06 ppm represent the two CH2 groups of the 7’ carbons 
(C-7’). The peak in the region 5.52-5.56 ppm are from the C-H and the CH-OH of the 







































































Figure 2.2.2: 1H-NMR 2-fluorobenzyl-α-hydroxy dibenzyl phosphonate aliphatic region expanded 
The peaks in the region 6.95-7.73 ppm represent the hydrogens bonded to the two types of 
aromatic rings; the two identical phenyl groups and the 2-fluoro benzyl ring. The two phenyl 
groups are symmetrical so will only give three signals each. The peaks for the phenyl rings 
should correspond to ten hydrogens that resonate in the same region. The peaks in this region 
will overlap, therefore, they cannot be identified individually.      
The peaks of the 2-fluoro benzyl ring will experience fluorine coupling which results in the 
splitting of the peaks, generating multiplets. The multiplet at 7.69-7.73 ppm (3J19F - 1H-o = 7.4 
Hz) is the hydrogen that is adjacent to the C-F group. This peak experiences the strongest 
fluorine coupling which generates the complex multiplet, which is observed. This peak is 
observed in this region because of the electron-withdrawing effects of the adjacent 
electronegative fluorine which pulls the H-3 hydrogen further downfield. The effects of the 
fluorine coupling become weaker the further away the peaks are from the C-F bond resulting 
in smaller longer range coupling. The remaining peaks of the 2-fluoro benzyl ring will overlap 



































































































Figure 2.2.3: 1H-NMR 2-fluorobenzyl-α-hydroxy dibenzyl phosphonate aromatic region expanded 
2.2.2 13C-NMR000001 
The doublets at 68.27-68.33 ppm (2J31P - 13C = 7.6 Hz) and 68.72-68.77 ppm (2J31P - 13C = 6.3 Hz) 
are from the CH2 (C-7’) from the dibenzyl group. The peaks at 63.28-63.30 ppm and 64.58-
64.60 ppm (1J31P - 13C = 163.5 Hz); (3J19F – 13C = 2.7 Hz) are from the asymmetric carbon (C-7).  
EKKnmr000001.020.001.1r.esp



































Figure 2.2.4: 13C-NMR 2-Fluorobenzyl-α-hydroxy dibenzyl phosphonate aliphatic region expanded 
The peaks between 114.92 ppm and 160.65 ppm represent the two phenyl groups and the 2-
fluoro benzyl ring. The similar phenyl groups will produce 4 peaks each which will resonate 
in the same region. The 2-fluorobenzyl group produces 6 peaks, the peak at 158.62-158.68 
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ppm and 160.60-160.65 ppm are from the C-F in the 2-fluorobenzyl ring. This peak appears 
as a doublet of a doublet due to the coupling effect from the phosphorus (4J31P-13C = 6.3 Hz; 
4J31P-13C = 7.6 Hz) and fluorine (1J19F - 13C = 255.78 Hz) resulting in splitting of the peaks. This 
peak resonates furthest downfield because it is directly attached to the electronegative fluorine. 
The peaks in the region 115.09-136.01 represent the remaining peaks of both the two phenyl 
rings and the 2-fluorobenzyl ring. 
EKKnmr000001.020.001.1r.esp

















































































































Figure 2.2.5: 13C-NMR 2-fluorobenzyl-α-hydroxy dibenzyl phosphonate aromatic region expanded 
2.2.3 31P-NMR00001 
The phosphorus NMR shows one peak, a doublet, in the region 22.18-22.22 ppm. No other 
phosphorus containing compounds are present in the sample.  
The NMR peaks of the remaining compounds in the same class had similar patterns. 
2.3 Mass Spectrometry (EIMS+) (6) 
2.3.1.1 MS0001  
There is no molecular ion present therefore fragments from the molecular ions will be used to 
indicate the presence of the molecular ion. The Mr of the ion is 386.  The peak at m/z 262 
indicates the loss of 125 amu from the molecular ion. This peak represents the dibenzyl 
phosphate ion (PhCH2O)2PO fragment. The peak at m/z 180 is from the C6H4CHPO3C+ 
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fragment. The peak at m/z 171 is from the FC6H4CPO2+ fragment ion. The peak at m/z 123 is 
from the 2-fluoro benzyl ring FC6H4CO+. The peak at m/z 91 is from the C6H5CH2+ fragment. 
2.4 Substituted benzyl-α-hydroxy diethyl phosphonates 
The synthesis of these compounds was straightforward and produced very clean solid 
compounds except for 2-cyano benzyl-α-diethyl phosphonate. The compound 2-cyano benzyl-
α-diethyl phosphonate showed four spots which corresponded to four different products on the 
TLC plates (hexane: ethyl acetate; 1:1 and 2:8), one of which was the starting aldehyde, 2-
cyanobenzaldehyde. Upon purification of the product by column chromatography, NMR 
determined that instead of the 2-cyano benzyl-α-diethyl phosphonate being formed, the 1,2-
benzyl-γ lactone- diethyl phosphonate had been formed. Column chromatography separated 
the fractions clearly and any remaining impurities were washed off with a mixture of 1:1 
hexane diethyl ether. NMR of this resultant product showed that the product was pure but it 
confirmed that a different reaction had occurred. The proximity of the α-hydroxyl group with 
the 2-cyano group resulted in the basic alumina catalysing the conversion of the two groups 
into a lactone. This was confirmed by infra-red spectroscopy which showed the presence of a 
C=O peak, and this confirmed that the 2-cyano group had been converted to the lactone.  
Table 4: Synthesized substituted benzyl-α-hydroxy diethyl phosphonates and their respective yields 
Compounds Yield % 
2-Fluorobenzyl-α-hydroxy diethyl phosphonate (12) 47 
3-Cyanobenzyl-α-hydroxy diethyl phosphonate (13) 82 
4-Cyanobenzyl-α-hydroxy diethyl phosphonate (14) 85 
4-Nitrobenzyl-α-hydroxy diethyl phosphonate  (16) 98 
3-Nitrobenzyl-α-hydroxy diethyl phosphonate (15) 95 
2-Nitrobenzyl-α-hydroxy diethyl phosphonate (17) 74 




2.4.1 Reaction mechanism for the synthesis of the 1,2-benzyl-γ-lactone 
diethyl phosphonate (18) 
 
Figure 2.4.1: General reaction mechanism for the synthesis of 1,2-benzyl-γ-lactone diethyl phosphonates 
Table 5: Distinguishing peaks of the substituted benzyl-α-hydroxy diethyl phosphonates 






δP (ppm) 1J 31P-13C 
(Hz) (C-7) 
12 5.40 4.65 63.87 21.35 162.54 
13 5.09 5.55 69.74 20.56 161.28 
14 5.06 5.11 70.15 20.43 157.50 
15 5.18 5.55 69.86 20.36 160.02 
16 5.18 5.11 70.11 20.20 157.50 
17 6.29 5.40 65.62 20.58 161.28 
18 5.69 - 75.56 13.80 165.06 
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2.5 2-Fluoro benzyl-α-hydroxy diethyl phosphonate (12) 
 
Figure 2.5.1: 2-fluorobenzyl-α-hydroxy diethyl phosphonates with numbered carbons 
2.5.1 1H-NMR012A 
The mutiplet at 1.20-1.36 ppm represent the two CH3 groups of the C-2’ carbon. The two peaks 
are observed as two triplets that overlap generating a multiplet. The peaks in the region 4.00-
4.21 ppm represent the two CH2 groups of the C-1’ carbon. The two peaks are observed as two 
quartets that overlap creating a multiplet.  The peak in the region 5.38-5.42 ppm (2J31P - 1H = 15 
Hz; 4J19F - 1H =10 Hz) is from the CH of the asymmetric carbon (C-7). The peak of the hydroxyl 
group of the CH-OH asymmetric carbon resonates in the region 4.64-4.66 ppm (2J31P - 1H = 10 
Hz; 4J19F - 1H =10 Hz).  
EKKnmr012a.010.001.1r.esp






































































Figure 2.5.2: 1H-NMR 2-fluorobenzyl-α-hydroxy diethyl phosphonate aliphatic region expanded 
The peaks in the regions 7.02-7.71 ppm are from the hydrogens in the 2-fluoro-benzyl ring. 
The hydrogens in the aromatic region are observed as multiplets due to the fluorine coupling 
which leads to splitting of the peaks. The multiplet at 7.67-7.71 ppm (3J19F - 1H-o = 10.0, 5.0 Hz) 
is the hydrogen that is in closest proximity to the C-F group. This peak experiences fluorine 
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coupling, generating a multiplet, which is observed. The effects of the fluorine coupling 
become weaker the further away the peak is from the C-F bond on carbon C-2 resulting in 
smaller longer range coupling. This peak resonates in this region because of the electron-
withdrawing effects of the adjacent electronegative fluorine which pulls the H-3 hydrogen 
downfield. The peaks in the region 7.02-7.32 ppm shift upfield and are from the remaining 
hydrogens in the 2-fluoro benzyl ring.       
EKKnmr012a.010.001.1r.esp
























































































Figure 2.5.3: 1H-NMR 2-fluorobenzyl-α-hydroxy diethyl phosphonate aromatic region expanded 
2.5.2 13C-NMR012A 























Figure 2.5.4:  13C-NMR 2-fluorobenzyl-α-hydroxy diethyl phosphonate aliphatic region expanded 
The doublets at 63.12-63.18 ppm (2J31P - 13C = 7.6 Hz) and 63.56-63.62 ppm (2J31P - 13C = 7.6 Hz) 
represent the two CH2 groups from the carbon C-1’. The doublet of a doublet at 63.21-63.24 
ppm and 64.50-64.53 ppm (1J31P - 13C = 162.54, 3J19F -13C = 3.8 Hz) represent the asymmetric 
carbon C-7.  
EKKnmr012a.020.001.1r.esp



































Figure 2.5.5: 13C-NMR 2-fluorobenzyl-α-hydroxy diethyl phosphonate aliphatic region expanded 
The peaks in the region 114.93-160.74 ppm are from the carbon atoms of the aromatic 2-
fluoro-benzyl ring which produce 6 unique peaks.  All of the peaks of the 2-fluoro-benzyl ring 
will experience C-F coupling and will be split hence they are observed as doublets. The doublet 
of a doublet at 158.72-158.78 and 160.68-160.74 ppm (4J31P-13C = 7.6 Hz; 1J19F - 13C = 254.52 
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Hz) are from the C-F, (C-2) in the 2-fluorobenzyl ring. This peak experiences phosphorus and 
fluorine coupling generating the doublet of a doublet.  
EKKnmr012a.020.001.1r.esp























Figure 2.5.6: 13C-NMR 2-fluorobenzyl-α-hydroxy diethyl phosphonate aromatic region expanded 
This peak is furthest downfield because it is directly attached to the electronegative fluorine. 
The effects of the fluorine coupling become weaker the further away the peaks are from the 

































































































Figure 2.5.7: 13C-NMR 2-fluorobenzyl-α-hydroxy diethyl phosphonate aromatic region expanded 
2.5.3 31P-NMR012A 
There is one peak present, a doublet, which is in the region 21.35-21.39 ppm. No other 
phosphorus containing compounds can be observed in the spectra. 
2.6 Mass Spectrometry (EIMS+) (12) 
2.6.1 MS012A  
The Mr of the ion is 262. The peak at m/z 262 is the molecular ion. The peak at m/z 245 
represents a loss of 17 amu, which indicates a loss of the hydroxyl group. The peak at m/z 233 
is a loss of 29 amu which is a loss of CH3CH2+ from the molecular ion. The CH3CH2+ is from 
one of the ethyl groups from the diethyl group. The peak at m/z 217 arises from the loss of 45 
amu, which is one of the OCH2CH3+ groups, from the molecular ion. The fragment at m/z 186 
is from the loss of 76 amu, which is the phenyl ring. The peak at m/z 172 is a fragment arising 
from the loss of both OCH2CH3+ from the molecular ion. The fragment at m/z 153 represent 
the fragment CHPO(OCH2CH3)2. The peak at m/z 138 is an F-C6H4CP fragment that has 
cleaved off from the molecule. The peak at m/z 97 is a fragment representing the ion C6H4F. 




2.7 1,2-Benzyl-γ-lactone-2-diethyl phosphonate (18) 
 
Figure 2.7.1: 1,2-benzyl-γ-lactone diethyl phosphonates with numbered carbons 
2.7.1 1H-NMR022A1 
The triplets at 1.07-1.10 ppm and 1.40-1.43 ppm represent the two CH3 groups of the C-2’ and 
C-2’’ carbons. The peaks are observed as two distinct separate peaks due to the presence of 
the γ-lactone ring, which confers a certain amount of rigidity and steric hindrances within the 
structure, therefore, the two diethyl groups are unable to rotate freely around the structure. As 
a result, each of the diethyl groups is in different environments and the hydrogens will appear 
in different areas of the spectra. The hydrogens of the C-2’’ carbon are closer to the 
electronegative oxygen atoms of the γ-lactone ring, therefore, the peaks will resonate further 
downfield. The hydrogens of the C-2’ carbon are closer to the benzyl ring which is less 
electron-withdrawing than the cyclic ester, hence will resonate further upfield in the region. 
EKKnmr022a1.010.001.1r.esp































Figure 2.7.2: 1H-NMR 1,2-benzyl-γ-lactone diethyl phosphonates aliphatic region expanded 
The multiplets at 3.85-3.90 ppm, 3.99-4.04 ppm and 4.28-4.32 ppm represent the two CH2 
groups of the C-1’ and C-1’’ carbons. The hydrogens of the C-1’’ carbon are closer to the 
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electronegative cyclic ester which will pull the peaks further downfield. Both hydrogens of the 
C-1’’ carbon are represented within this multiplet. The hydrogens of the C-1’ carbon are closer 
to the benzyl ring which is less electron-withdrawing than the cyclic ester, therefore they will 
resonate further upfield in the region 3.85-3.90 ppm and 3.99-4.04 ppm. These peaks 
experience phosphorus coupling which results in splitting of the peaks, generating a multiplets. 
Due to the 3D spatial arrangement of the C-1’ carbon’s hydrogens, one of the hydrogens will 
be closer to the γ-lactone ring than the other and that hydrogen will be pulled slightly further 
downfield than the other hydrogen on the same carbon which is why the peaks of these 
hydrogens are observed as two separate peaks. 
EKKnmr022a1.010.001.1r.esp



























































































Figure 2.7.3: 1H-NMR 1,2-benzyl-γ-lactone diethyl phosphonates aliphatic region expanded 
The doublet at 5.68-5.71 ppm (2J31P - 1H = 15 Hz) is from the CH of the asymmetric carbon (C-
7); this C-H is observed further downfield because of the electron-withdrawing effects of the 
adjacent cyclic ester. The peak of the hydroxyl group is not available in this compound as it is 
now part of the cyclic ester. This peak is from a hydrogen that is attached to a carbon (C-7) 
which is directly bonded to the phosphorus and therefore, there is splitting that is observed as 




































































Figure 2.7.4: 1H-NMR 1,2-benzyl-γ-lactone diethyl phosphonates aliphatic region expanded 
The peaks in the regions 7.27-7.96 ppm are from the hydrogens in the 1,2- γ-lactone-benzyl 
ring. The peak that is at 7.94-7.96 ppm is the hydrogen that is closest to the C-O group of the 
cyclic ester which is H-3 in the benzyl ring. The nuclei of this hydrogen; H-3 is ‘deshielded’ 
due to the electron-withdrawing effects of the adjacent electronegative cyclic ester carbonyl 
group and therefore experiences greater influence from the external magnetic field and hence 
the chemical shifts resonate downfield. The rest of the peaks shift upfield as the hydrogens 
































































Figure 2.7.5: 1H-NMR 1,2-benzyl-γ-lactone diethyl phosphonates aromatic region expanded 
  
EKKnmr022a1.050.001.1r.esp































































Figure 2.7.6: 1H-NMR D2O shake 1,2-benzyl-γ-lactone diethyl phosphonates aliphatic region expanded 
2.7.2 13C-NMR022A1 
The doublets at 16.17-16.49 ppm (3J31P - 13C = 6.3 Hz) represent the two CH3 groups of the C-























Figure 2.7.7: 13C-NMR 1,2-benzyl-γ-lactone diethyl phosphonates aliphatic region expanded 
The doublets at 63.96-64.35 ppm (2J31P - 13C = 6.3 Hz) represent the two CH2 groups from the 
carbon C-1’and C-1’’. The peaks experience phosphorus coupling which results in splitting of 
the peaks, generating the doublets that are observed.  
EKKnmr022a1.020.001.1r.esp



















Figure 2.7.8: 13C-NMR 1,2-benzyl-γ-lactone diethyl phosphonates aliphatic region expanded 































Figure 2.7.9: 13C-NMR 1,2-benzyl-γ-lactone diethyl phosphonates aliphatic region expanded 
The peaks in the region 123.65-169.77 ppm are from the carbon atoms of the aromatic 1,2- γ-
lactone-benzyl ring which give 7 peaks. The peak in the region 143.83-143.86 ppm is from 
the C-C=O, (C-2) carbon. The peak at 169.77 ppm is from the carbonyl; C=O of the (C-8) 
carbon of the 1,2- γ-lactone ring.   
EKKnmr022a1.020.001.1r.esp































































Figure 2.7.10: 13C-NMR 1,2-benzyl-γ-lactone diethyl phosphonates aromatic region expanded 
2.7.3 31P-NMR022A1 
There is one peak present, which occurs at 13.80 ppm. No other phosphorus containing 
compounds can be observed in the spectra. 
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2.8 Mass Spectrometry (TOF MS ES+) (18) 
2.8.1 MS022A1  
The Mr of the ion is 270. The peak at m/z 271 which is the molecular ion, [M+H]+. The peak 
at m/z 243 is a loss of 29 amu indicating a loss of one of the diethyl group from the molecular 
ion. The peak at m/z 215 is a loss of 56 amu which represents a loss of two of the CH3CH2+ 
groups from the molecular ion. The peak at m/z 133 is from the fragment C8H5O2 which is the 
isobenzofuranone (benzyl-lactone ring). The lactone ring is susceptible to heterolytic cleavage, 
leading to the opening of the five-membered ring and formation of the acylium ion. The peak 
at m/z 293 arises from the addition of a sodium ion to the molecular ion, [M+Na]+. 
2.9 Infrared spectroscopy (18) 
The IR spectrum of 1,2-benzyl lactone-2-diethyl phosphonate was obtained and confirmed the 
presence of the lactone ring. The absence of the nitrile stretch in the 2229 cm-1 region 
confirmed that the nitrile group had reacted. That in combination with the presence of the C=O 
peak in the 1771 cm-1 region suggested the formation of the lactone ring. The C=O peak is not 
observed in the IR spectra of all the other R-benzyl-α-hydroxyl diethyl phosphonate 
compounds. The O-H stretch is absent in the IR spectrum of this compound. 
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2.10 Conversion of the α-hydroxyl to the methylene group 
2.10.1 Reaction mechanism 
 
Figure 2.10.1: General reaction mechanism for the synthesis of substituted benzyl-α-methylene 
phosphonates 
These reactions were adapted from the one step conversion of alcohols into alkyl halides 
through oxycarbonylimidazolium intermediates (Kamijo. T, et al 1983). It seemed feasible to 
replace the hydroxyl group of the α-carbon with hydride anion by making a slight alteration to 
the original procedure. The lone pair of electrons of the oxygen of the starting hydroxyl group 
acts as a nucleophile and attacks the carbonyl group of the carbonyl diimidazole group to give 
an imidazolate ester, following deprotonation of the resulting intermediate by the displaced 
imidazolate anion. The formation of this complex is very crucial for the substitution of the 
hydroxyl group. This step must occur in dry conditions because any moisture will stop the 
reaction from occurring. As such, water and all protic solvents must be avoided as they react 
with the hydride anion. This esterification process makes the α-carbon a good electrophile and 
therefore an excellent target for a hard nucleophile such as a halide. For the purposes of our 
reaction, the hard nucleophile was the hydride anion (H-). The H- attacks the δ+ α-carbon which 
results in the breaking of the C-O bond to form a carbon dioxide molecule and another 
imidazole anion. The imidazole anion is then deprotonated during the work up to generate 
imidazole. This step completes the final substitution from the α- hydroxyl carbon to the α- 
methylene carbon. The final products are the α- methylene compound, carbon dioxide and 
imidazole. The reaction is cost effective when compared to similar methods that are used in 
organic substitution reactions which convert a C-OH to a C-H. Since substitution is a crucial 
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method for functional groups interconversion, it is important to continually find ways to make 
the reaction as environmentally friendly and non-toxic as possible. This is not currently 
possible with current reducing agents such as lithium aluminium hydride, borane and hydrogen 
which are all hazardous (Lawrence. J. N, et al 1999).   
All the attempted reactions were observed to proceed to completion through TLC, and, 
following aqueous work-up and column chromatography, the products were obtained as oils 
in moderate to good yields. Most of the starting α-hydroxyl phosphonates compounds 
dissolved in dry acetonitrile with the exception of 3-nitrobenzyl-α-hydroxy dibenzyl 
phosphonate and 4-nitrobenzyl-α-hydroxy dibenzyl phosphonate which were dissolved in dry 
THF. The compounds 3-nitrobenzyl-α-methylene dibenzyl phosphonate, 2-nitrobenzyl-α-
methylene dibenzyl phosphonate and 2-nitrobenzyl-α-methylene diethyl phosphonate were 
synthesised but could not be purified due to the presence of competing reactions. The TLC 
profiles of these compounds showed two spots which corresponded to two different products 
with similar Rf values, therefore, eluted from the column at the same time. These two products 
could not be resolved by either changing the eluent systems, column size or the amount of 
silica gel used. Some of the solvent systems that were attempted were hexane: ethyl acetate 
2:8, 1:1 and 4:6. Diethyl ether: ethyl acetate 1:1 and 2:8. Hexane: ethyl acetate: 
dichloromethane 2:6:2. Alternative purification methods such as the use of Prep TLC plates 
were unsuccessfully attempted. It is assumed, at the moment, that the reason that these three 
compounds are forming more by-products is due to hydride abstraction of the relatively acidic 
hydrogen on the asymmetric carbon. 
The synthesis of these substituted benzyl-α-methylene phosphonates suggested that there is a 
possibility for the hydroxyl group to be substituted with various functional groups to give 
different compounds. The rationality being that an activated imidazolium ester of the 
substituted benzyl-α-hydroxy phosphonate could turn the hydroxyl into a good leaving group 
that could be replaced easily by a good nucleophile. Consequently, it seems feasible to convert 
the hydroxyl group to an amine and or amide functional group by using sodium azide which 
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could then be reduced to the amine by catalytic hydrogenation or by sodium borohydride 






















2.11 Possible side reactions for the substituted benzyl-α-methylene 
phosphonates 
2.11.1 Possible side reaction 1 
 
Figure 2.11.1: Possible side reaction mechanism for the substituted benzyl-α-methylene phosphonates 1 
2.11.2 Possible side reaction 2 
 





Figure 2.11.3: substituted benzyl-α-methylene phosphonates reaction scheme 
Table 6: Synthesized substituted benzyl-α-methylene dibenzyl phosphonates and their respective yields 
Compounds  Yield % 
2-Fluorobenzyl-dibenzyl phosphate (19) 24 
2-Fluorobenzyl-diethyl phosphate (20) 93 
4-Cyanobenzyl-diethyl phosphate (22) 59 
3-Cyanobenzyl-diethyl phosphate (21) 14 
3-Nitrobenzyl-diethyl phosphate (23) 47 
4-Nitrobenzyl-α-methylene diethyl phosphonate (25) 20 
4-Nitrobenzyl-α-methylene dibenzyl phosphonate (24) 25 
 
The α-CH2 hydrogens of the desired α-methylene phosphonate esters should resonate at 
3.00ppm and not 5.00ppm in the 1H-NMR spectra. With the exception of the 4-nitro derivative 
(24 and 25), all of the α-CH2 hydrogens of the synthesised methylene compounds resonated at 
5.00ppm. A closer examination of the 31P-NMR and 13C-NMR spectra also highlighted a few 
substantial irregularities;  
1) The phosphorus resonances and the observed phosphorus-α-carbon (C-7) coupling 
constants. With the exception of the 4-nitro derivative, all of the benzyl-phosphonates 
had JP-C7 coupling constants of 5.0 Hz instead of the expected values, which are in the 
region of 150 Hz.  
2) The 31P-NMR δ-values were all in the 0.35 to -0.60 ppm range, which is expected for 
phosphates, but not phosphonates, whose 31P-NMR δ-values occur in the 15 to 30 ppm 
region.   
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3) Closer examination of the electron-impact mass spectra of the benzyl-phosphonates, 
clearly show the presence of the relevant substituted benzyl carbocations in very high 
relative abundances, which is not expected for phosphonates but very commonly 
observed in phosphates.  The 2-fluoro derivatives 19 and 20 show the expected 
carbocation C7H6F+ (m/z 109.0) in 60% and 100% relative abundances respectively. 
The 3-nitro derivative 23 shows the expected carbocation C7H4NO2+ (m/z 134.0) at 
100% but the 4-nitro derivatives 24 and 25 display this carbocation at 35% and 12% 
relative abundances, respectively. The 3- and 4-cyano derivatives 21 and 22 all show 
the expected carbocation C8H6N+ (m/z 116.0) at 100% abundances. Furthermore, 
peaks that correspond to the molecular ion peak for the phosphate ester products have 
been observed in the electron-impact mass spectra for the compounds 19, 20, 21, 22 
and 23. 
4) All attempted hydrolysis reactions of the benzyl-phosphonate esters did not yield the 
expected phosphonic acids or their salts. Using either of the procedures mentioned in 
the hydrolysis section of this thesis below, in all cases the attempted hydrolysis of 
these compounds produced solid residues that were insoluble in all NMR solvents or 
solvent mixtures (DMSO, DMSO-D2O, D2O-NaOD, methanol) and as a result we 
were unable to obtain any NMR data. 
This data suggests strongly that our modified Kamijo reaction has possibly yielded phosphate 
ester products rather than our desired phosphonates, with the exception of the 4-nitro 
derivatives (24 and 25). This occurs by means of a 1,2- Phospha-Brook rearrangement, which 
is an intramolecular phosphonate-phosphate rearrangement under basic conditions. This 
rearrangement has been well studied but, has shown to have limited applicability to substrates 
having α-H (Khan. S, et al 2016). The Phospha-Brook rearrangement is mechanistically 
analogous to the Brook rearrangement, which comprises the anionic migration of a silyl group 
from a carbon atom to an oxygen atom, thereby converting an oxyanion (typically a lithium 
alkoxide) to a carbanion (an organolithium) in the presence of catalytic base such as NaOH, 
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NaOEt, NaH, Na-K, Et2NH and DBU (Smith. A, et al 2006; Prechelmacher. S, et al 2018). 
The simplest Brook rearrangement being the 1,2- Brook rearrangement, has been shown to 
proceed intramolecularly, via a hypervalent pentacoordinate silicon species with retention of 
configuration at silicon and inversion of configuration at carbon (Brook. A. G, et al 1974). The 
Phospha-Brook intramolecular rearrangement proceeds via a pentacoordinate phosphorus 
species with retention of configuration at phosphorus and inversion of configuration at carbon 
(Pudovik. A. N, et al 1980). An alternate method to make the hydroxyl a good leaving group 
is to convert it into a sulfonate ester [methanesulfonates (mesylates)] which can then take part 
in a substitution reaction. 
The rearrangement under the reaction conditions could arise from the failure of the reaction 
with carbonyl diimidazole, presumably for steric reasons, and then reaction with hydride anion 
which deprotonates the alcohol, leading to the formation of a charged epoxy phosphono- 
intermediate, which then ring opens to yield the benzyloxy carbanion, which is resonance 
stabilized by the presence of the electron-withdrawing substituents, in particular CN and NO2 
on carbons 2 and 4. This does not fully explain why the C-3 derivatives also presumably 
undergo this rearrangement, nor why, in the case of the 4-nitro derivatives (24 and 25), the 
desired products have been formed. The failure of the hydrolyses reactions carried out on the 
putative benzyl-phosphonate esters (19-25) may be explained by the rapid hydrolyses of the 
phosphates to yield phosphoric acid which was then converted into insoluble polyphosphates 





Figure 2.11.4: A possible phosphonate to phosphate rearrangement, via an epoxy-phosphono-
intermediate, that occurs in the attempted conversion of the α-OH compounds into their benzyl phosphate 






















Table 7: The observed JP-C7 coupling constants and 31P δ-values for all of our synthesized targets (PA = 
phosphonic acids). 




C7-X’ JP-C7 /Hz 31P / δ 
6 2-F PhCH2 OH 163.50 22.19 
9 2-NO2 PhCH2 OH 158.76 21.59 
18 2-CO2-lactone PhCH2 OH 165.06 13.80 
29 2-F PA OH 152.50 16.55 
30 2-NO2 PA OH 142.38 15.57 
27 2-CO2-lactone PA OH 158.58 12.86 
34 2-F PA NH2 165.06 13.80 
26 3-CO2H PA OH 163.80 20.68 
28 4-CO2H PA OH 161.28 20.38 
20 2-F CH3CH2 H 5.0 -0.60 
19 2-F PhCH2 H 5.0 -0.51 
21 3-CN CH3CH2 H 5.0 -0.49 
7 3-CN CH3CH2 OH 160.02 21.39 
13 3-CN PhCH2 OH 161.28 20.56 
10 4-CN PhCH2 OH 157.50 21.20 
14 4-CN CH3CH2 OH 157.50 20.43 
8 3-NO2 PhCH2 OH 158.70 21.17 
11 4-NO2 PhCH2 OH 157.50 21.03 
12 2-F CH3CH2 OH 162.54 21.35 
15 3-NO2 CH3CH2 OH 160.02 20.36 
16 4-NO2 CH3CH2 OH 157.50 20.20 
17 2-NO2 CH3CH2 OH 161.28 20.58 
22 4-CN CH3CH2 H 6.30 -0.49 
23 3-NO2 CH3CH2 H 5.0 -0.46 
25 4-NO2 CH3CH2 H 137.34 24.61 
24 4-NO2 PhCH2 H 137.34 25.85 
 
The distinct section of the 1H and 13C-NMR for these compounds was the asymmetric section 
[–α-CH2-P-]; (C-7). As with the -α-hydroxy phosphonates, the peaks in this region experience 
phosphorus coupling therefore splitting is observed with these peaks due to (P-H) and (P-C) 
phosphorus coupling. Compounds in which the aryl group contained fluorine resulted in the 
 
84 
asymmetric section experiencing additional splitting from long range fluorine coupling hence 
the peaks were observed as multiplets. The absence of the –α-C(OH) confirmed the conversion 
to –α-CH2 had occurred for the compounds 24 and 25, the rest the rearrangement reaction had 
occurred. 
Table 8: Distinguishing peaks of the substituted benzyl-α-methylene dibenzyl phosphonates/phosphates 
Compound  δH  CH2 (ppm) δC CH2 (ppm δP (ppm) J 31P-13C (Hz) 
(C-7) 
19 5.09 63.14 -0.51 5.0 
20 5.14 62.88 -0.60 5.0 
21 5.09 67.49 -0.49 - 
22 5.13 67.64 -0.49 6.3 
23 5.17 67.42 -0.46 5.0 
24 3.21 34.33 25.85 137.34 
25 3.25 34.01 24.61 137.34 
 
2.12 2-Fluorobenzyl-dibenzyl phosphate (19) 
  
Figure 2.12.1: 2-fluorobenzyl-phosphate with numbered carbons 
2.12.1 1H-NMR001B2 
The doublet at 5.02-5.04 ppm (3J31P - 1H = 10 Hz) represent the two CH2 groups of the 7’ carbons 





















Figure 2.12.2: 1H-NMR 2-fluorobenzyl-dibenzyl phosphate aliphatic region expanded 
The peaks in the region 7.02-7.37 ppm represent the hydrogens of the two types of aromatic 
rings; the two identical phenyl rings and the 2-fluoro benzyl ring. The multiplicities of these 
peaks will interfere with each other therefore, cannot be identified individually.  
EKKnmr001b2.010.001.1r.esp





















































































Figure 2.12.3: 1H-NMR 2-fluorobenzyl-dibenzyl phosphate aromatic region expanded 
2.12.2 13C-NMR001B2 
The multiplet at 63.11-63.19 ppm (2J31P - 13C = 5.0 Hz) represent the α- methylene carbon (C-
7). The doublets at 69.32-69.37 ppm (2J31P - 13C = 6.3 Hz) are from the two CH2 groups of the 



























Figure 2.12.4: 13C-NMR 2-fluorobenzyl-dibenzyl phosphate aliphatic region expanded 
The peaks in the region 115.31-161.58 ppm represent the two phenyl groups and the 2-fluoro 
benzyl ring. The doublet at 159.61-161.58 ppm (1J19F - 13C = 249.48 Hz) is from the C-F bond 
in the 2-fluorobenzyl ring. The peaks of the carbons in the 2-fluoro benzyl ring will overlap 
with the peaks of the carbons of the two benzyl rings.  
EKKnmr001b2.020.001.1r.esp







































































































Figure 2.12.5: 13C-NMR 2-fluorobenzyl-dibenzyl phosphate aromatic region expanded 
2.12.3 31P-NMR001B2 
The phosphorus NMR shows one peak, which occurs at -0.51 ppm. No other phosphorus 
containing compounds can be observed in the spectra. This is expected for the rearranged 
phosphates, but not for the desired phosphonates. 
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2.13 Mass Spectrometry (EIMS+) (19) 
2.13.1 MS001B2 
The Mr for the expected phosphonate ion is 370. There is no phosphonate molecular ion peak 
in the mass spectra. The peak at m/z 387 represents the molecular ion peak for the phosphate 
compound. The peak at m/z 277 represents a loss of 110 amu which is a loss of C6H4F(CH2)+ 
from the molecular ion. The peak at m/z 199 represents the [(C6H5CH2O)(OCH2)PO-CH2-]+ 
fragment that has been cleaved from the molecular ion.  The peak at m/z 109 represents the 
[FC6H4CH2]+ fragment that has cleaved from the molecule. The peak at m/z 91 represents the 
[C6H4CH2]+ fragment that has cleaved from the molecule. 
2.14 2-Fluorobenzyl-diethyl phosphate (20)  
 
Figure 2.14.1: 2-fluorobenzyl-diethyl phosphate with numbered carbons 
2.14.1 1H-NMR012B3 
The multiplet at 1.30-1.33 ppm represent the two CH3 groups of the C-2’ carbons of diethyl 
phosphate. The multiplet at 4.09-4.14 ppm represent the two CH2 groups of the C-1’ carbon. 
























































Figure 2.14.2: 1H-NMR 2-fluorobenzyl-diethyl phosphate aliphatic region expanded 
The peaks in the region 7.06-7.47 ppm are from the 4 hydrogens of the in the fluoro benzyl 
ring. The multiplet at 7.45-7.48 ppm is the hydrogen that is in closest proximity to the C-F 
group. The peaks in the region 7.06-7.35 ppm shift upfield as the hydrogens resonate further 
away from the electronegative fluorine group. 
EKKnmr012b3.010.001.1r.esp



































































Figure 2.14.3: 1H-NMR 2-fluorobenzyl-diethyl phosphate aromatic region expanded 
2.14.2 13C-NMR012B3 
















Figure 2.14.4: 13C-NMR 2-fluorobenzyl- diethyl phosphate aliphatic region expanded 
The peak at 63.88-63.93 ppm is from the two CH2 groups from the diethyl phosphate from the 
carbon C-1’. The multiplet at 62.84-62.92 ppm is from the α-methylene CH2 carbon C-7.  
EKKnmr012b3.020.001.1r.esp























Figure 2.14.5: 13C-NMR 2-fluorobenzyl- diethyl phosphate aliphatic region expanded 
The peaks in the region 115.31-130.46 ppm are from the carbon atoms of the 2-fluoro-benzyl 
ring which produces 6 unique peaks. All the peaks of the 2-fluoro-benzyl ring will experience 
C-F coupling and will hence be split. The doublet at 159.66-161.64 ppm (1J19F - 13C = 249.48 














































































Figure 2.14.6: 13C-NMR 2-fluorobenzyl-diethyl phosphate aromatic region expanded 
2.14.3 31P-NMR012B3 
The phosphorus NMR shows one peak, which occurs at -0.60 ppm, no other phosphorus 
containing compounds can be observed in the spectra. This is expected for the rearranged 
phosphates, but not for the desired phosphonates. 
2.15 Mass Spectrometry (EIMS+) (20) 
2.15.1 MS012B2 
The Mr for the expected phosphonate ion is 246. There is no phosphonate molecular ion peak 
present in the mass spectra. The peak at m/z 262 represents the molecular ion peak for the 
phosphate compound. The peak at m/z 233 is a loss of 29 amu which is a loss of CH3CH2+ 
from the molecular ion.  The peak at m/z 214 represents a loss of 19 amu from the fragment 
m/z [233]+ which is the loss of the fluorine. The peak at m/z 186 represents the FC6H4CPO3+ 
fragment that has been cleaved from the molecular ion. The peak at m/z 109 represents the 
FC6H4CH2+ fragment. 
2.16 Synthesis of substituted benzyl–α-hydroxy phosphonic acids 
from their diethyl phosphonate precursors. 
The substituted benzyl-α-hydroxy diethyl phosphonates and substituted benzyl-α-methylene 
diethyl phosphonates were selected for hydrolysis to their respective phosphonic acids instead 
of the corresponding substituted R-benzyl-α-hydroxyl dibenzyl phosphonates and substituted 
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benzyl-α-methylene dibenzyl phosphonates. The diethyl phosphonates were hydrolysed in two 
main ways: 
1) Hydrolysis by the use of strong acid, in this instance, 6M HCl and concentrated acetic 
acid (AcOH).  
2) Dealkylation with chlorotrimethylsilane or bromotrimethylsilane/metal halide 
(Morita. T, et al 1981) for compounds that could not be successfully hydrolysed to 
their phosphonic acids by acid hydrolysis. 
This is a milder method for dealkylation which involves the conversion of the dialkyl 
phosphonate into their silyl esters and hydrolysing the silyl ester with a strong base, 1M 
sodium hydroxide (NaOH). Bromotrimethylsilane and iodotrimethylsilane have been 
considered to be the most efficient reagents for this dealkylation process but they are much 
more expensive. Chlorotrimethylsilane, on the other hand, is much cheaper but has been 
considered to be an inefficient dealkylation agent (Morita. T, et al 1981).  
AcOH, 6M and concentrated HCl were not strong enough to hydrolyse the 2-fluorobenzyl-α-
hydroxy diethyl phosphonate (12) and the 2-nitrobenzyl-α-hydroxy diethyl phosphonate (17), 
these acids did not produce the required phosphonic acids for the respective compounds when 
the reflux was carried out for 48-72 hours. As a result, chlorotrimethylsilane was used to 
dealkylate compounds 12 and 17 to their respective phosphonic acids. There were concerns 
that utilising concentrated HCl to hydrolyse the diethyl phosphonates would decompose them 
therefore, 6M HCl was used. The melting point of compound 29 was >300 °C which was 
beyond the limits of the instruments that were utilised. The melting point of compound 30 was 
difficult to attain because the compound decomposed at 155-158 °C.  
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2.17 Synthesis of substituted benzyl-α-hydroxy phosphonic acids 
from their diethyl phosphonate precursors by acid hydrolysis  
2.17.1 Reaction mechanism  
 
Figure 2.17.1: General reaction mechanism for the dealkylation of substituted benzyl-α-diethyl 
phosphonates by acid hydrolysis 
The acid will protonate the oxygen atom of the ethoxy group which is then followed by an SN2 
attack on the adjacent CH2 by the chloride anion and the displacement of phosphonate 




Figure 2.17.2: General reaction mechanism for the acid hydrolysis of nitrile groups 
The nitrile group has two pi triple bonds and a lone pair of electrons on the nitrogen. The 
nitrogen of the nitrile group is protonated by the H3O+ resulting in the formation of an activated 
nitrile which has a positively charged nitrogen. This is then followed by the addition of water 
to the carbon of the nitrile to give a primary amide. The carbonyl of the primary amide is then 
protonated by the H3O+, the positive charge that is generated makes that carbon more 
electrophilic making the addition of another water molecule on to the carbon possible resulting 
in a neutral tetrahedral intermediate. The amine is much more basic than the oxygen and is 




2.18 Synthesis of substituted benzyl-α-hydroxy phosphonic acid 
from their diethyl phosphonate precursors by 
bromotrimethylsilane (TMSiBr). 







Figure 2.18.1: Reaction mechanism for the dealkylation of Benzyl-α-diethyl phosphonates by 
bromotrimethylsilane (TMSiBr) 
McKenna’s method reported in 1977 occurs by oxophillic substitution on the silicon atom 
whereby the bromide ion acts as a leaving group to produce the di-silylated ester. The 
hydrolysis of this di-silylated ester produces the phosphonic acid. The P=O double bond acts 
as a nucleophile that attacks the electropositive silicon atom resulting in silicon giving up its 
electrons to the bromide leaving group (Sevrain. M. C, et al, 2017). The next stage of the 
reaction will progress as an SN2 reaction resulting in the removal of the alkyl group. This 
reaction is repeated resulting in the formation of the di-silylated ester. The final products at 
this stage in the reaction are two bromoethane molecules and a disilyl phosphonate.  
The last stage of the mechanism is the removal of the silyl esters by either, methanolysis with 
a strong base, sodium hydroxide, or hydrolysis with water to give the final phosphonic acids, 
this occurs again as an SN2 reaction. The hydroxyl (OH-) is drawn toward the phosphorus 
creating a new P-OH bond, this results in the generation of an oxyanion followed by a 
concerted electron pair shift from the oxyanion to the silyl ester leaving group. The final 
products from this reaction are the volatile methoxy trimethylsilane and the phosphonic acid. 
The by-products that are generated if the removal of the silyl esters is carried out by hydrolysis 
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with water are trimethylsilanol and hexamethyldisiloxane. This milder method to prepare 
phosphonic acids by the transesterification of dialkyl phosphonates reaction mechanism has 
been confirmed (Sevrain. M. C, et al (2017), Bartlet. P. A, et al (1991) and the experimental 
proof was obtained by using 17O and 18O enriched benzyl diethyl phosphonate. These 
experiments showed that the terminal P=O was the nucleophile that attacked the silicon 
(Sevrain. M. C, et al (2017). The nucleophilicity of the bromide only works for alkyl chain 
phosphonates but was not very efficient for dibenzyl phosphonates (Pohjala, E. et al, (1993). 
Table 9: Synthesized substituted carboxy benzyl-α-phosphonic acids and their respective yields 
Compounds Yield % 
2-Fluorobenzyl-α-hydroxy phosphonic acid (29) 19 
3-Carboxybenzyl-α-hydroxy phosphonic acid (26) 97 
4-Carboxybenzyl-α-hydroxy phosphonic acid (28) 85 
2-Carboxybenzyl-α-hydroxy phosphonic acid (27) 14 
2-Nitrobenzyl-α-hydroxy phosphonic acid (30) 68 
 
The compounds that were synthesised by dealkylation with TMSiCl were resynthesised with 
TMSiBr to find out if the yields could be improved. The yields of the compounds synthesised 
via the TMSiCl route improved on using TMSiBr. This is due to the fact that TMSiBr is more 
reactive and Br- is a better leaving group than Cl-. 
Table 10:Comparisons in yields between synthesis with TMSiCl and TMSiBr 





2-Fluorobenzyl-α-hydroxy phosphonic Acid (29) 19 88 
2-Nitrobenzyl-α-hydroxy phosphonic Acid (30) 68 75 
 
The main distinguishing peaks for the phosphonic acids was the absence of the phosphonate 
ester derivatives in the 1H-NMR and the 13C-NMR. Additionally, the presence of peaks 
corresponding to the –COOH resonating in the region 169-173 ppm of the 13C-NMR (for 
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compounds which previously had a –CN group). The benzonitrile -CN peak resonates in the 
region 118 ppm. The spectra were run in methanol or D2O, which will exchange with OH and 
NH2 groups.  
Table 11: Distinguishing peaks of the substituted benzyl-α-hydroxy/amino phosphonic 




δP (ppm) 1J 31P-13C (Hz) 
(C-7) 
26 3.62 71.87 20.68 163.8 
27 5.80 78.55 12.86 158.8 
28 5.02 72.13 20.28 161.28 
29 5.13 66.52 16.55 152.5 
30 5.76 69.05 15.57 142.38 
34 4.13 51.00 18.20 132.30 
 
2.19 NMR of 2-carboxy benzyl-α-hydroxy phosphonic acid (27) 
 
Figure 2.19.1: 2-carboxybenzyl-α-hydroxy phosphonic acid with numbered carbons 
2.19.1 1H-NMR022D2 
















Figure 2.19.2: 1H-NMR 2-carboxybenzyl-α-hydroxy phosphonic acid aliphatic region 
The peaks in the regions 7.61-7.90 ppm are from the 4 hydrogens in the 2-carboxyl benzyl 
ring.  
EKKnmr022d2.010.001.1r.esp































Figure 2.19.3: 1H-NMR 2-carboxybenzyl-α-hydroxy phosphonic acid aromatic region 
2.19.2 13C-NMR022D2 



















































Figure 2.19.4: 13C-NMR 2-carboxybenzyl-α-hydroxy phosphonic acid aliphatic region 
The peak at 172.48 ppm is from the -COOH bond. The peaks in the region 124.76-146.90 ppm 
are from the carbon atoms of the phenyl ring. All the peaks of the 2-carboxy benzyl ring are 
accounted for in this region. 
EKKnmr022d2.020.001.1r.esp











































Figure 2.19.5: 13C-NMR 2-carboxybenzyl-α-hydroxy phosphonic acid aromatic region 
2.19.3 31P-NMR022D2 
The phosphorus NMR shows one peak, which occurs at 12.86 ppm, no other phosphorus 
containing compounds can be observed in the spectra. 
2.20 Mass spectrometry (TOF MS ES-) (27) 
2.20.1 MS022D1 
The peak at m/z 232 [M- H]-is from the molecular ion.  
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2.21 Synthesis of substituted benzyl-α-amino phosphonic acids 
2.21.1 Reaction mechanism 





The amine attacks the aldehyde to form a hemiaminal intermediate 31. An acid catalyst is not 
necessary for this step, an acid catalyst at this stage would only slow the reaction as the 
nucleophilic amine would be removed as a salt. Dehydration of the hemiaminal gives the imine 
32, the iminium ion loses a proton and becomes a neutral imine, this step requires an acid 
catalyst, the catalyst will make the hydroxyl group a better leaving group. The ideal pH for the 
formation of the imine should be between 4-6, at a lower pH too much of the amine is 
protonated and the rate of the first step is too slow. At a pH above 4-6, the proton concentration 
is too low to allow for the protonation of the hydroxyl leaving group in the dehydration step. 
As a result, a boron trifluoride catalyst is used to activate the aldehyde and make it a better 
electrophile. This compound 33 is then hydrolysed by a strong acid to produce the required 
aminophosphonic acid 34. 
The NMRs of the compounds 2-carboxybenzyl-α-amino phosphonic acid, 3-carboxybenzyl-
α-amino phosphonic acid and 4-carboxybenzyl-α-amino phosphonic acid showed extra peaks 
in the 31P NMRs indicating the presence of more than one phosphorus containing compound, 
hence, the compounds were impure. The 2-fluoro benzyl-α-amino phosphonic acid 34 was 
isolated as a pure compound 
2.22 NMR of 2 –fluoro benzyl-α-amino phosphonic acid (34) 
 
Figure 2.22.1: 2-fluorobenzyl-α-amino phosphonic acid with numbered carbons 
2.22.1 NMR0004B 1H NMR 
The peak in the region 4.11-4.15 ppm (2J31P - 1H = 20.0 Hz) is from the CH of the asymmetric 
carbon (C-7).  
The peaks in the regions 7.10-7.48 ppm are from the hydrogens in the 2-fluoro-benzyl ring, 
these peaks will experience fluorine coupling as the other fluorine containing compounds. The 
multiplet at 7.45-7.48 ppm is the hydrogen that is adjacent to the C-F group. The peaks in the 
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region 7.10-7.33 ppm shift upfield as the hydrogens are located further away from the 
electronegative fluorine group. 
EKKnmr004bn.010.001.1r.esp




































































































Figure 2.22.2: 1H-NMR 2-fluorobenzyl-α-amino phosphonic acid aromatic region 
2.22.2 NMR004B 13C NMR 
The doublet at 50.48-51.53 ppm (1J31P - 13C = 132.30 Hz) is from the asymmetric carbon (C-7). 
The peaks in the region 117.51-163.50 ppm are from the carbon atoms of the aromatic 2-
fluoro-benzyl ring which produce 6 unique peaks. The doublet at 161.57-163.50 ppm (1J19F - 
13C = 243.18 Hz) is from the C-F, (C-2) carbon. All the peaks of the 2-fluoro benzyl ring are 

























































Figure 2.22.3: 13C-NMR 2-fluorobenzyl-α-amino phosphonic acid aromatic region 
2.22.3 NMR0004B 31P NMR  
There is one peak that is observed at 18.20 ppm region of this spectrum, no other phosphorus 
containing compounds can be observed in the spectra. 
2.23 Mass spectrometry (EIMS+) (34) 
2.23.1 MS004B 
The Mr of the compound is 205, there is no peak for the molecular ion that can be observed in 
the spectrum. The peak at m/z 83 is from the fragment [PO3H3]+. The peak at m/z 109 is from 









3  BIOLOGICAL EVALUATION RESULTS  
3.1 Introduction  
The synthesised compounds were sent to St Andrews University and Cambridge University 
where they were tested against other protozoan parasitic diseases and the malaria parasite 
respectively. The St Andrews team tested the synthesised compounds against Trypanosomiasis 
brucei, Trypanosomiasis cruzi, Leishmania major and the HeLa cells. HeLa cells were used 
as surrogates for human cells, compounds that were active against the HeLa cells will be toxic 
against human cells as well. The compounds were tested against malaria P. falciparum parasite 
3D7 and Dd2 strains at the Sanger Institute at Cambridge University.  
Trypanosomiasis brucei is an extracellular flagellate protozoan parasite transmitted by the 
tsetse fly. The parasite has two subspecies that are responsible for two variants of the disease, 
Human African Trypanosomiasis (HAT) or sleeping sickness. Trypanosomiasis brucei 
gambiense causes the chronic form of the disease that is predominantly found in Central and 
West Africa which represents >95% of all cases (Brun. R, et al 2018). The disease affects 
primarily the poorest, rural parts of the least developed African Countries and has between 
300,000-500,000 cases annually. The currently available treatments for the Human African 
Trypanosomiasis (HAT) or sleeping sickness are inadequate and the chemotherapies such as 
Melarsoprol (Mel B) which are used for the late stages of the disease are highly toxic to 
humans. Like most parasitic diseases there, are no prophylactic treatments and efforts for a 
viable vaccine have been unsuccessful to date (Berriman. M, et al 2005). Trypanosomiasis 
brucei rhodesiense is responsible for the more acute form of the disease that is found in East 
and Southern Africa and is predominantly found in animals such as horses and cattle but can 
be transmitted to humans. Both diseases are fatal to humans if they are left untreated (Brun. R, 
et al 2018). 
Trypanosomiasis cruzi is the protozoan causative agent of the acute form of Chagas disease. 
This infection is primarily prevalent in South and Central America and can cause an acute 
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form of the disease that can be fatal, but, it can evolve into a debilitating chronic, systematic 
condition which results in death. It is estimated that Chagas disease has between 5-18 million 
cases and approximately 21,000 deaths annually. The number of cases of Chagas disease has 
been decreasing in recent years due to a concerted effort to remove the vector (triatomine bug) 
and improvements in health care management systems in areas that the disease is prevalent. 
However, since the levels of funding that have been available to enable this level of progress 
cannot be maintained indefinitely coupled with the high risk of political instability in the 
region the disease is prevalent, there are concerns that the progress that has been made will be 
reversed (El-Sayed N. M, et al 2005). Another factor that has resulted in the re-classification 
of Chagas disease by WHO as both a re-emerging and neglected tropical disease is the 
changing distribution of the disease in endemic and non-endemic countries because of 
migration. Human migration has resulted in the geographical expansion to the regions where 
the disease is now present (Conners. E. E, et al 2016). The protozoa are mainly transmitted 
through the blood sucking reduviid bugs, a sub-family of Triatominae by means of a blood 
meal. However, the disease can also be transmitted to humans by non-vectoral means such as 
blood transfusions and mother-infant transmissions (Rassi Jr. A, et al 2010). Attempts to find 
vaccines against parasitic diseases including Chagas diseases have been unsuccessful to date 
(Rassi Jr. A, et al 2010).   
Leishmania is a neglected protozoan parasite species that causes a variety of human diseases 
that are predominantly found in the tropical and sub-tropical regions of the world with 
approximately 2 million reported new cases annually in 88-98 countries across five continents 
(Sohrabi. Y, et al 2018). Leishmania major is the causative agent of the cutaneous 
leishmaniasis which is characterised by painless ulcerous lesions which can appear as isolated 
lesions or as multiple lesions (Zahirnia. A. H, et al 2018). About 20 species of the parasite 
leishmania are responsible for infections in humans and the disease is transmitted by the Sand-
fly which acts as the vector. Most of the lesions that result from leishmaniasis will self-heal 
over time but in rare cases, the lesions will not heal as a result of secondary bacterial infections. 
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The trypanosomatids family of parasitic protozoa have been shown to be sensitive to reactive 
oxygen species ROS and share some of the similar systems and enzymes that are involved in 
maintaining homeostasis regarding ROS and antioxidant balance (Leroux. A, et al 2016). The 
exact enzymatic pathways that are involved in the protection of trypanosomatids from ROS 
are not yet fully understood but, presently, it is believed that they combat oxidative stresses 
through a unique thiol redox system using trypanothione [T(SH)2] which comprises of a 
spermidine moiety linked to two glutathione molecules. Compounds such as andrographolid 
result in the rise of ROS levels and rupture of the mitochondrial membrane, releasing EndoG 
which, together with other nucleases, form a DNA-degradation complex and fragmentizes the 
parasite’s DNA leading to trypanosomatids apoptosis. Andrographolid has been shown to be 
active against the erythrocytic stages of P. falciparum with an IC50 of 9.1μM and non-toxic in 
in-vivo systems. It is not yet understood how it exerts its anti-malaria effect but it is thought 
to involve inhibition of enzymes that combat oxidative stresses within the erythrocyte 
(Banerjee. M, et al 2017). All three parasites Trypanosomiasis brucei, Trypanosomiasis cruzi 
and Leishmania major have been observed to have GDH that closely resemble bacteria, fungi 
and plants respectively, therefore, are very distinct from mammalian GDH. Leishmania major 
has two different types of GDH, an NADP-linked and an NAD-linked. The NAD dependant 
enzymes are probably localized in the mitochondrion and it is possibly these enzymes that are 
inhibited by Andrographolid. The biochemical information and the roles of the GDH in the 
parasites Trypanosomiasis brucei, Trypanosomiasis cruzi and Leishmania major is still 
deficient (Nowicki. C, et al 2008). 
The HeLa cell line is the first continuous human cancer cell line that was shown to be able to 
survive in a test tube and could be reproduced readily.  Its aggressive growth rate and the high 
survivability of the cell line after numerous replications have made it very useful to medical 
research. It is used to study the effects of a disease, develop medications and vaccines 
(Rahbari. R. et al., 2009).  The rapid growth and multiplication of the HeLa cells enabled 
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researchers at the University of Minnesota Hospital to grow the poliovirus and develop the 
vaccine (Scherer. W. F et al., 1953). 
3.1.1 London Metropolitan University (LMU) compounds submitted for 
testing 
3.1.1.1 Glutamic acid (glutamate) analogues 
There are 8 glutamate analogues supplied; compounds 6, 9, 18, 29, 30, 27 and 34. 18 and 27 
are direct analogues of glutamic acid which contain two acidic functional groups, a carboxylic 
acid (CO2H) and a phosphonic acid (-PO(OH)2) separated by three carbon atoms. Compounds 
6, 9, 29, 30 and 34 contain carboxylic acid analogues; the nitro (NO2) group in compounds 9 
and 30, and a fluorine atom (F) in compounds 6, 29 and 34. 
3.1.2 ‘Protected’ glutamic acid (glutamate) analogues  
The five compounds below contain esterified phosphonates; dibenzyl phosphonates in 
compounds 6 and 9, and diethyl phosphonates in compounds 12 and 17. These esterified 
glutamate analogues will have greater bioavailability than their phosphonic acid counterparts, 
and the two ester groups will be susceptible to hydrolysis by esterase enzymes. The 5-
membered lactone ring in compound 18 will also be very susceptible to esterase hydrolysis, 
yielding the full glutamate analogue compound 27, and hence could be considered to be a pro-
drug of compound 27. 
 




3.1.3 ‘Unprotected’ glutamic acid (glutamate) analogues  
 
Figure 3.1.2: ‘Unprotected’ Glutamic acid analogues 
3.1.4 Non-glutamic acid (glutamate) analogues  
Compounds 26 and 28 are not direct glutamic acid analogues as they contain 4- and 5 carbon atoms 
between the acidic functional groups rather than 3 carbon atoms, therefore, compounds 26 and 28 
are not expected to be active. Compounds 26 and 28 are isomers of compound 27 and hence possess 
the same molecular weights (M.Wt). 
 





3.1.5 Malaria fluorescence tests  
 
Figure 3.1.4: LMU compounds that had similar fluorescence reduction profiles of the P. falciparum strains 3D7 and Dd2 to the control compounds Chloroquine (CQ) 





3.1.6 Malaria fluorescence tests 
The fluorescence tests were carried out on both P. falciparum strains 3D7 and Dd2. The graphs 
of Chloroquine (CQ) and Dihydroartemisinin (DHA) which are known and currently utilised 
antimalarial chemotherapies were the controls of the experiment. The fluorescence unit 
decreased on addition of the drugs from around 3000 fluorescence units to about 1000 
fluorescence units. This reduction in the fluorescence indicated the reduction of the levels of 
the parasite in the cells. The graphs also show the rate of decrease of the fluorescence and the 
concentration that the reduction in fluorescence occurs. The error bar indicates the variation 
of the corresponding coordinate of the point hence, showing the standard deviation of the data 
set.  
Chloroquine(CQ) reduced the parasite levels from about 2500 to 1000 fluorescence units and 
had an EC50≈0.4 μM, Dihydroartemisinin (DHA) reduced the parasite levels from about 2500 
to 1000 fluorescence units and had an EC50 ≈1.5 nM.  
The synthesised compounds 6, 9 and 34 produced inhibition curves which had similar profiles 
to those of the control drugs, these profiles showed that there was a significant reduction in 
the parasites levels on addition of the compounds. These compounds clearly reduced the level 
of parasites in the cells. Compound 6 had an EC50 ≈17 μM, the compound reduced the 
fluorescence units from about 3000 to 2000. Compound 9 had an EC50 ≈14 μM, the compound 
reduced the fluorescence units from about 3000 to 1500. This compound showed the biggest 
reduction in fluorescence and had an inhibition curve that closely resembled the control drugs 
Chloroquine (CQ) and Dihydroartemisinin (DHA). Compound 34 had an EC50 ≈51 μM, the 
compound reduced the fluorescence units from about 3000 to 2000. Compound 9 had the best 
reduction in fluorescence of the LMU tested compounds. 
The compounds 18, 29, 30, 27, 26 and 28 did not significantly reduce the parasite fluorescence 
and the data from these compounds had large error bars indicating that any reduction was not 




Figure 3.1.5: LMU compounds that did not show similar fluorescence reduction profiles of the P. falciparum strains 3D7 and Dd2 to the control compounds Chloroquine (CQ) 
and Dihydroartemisinin (DHA). 
 
112 
3.2 Malaria growth inhibition tests 
The graphs below show the growth inhibition graphs for each compound, tested against two 
different parasite strains. These are Pf 3D7, which is sensitive to chloroquine and other 
antimalarials, and Pf Dd2, a Southeast Asian strain that is multidrug resistant (including 
chloroquine and pyrimethamine). The graphs also include DMSO titrations that reflect what 
the parasite growth would be in the presence of the equivalent amount of solvent. Most of the 
compounds were solubilised at high concentrations so that the highest DMSO level was 0.2%. 
However, the compounds 29, 30 and 34 were not very soluble and required DMSO levels of 
1% or 2%. At these DMSO concentrations, the DMSO inhibited the malaria parasites’ growth. 
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3.2.1 Compounds that inhibited malaria growth 
 





The growth inhibition of both strains of malaria by the known antimalarials chloroquine and 
pyrimethamine was the control for the experiment for which the rest of the synthesised 
compounds were compared to. Chloroquine began inhibiting the growth of the Pf 3D7 strain 
at concentrations of ≈4 nM, the rate of growth inhibition was exponential and reached ≈100% 
growth inhibition at a concentration of ≈7 nM. The drug concentration required to inhibit the 
Pf Dd2 strain was much higher than that required to inhibit the Pf 3D7 strain. Chloroquine 
began inhibiting the growth of the Pf Dd2 strain at concentrations of ≈90 nM, the rate of 
growth inhibition was exponential and reached ≈100% growth inhibition at a concentration of 
≈200 nM. Chloroquine had an EC50 ≈5 nM for the Pf 3D7 strain and an EC50 ≈100 nM for the 
Pf Dd2 strain. Compound 6 began inhibiting the growth of the Pf 3D7 strain at concentrations 
of ≈10 μM, the growth inhibition increased at a steady rate until the concentration of the 
compound reached ≈20 μM when the rate of growth inhibition became exponential and 
reached ≈100% inhibition at a concentration of ≈90 μM. Compound 6 began inhibiting the 
growth of the PfDd2 strain at a concentration of  ≈1 μM, the rate of growth inhibition increased 
with the increase in concentration of the compound up until the concentration of the compound 
reached  ≈20 μM when growth inhibition became exponential and reached ≈100% inhibition 
at a concentration of ≈90 μM. Compound 6 had an EC50 ≈40 μM for both the Pf 3D7 strain 
and the Pf Dd2 strain, from the ≈20 μM, the growth inhibition profiles of the two strains were 
similar for this compound.  
Compound 9 began inhibiting the growth of the Pf 3D7 strain at a concentration of ≈3 μM, the 
rate of growth inhibition generally increased with increase in concentration of the compound 
until the concentration of the compound reached ≈11 μM when growth inhibition became 
exponential up until ≈90% inhibition was reached at a concentration of ≈30 μM. The rate of 
growth inhibition began to level off and reached ≈100% inhibition at a concentration of ≈90 
μM. Compound 9 began inhibiting the growth of the Pf Dd2 strain at a concentration of ≈2 
μM, the rate of growth inhibition generally increased with increase in concentration of the 
compound until the concentration of the compound reached ≈20 μM, when rate of growth 
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inhibition became exponential and reached ≈100% inhibition at a concentration of ≈90 μM. 
Compound 9 had an EC50 ≈25 μM for the Pf 3D7 strain and an EC50 ≈50 μM for the Pf Dd2 
strain. Compounds 6 and 9 were the compounds that showed the best malaria parasite growth 
inhibition activity. The strain Pf 3D7 is two times more sensitive to the compound 9 than the 
strain Pf Dd2. As a comparison with chloroquine, the difference in sensitivity between the Pf 
3D7 strain and the Pf Dd2 strain is greater than 2-fold, which is not surprising due to the 
presence of the mutant Pf CRT (P. falciparum chloroquine resistance transporter) gene in 
malaria parasite strain Pf Dd2, which makes this strain (Pf Dd2) chloroquine resistant. The 
strains Pf 3D7 and Pf Dd2 had the same level of sensitivity to the compound 6 suggesting that 
the strain Pf Dd2 has not developed any resistance to this compound yet.  
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3.2.2 Compounds that did not have malaria growth inhibition 
 
Figure 3.2.2: LMU compounds that did not have malaria growth inhibition for the P. falciparum strains 3D7 and Dd2. 
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The compounds 18, 29, 30, 27, 26 and 28 did not have any significant malaria parasite growth 
inhibition activity. The parasite growth inhibition rate for these compounds was similar to the 
parasite growth inhibition rate of DMSO therefore, the effects of the compounds cannot be 
distinguished from that of the DMSO control.  
While both the parasite fluorescence and the parasite growth inhibition tests come to the same 
general conclusion with regards to the compounds with antimalarial activity, the growth 
inhibition tests contain more details and are more accurate. This is because the growth 
inhibition tests include the DMSO controls which are not included in the fluorescence tests. 
The DMSO controls helped eliminate compound 34, since some of the compounds were 
readily soluble in DMSO, whereas others required a higher concentration of DMSO, and thus 
the final DMSO concentration in some cases is quite high (1-2%) at the highest drug 
concentration. At these levels of DMSO concentration (1-2%), the DMSO interfered with the 
tests. Compound 34 were considered active in the fluorescence test but the growth inhibition 
test results suggest that any activity these compounds had was due to the high DMSO 
concentrations rather than the compounds. Another advantage of the growth inhibition test 
was that it distinguished activity of the compounds between the two different parasite strains, 
the Pf Dd2 strain which is multidrug resistant (including chloroquine and pyrimethamine) and 
the Pf 3D7 which is still drug-sensitive.  
The compounds that showed activity against the malaria parasites were the substituted benzyl-
α-hydroxy phosphonate dibenzyl esters compounds 6 and 9. The dibenzyl esters enabled the 
compounds 6 and 9 to diffuse through the cell membranes and get into the cells. The 
corresponding unprotected phosphonic acids which are compounds 29 and 30 were not soluble 
in DMSO so they were unable to enter the cells and thus did not have any activity. The 
compounds that showed activity had the -α-hydroxyl group meaning the hydroxyl functional 




3.2.3 Activity of compounds against these parasites 

















30.4 ± 2.1 106.3 ± 5.3 30.4 ± 1.1 37.3 ± 2.1 
 
26.7 ± 1.7 >250 16.5 ± 1.0 112 ±18 
 
>250 >250 >250 >250 
 
>250 >250 >250 >250 
 
>250 >250 >250 >250 
 
>250 >250 >250 161.2 ± 5.9 
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Table 13: Activity of tested compounds against T. brucei, T. cruzi, L. major and HeLa 
 
Table 14: Activity of tested compounds against T. brucei, T. cruzi, L. major and HeLa 
Compound 










>250 >250 >250 >250 
 
>250 >250 130.2 ± 6.8 148.6 ± 7.1 
 
>250 >250 124.8 ± 6.2 >250 
 
125.9 ± 13.5 110.6 ±5.0 68.7 ± 2.7 91.7 ± 3.8 
 
57.4 ± 3.1 139.7 ± 6.2 81.9 ± 3.9 114.3 ± 5.9 
 





Of all the compounds tested, 2-nitrobenzyl-α-hydroxy dibenzyl phosphonate (9) was most 
active against L. major; EC50 =16.5 ± 1.0 μM and T. brucei; EC50 =26.7 ± 1.7 μM. 1,2-benzyl-
γ-lactone diethyl phosphonate (18), 2-fluorobenzyl-α-hydroxy phosphonic acid (29), 2-
nitrobenzyl-α-hydroxy (30) phosphonic acid and 2-fluorobenzyl-α-amino phosphonic acid 
(34) were inactive against all the parasites. Any compound that had activity greater than EC50 
>100.00 μM were also considered inactive. Compounds that inhibited HeLa cells were 
cytotoxic to human cells since HeLa cells were used as surrogates for human cells. Compound 
6 had the lowest concentration required to inhibit HeLa cells and is therefore the most toxic. 
The concentrations of compound 6 that were required to inhibit T. brucei and L. major was 
relatively similar to the concentrations required to inhibit the HeLa cells, suggesting that its 
cytotoxicity might be the reason for its potency. Crucially, compound 9 required an EC50 
>100.00 μM (112 ±18 μM) to inhibit the HeLa cells indicating that the compound would 
potentially be well tolerated and not cytotoxic to human cells.  
The low logP values (-0.8-1.72) of the compounds, 26, 27, 28, 29, 30 and 34, indicate that 
these compounds are hydrophilic and will not be absorbed into the cells therefore, they have 
low bioavailability limiting their efficacy against all the parasites the compounds were tested 
against. The compound 18 has a LogP value (2.33) that would allow it to be absorbed into the 
Compound 










0.0016 ± 0.0001    
 
 2.16 ± 0.32   
 
  5.31 ± 0.29  
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cells, but, its low solubility limits its availability for absorption and therefore restricts its 
activity against all parasitic agents. The benzyl esters 6 and 9 have a high LogP values (3.2 
and 5.34 respectively) indicating that they are lipophilic, allowing for the absorption of an 
adequate concentration of the compound to the site of action, stimulating a response in both 
the antimalarial tests and the tests against other parasites. The substituted benzyl-dialkyl-
phosphates, 19, 20 and 21 have logP values (2.58, 5.45 and 2.47 respectively) indicating that 
they are lipophilic allowing for the absorption of an adequate concentration of the compound 
to the site of action, but, these compounds had moderate or no action against the parasites T. 
brucei, T. cruzi, L. major. The inactivity of these compounds 19, 20 and 21 against the parasite 
T. cruzi cannot be attributed to inadequate bioavailability of the compounds but to other factors 
such as but not limited to poor structure activity relationship (SAR). The compounds that 
showed activity had the -α-hydroxyl group meaning the hydroxyl functional group in this 
position is important for the structure activity relationship (SAR). Compounds 19, 20 and 21 
have the -α- methylene instead of the -α-hydroxyl and they are the phosphates version instead 
of the phosphonate version of the compounds, thus, they are not direct glutamic acid analogues 
as they contain 5- and 6 bonds between the acidic functional groups rather than 3 bonds, 










Table 15: Summary of the tested compounds and the parasites they are active against 
Compound Name  Compound Code Parasite active against  
2-Fluorobenzyl-α-hydroxy 
dibenzyl phosphonate 




9 T. brucei, L. major 
1,2-benzyl-γ-lactone diethyl 
phosphonate 








































4 CONCLUSION AND FUTURE WORK  
The final substituted benzyl- α-hydroxy phosphonic acids; 3-nitrobenzyl-α-hydroxy 
phosphonic acid and 4-nitrobenzyl-α-hydroxy phosphonic acid had extremely poor yields 
(5.2% and 7.7%) respectively and both compounds were insoluble in different NMR solvents 
or solvent mixtures (DMSO, DMSO-D2O, D2O-NaOD, methanol). Attempts to dissolve these 
compounds in other alcohols; ethanol, isopropanol and butanol proved to be just as 
unsuccessful. These compounds were insoluble even when they were ionised with up to 11M 
deuterated sodium hydroxide. Synthesis of the substituted benzyl-α-methylene phosphonates 
must be repeated using carefully controlled conditions; various temperatures (-20 °C, 0 °C, 
RT or 50 °C) and equimolar amounts of CDI and NaH. Careful controlling of the conditions 
would prevent the 1,2-Brook intramolecular phosphonate-phosphate rearrangement from 
occurring. The formation of the substituted benzyl- phosphates resulted in the failure of the 
hydrolysis reactions carried out on the compounds (19-25) which may be explained by the 
rapid hydrolyses of the phosphates to yield phosphoric acid which was then converted into 
insoluble polyphosphates upon workup, in particular, during rotary evaporation of the highly 
acidic 6M HCl solutions employed. An alternate method to make the hydroxyl a good leaving 
group, and enable substitution by hydride, requires the sulfonylation of the alcohol O-H with 
methanesulfonyl chloride (mesyl chloride) in the presence of pyridine (Clayden. J, et al, 
Organic Chemistry, second edition 2001). The resulting methanesulfonate esters are good 
leaving groups that are readily displaced by nucleophiles, including hydride anions. 
Alternate methods of producing phosphonic acids from their precursors could improve the 
purity and yields of these phosphonic acids. These methods include, catalytic hydrogenolysis 
of the dibenzyl phosphonates precursors with a Palladium on charcoal catalyst. 
Hydrogenolysis of diallyl phosphonates with Wilkinson catalyst (ClRh(PPh3)3) has been 
reported to be an efficient way to produce phosphonic acids (Sevrain. M. C, et al, 2017).  
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Further work is needed to attempt to improve the solubility, purity and yields of the substituted 
benzyl-α-amino phosphonic acids. substituted benzyl-α-amino phosphonic acids were 
sparingly soluble in different NMR solvents therefore, the peaks in the 13C-NMR for these 
compound were too small to be identified. Zooming the spectra led to the peaks being covered 
up by the NMR background or “noise”. The 31P-NMRs for most of the synthesised   benzyl-
α-amino phosphonic acids showed more than one peak suggesting the products were impure.  
Alternate synthetic routes to make these compounds have been proposed and are yet to be 
attempted. It is hoped that these synthetic routes will produce products with fewer 
intermediates and therefore improve the purity and yields of the final product. The proposed 
synthetic route would involve a modified version of the Kamijo method, using CDI and azide 
anion (N3-). The resulting substituted benzyl-α-azide diethyl phosphonate can then be 
converted to its respective substituted benzyl-α-amine diethyl phosphonate by reduction of the 
azide to an amine by catalytic hydrogenation over Palladium catalyst or by 
triphenylphosphines in what is known as the Staudinger reaction or by lithium aluminium 
hydride (LiAlH4) or by sodium borohydride (NaBH4) in methanol. Dealkylation of the diethyl 
phosphonate groups before reduction of the azide with NaBH4 in methanol would prevent 
reactivity of the sensitive amine functional group. This method could be most optimal as the 
reduction of the azide to the amine will occur easily on the resulting azidophosphonic acids. 
The dealkylation of diethyl phosphonate groups containing amines, amino acids or peptides 
requires mild conditions to avoid reactivity with these functional groups. Me3SiBr can also be 
used to dealkylate diethyl phosphonates with an amine or peptide functionalized groups. Other 
mild conditions, that may be able to dealkylate amine containing diethyl phosphonates include, 
the use of a combination of trimethylsilyl trifluoromethanesulfonate (TMS-OTf) as a silylating 
agent, trifluoroacetic acid (TFA) as the acidic reagent, and dimethylsulfide (DMS) and m-
cresol to avoid side reactions associated with the generation of carbocations under the 
deprotecting conditions. The role of DMS is to encourage or ‘push’ the acidolytic cleavage of 
the protecting group, the cleavage reaction is driven by the addition of H+ (a hard acid - Lewis 
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acids that are only weakly polarizable.) to the oxygen atom (a hard base) of the protecting ester 
group and the nucleophilic attack of the sulphur atom (a soft base) on the electron deficient 
carbon of the leaving group (soft acid). The reaction involves the cooperative action of the soft 
nucleophile and the hard electrophile on the substrate (push-pull mechanism). This reagent 
mixture is a milder form of acidic deprotection than using 6M HCl (Kiso. Y, et al 1979). The 
rate of reaction is depended on the nature of the attacking soft nucleophiles, hence, the 
cleavage reaction becomes more favourable in the order; thioanisole > dimethyl sulfide > 
ethanedithiol - phenol > anisole. More importantly, thioanisole has been found to be an 
alkyating agent at the moderate acidity of the SN2 reaction conditions and thus may not be an 
optimal weak base (Tam. J. P, et al, 1986). Since dimethyl sulfide (DMS) does not possess 
this alkylating property, it is a more suitable choice as a weak base for the SN2 studies. (Kiso. 
Y, et al 1980). This method has been reported as having the potential to generate phosphonic 
acids from sensitive amine, amino acids or peptides containing diethyl phosphonates (Tam. J. 
P, et al, 1986, Sevrain. M. C, et al, 2017).   
 
Figure 3.2.1: Proposed alternate reaction mechanism to synthesise substituted benzyl-α-amino 
phosphonic acid 
Monophosphonates and monophosphates drug development has long been hindered by their 
inherent poor drug likeness properties and poor in vivo stability. This is due to 
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monophosphonates and monophosphates being negatively charged at physiological pH which 
results in them having poor bioavailability (Hecker. S, et al 2008). Consequently, these 
compounds have poor in vivo stability which increases the chances of their dephosphorylation 
in the blood stream and their inefficient transportation into the cells leading to these molecules 
having low concentrations at the target site (Mehellou. Y, et al 2017). The optimization of these 
compounds to include the application of prodrug strategies that have been successfully applied 
in the development of some anti-viral and anti-cancer drugs could improve their effectiveness 
(Thornton. P, et al 2016). Phosphonic acids are rarely found in drug candidate moieties, 
despite the potential that the functional group could provide unique binding interactions with 
a target enzyme or receptor. Similarly, organophosphonates are rarely incorporated into drug 
candidates despite the common appearance of phosphates in nucleosides, proteins, lipids and 
carbohydrates in nature.  
Much of the reluctance to use these groups in pharmaceutical compounds stems from the 
reasons mentioned above which are;  
1) Their negative charge at physiological pH   
2) The inability for these molecules to achieve high concentrations at the target site due 
to poor oral bioavailability and or cell penetration 
3) Their instability in most biological fluids. 
Despite these shortcomings a number of nucleoside phosphates and their phosphonate 
analogues have proven to be extremely important anti-cancer and antiviral therapies. 
Consequently, phosphonate containing drugs are increasingly being explored in other 
therapeutic areas. In order to achieve adequate oral bioavailability and intracellular delivery 
of phosphonates and similar compounds, pro drug strategies have to be employed (Hecker. S, 
et al 2008). Theoretically, a diester is the simplest derivative of a phosphonic acid that is 
uncharged at physiological pH, that allows for the phosphonic acid to be transported into cells, 
the simplest diester being dimethylesters. Such dialkylesters are simple to synthesise and do 
not offer any stereogenic issues at the phosphorus position but, even with the emergence of 
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organophosphonate hydrolases in bacteria that have probably been driven by the widespread 
use of phosphorus-based insecticides, these dialkylesters are surprisingly stable in mammalian 
systems. Some phosphonate benzyl esters have shown more promise, but they tend to be 
cleaved and release their phosphonic acids too slowly to be of value. Simple dialkylesters are 
sometimes unrecognised by esterases and do not undergo the necessary bioconversion to their 
phosphonic acid therefore, simple dialkylesters could not function as prodrugs. However, 
diphenyl esters have performed better, being able to release the free phosphonic acid in vivo 
at high concentrations as well as having physiochemical properties that were more conducive 
to pharmaceutical formulation.  (Wiemer. A, et al 2016). A successful phosphonate prodrug 
has to be able to: 
1) Survive the gastrointestinal tract and be absorbed into the systemic circulation 
2) Remain intact long enough for it to be distributed in specific cell tissues.  
The lack of adequate aqueous and metabolic stability greatly limits the effectiveness of many 
prodrug classes (Hecker. S, et al 2008).   
Prodrug strategies for phosphates and phosphonates seek to achieve passive diffusion through 
the cell membrane by masking the negative charges until the compounds are inside the cell. 
Therefore, the main considerations include what type of derivative will be used and what 
process or processes will be entrusted to remove the protecting groups once the prodrug is in 
the cell. The most common type of derivatives used to protect phosphates and phosphonates 
are esters and amides, yet, even after the initial choice, there are other concerns to be addressed 
and a variety of solutions and options that could be attempted. Some of these choices and 
options when attempting to mask two negative charges include using the same group 
(symmetrical diesters) or two different groups (unsymmetrical diesters). Different groups 
(unsymmetrical diesters) create a stereogenic centre at the phosphorus which brings its own 
challenges and benefits. Different groups may allow more flexibility in terms of the cleavage 
steps. These concerns have to be addressed in determining whether the ester or amide routes 
are taken. Another prodrug route that is gaining popularity is mixed ester-amides which have 
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shown to have an advantage in terms of both the cleavage step and organ or tissue targeting. 
Determination of the enzymes within the cells that will be involved in the regeneration of the 
desired drug adds to the complexity of the design as there are several different types of 
enzymes that could do the job. These include but are not limited to esterases, amidases, 
phosphatases, or even a redox process. Some reported prodrugs rely on thermal and 
photochemical cleavage and are available through photodynamic therapy approaches 
(Wiemer. A, et al 2016).  
Work on the development of ProTides prodrug strategies began in the late 1980s with the 
objective of masking the oxygen atoms of phosphate groups in nucleoside monophosphate 
analogues so that they are neutral at physiological pH and hence have a better uptake into cells. 
ProTide prodrug strategy development process took at least two decades and was divided into 
six phases which began with utilising simple alkyl groups and evolved into utilising the 
intelligent masking of the phosphate with aryl groups and amino acid esters, which can be 
cleaved off inside the intact cells. The masking groups that were utilised in the phases of 
ProTide development strategies were (Mehellou. Y, et al 2017): 
1) Simple alkyl groups 
2) Alkyloxy and haloalkyloxy phosphoramidates 
3) Phosphorodiamidates 
4) Lactyl-Derived systems 
5) Diaryl phosphates 
6) Aryloxy phosphoramidates, referred to as ProTides 
ProTide phosphoramidate prodrugs are an example of a prodrug strategy that has been 
successfully utilised to deliver monophosphates and monophosphonates which Prof. Chris 
McGuigan began developing at University College London, UK between 1987-1990 and 
continued later on at Cardiff University, UK (Mehellou. Y, et al 2009). This approach involves 
the masking of the negative charges of the phosphate or phosphonate with an aryl motif and 
an amino acid ester group. In the cell, the nucleoside monophosphates/monophosphonates 
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analogue is released in two enzymatic steps. The first step is initiated by esterases which cleave 
the ester motif. Under physiological pH (< 7.4), the unmasked, negatively charged carboxyl 
group carries out a nucleophilic attack on the phosphate or phosphonate group. The second 
enzyme is a phosphoramidase-type enzyme which cleaves the P-N bond of this metabolite 
resulting in the release of the nucleoside analogue monophosphate or monophosphonate. This 
particular prodrug approach has been utilised in the development of sofosbuvir and tenofovir 
alafenamide and is being applied to numerous other nucleoside ProTides entering clinical 
trials. ProTide approach has been applied to the experimental anti-cancer medicine NUC-
1031, which is being developed by NuCana Biomed Ltd for treatment of lung, ovary, breast, 
colon and pancreatic cancers (Thornton. P, et al 2016). This ProTide, NUC-1031, was found 
to be effective against cancers that were resistant to the parent therapeutic nucleoside 
gemcitabine. The ProTide was more successful than the parent drug because:  
1) It was able to overcome active cellular uptake mechanisms that limit the efficacy of 
gemcitabine as the prodrug is more lipophilic and enters cells through passive 
diffusion. 
2) Overcame the dependency on the essential first activation step by deoxycytidine 
kinase, which is downregulated in some cancers. 
3) The delivery of gemcitabine monophosphate limited the deamination of the cytosine 
nucleobase, which generates the inactive uracil nucleos(t)ide metabolite, a process 
that reduces the efficacy of gemcitabine. 
Similar such improvements have been noticed in the efficacy of other compounds that this 
ProTide prodrug strategy has been applied to. This includes GS-5734, later renamed 
Remdesvir, an anti-HCV C-nucleotide ProTide developed by Gilead Science that has shown 
promising results as a potential treatment for the Ebola virus. GS-5734 (Remdesvir), has been 
reported to be a broad spectrum anti-viral agent that has exhibited potent activity against a 
variety of RNA viruses including COVID-19 (Mehellou. Y, et al 2017; Eastman. R. T, et al 
2020). Improvements have been noticed to the efficacy of the ProTide stampidine, a prodrug 
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of the anti-HIV reverse transcriptase inhibitor nucleoside stavudine and thymectacin, a phenyl 
L-alanine methyl ester prodrug of the therapeutic nucleoside brivudine (BVdU) which is used 
to treat herpes zoster (shingles) (Thornton. P, et al 2016).  
As with the diester, ProTides that consist of symmetrical diamidates avoid any phosphorus 
stereochemistry issues, diamidates have been shown to produce compounds that have good 
cellular activity. Additionally, preparation of symmetrical bisamidates from the symmetrical 
diesters has been reported (Wiemer. A, et al 2016).  Another example of 
phosphate/phosphonate prodrug strategy would be to target a specific organ or tissue; such is 
the case of the HepDirect approach. The HepDirect aims to design prodrugs that will 
predominantly be metabolised in the liver via the cytochrome P450 (CYP450) enzymes, hence 
achieving liver-targeted drug delivery. In this approach, the two negative charges of the 
phosphate/phosphonate are masked by the formation of a phenyldioxaphosphinane oxide. This 
prodrug will then undergo oxidation in the liver by the CYP3A enzymes. This prodrug 
approach has been extensively utilised in the design of hepatitis infections therapeutics. 
HepDirect prodrug compounds include pradefovir used in the treatment of HBV and MB07133 
which is used for the treatment of hepatocellular carcinoma.  
There are some phosphate/phosphonate prodrugs that are based on monoesters. In these 
prodrugs, one of the negative charge is masked and the other is left free. These mono 
phosphonate/phosphate esters are a form of lipid phosphoconjugates that have been inspired 
by the natural occurring lysophosphatidylcholine. These conjugates have been shown to 
benefit from active uptake mechanisms in the intestine resulting in higher oral bioavailability 
(Thornton. P, 2016). Another useful variant of monoesters is the cyclic monoester which offers 
unique opportunities as a prodrug as it is based on upon an intramolecular cyclization (Wiemer. 
A, et al 2016). A case in point for this type of prodrug is the hexadecyloxypropyl (HDP) 
monoester prodrugs which are thought to be metabolised in vivo by phospholipases such as 
phospholipase C. This approach has led to the development of two nucleotide prodrugs in 
clinical development, brincidofovir a prodrug of the antiviral cidofovir referred to as CMX-
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001 is dosed orally unlike its parent compound and is potent against a range of viruses that 
include adenoviruses, smallpox, cytomegalovirus (CMV), papillomavirus, polyomavirus and 
orthopoxviruses. CMX-157 is an alkoxyalkyl monoester of the clinically used nucleoside 
phosphonate tenofovir which is >300 times more active than the parent drug and is active 
against the major subtypes of the HIV-1 virus (Thornton. P, 2016). Work with azidothymidine 
(AZT) monophosphates reported that combining a monoester with a phosphoramidate led to 
unexpectedly good cellular potency. In the case of (AZT), the lactate derived aryloxy 
phosphoramidates led to a highly efficient prodrug (Wiemer. A, et al 2016).   
As demonstrated by the HepDirect prodrugs, in addition to masking the phosphorus moieties 
to allow for diffusion across cell membranes, by careful selection of the protecting groups and 
the processes entrusted to remove the protecting groups, prodrugs can impart cell type and 
tissue type specificity which can impact the distribution of the free drug. This will determine 
where and when the free drug can be released. The majority of current prodrugs require 
enzymatic cleavage prior to release of the free drug that leads to biological function. This 
enzymatic cleavage especially one that relies on simple esterases and other simple chemical 
decomposition methods such as early cycloSal compounds or thermolytic prodrugs offer the 
least amount of control over tissue distribution. Ester based prodrugs are prone to non-specific 
esterases which are found in most cells as well as in the blood. Therefore, when attempting to 
use esters as the protecting groups in a prodrug, it might be more effective to prioritize esterase 
specificity over improved oral absorption. Phosphoramidates have proven to have more 
plasma stability than acyloxyalkyl ester compounds which allows them to have selectivity as 
to the enzymes that decompose them thereby giving them cell and or tissue specificity. 
Diamidates or aryloxy amino acid amidates appear to be released through an initial enzymatic 
hydrolysis of the amino acid carboxyl ester by the enzyme carboxypeptidase Y (cathepsin A) 
or carboxylesterase (I), hence, they will target cells and or tissues that express these enzymes. 
Improvements in the cell and tissue specificity of prodrugs would be greatly aided by a detailed 
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understanding of the chemistry and the biological systems and pathways involved (Wiemer. 




Figure 3.2.2: The structures of ProTide and phosphate ester prodrugs that have been discussed in this 
section(Thornton. P, et al 2016, Mehellou. Y, et al 2017). 
 ProTide versions of the synthesised target compounds could have improved efficacy. There 
are three different strategies that can be applied to generate ProTides which are: 
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1) The coupling of a nucleoside with a diarylphosphite followed by subsequent oxidative 
amination,  
2)  The coupling of the nucleoside with a phosphorochloridate reagent, 
3)  Coupling of an amino acid to a nucleoside aryl phosphate (Mehellou. Y, 2017)  
The proposed synthetic route would be applied for the synthesis of PfGDH inhibitor-ProTides. 
This synthetic route would work well with the α-methylene derivatives but the α-OH 
compounds would need protecting with a silyl protecting group like t-butyl-dimethylsilyl 
((CH3)3C-Si-(CH3)2) which can be readily cleaved using tetrabutylammonium fluoride in 
acetonitrile (Bu4N+F-/CH3CN). 
 
Figure 3.2.3: Proposed  reaction scheme for the synthesis of PfGDH-inhibitor ProTides 
Two promising future targets are 1-amino-cyclopropane-1,2-dicarboxylic acid and 4-
methylene glutamic acid (Ezquerra. J, et al 1994), these are fascinating glutamate analogues 
with the potential to act as irreversible inhibitors of Pf GDH. The cyclopropane ring in the 
compound 46 and the alkene in the compound 44 are reactive and vulnerable to nucleophilic 
attack. The cyclopropane ring is highly strained due to the 60° bond angles within the ring 
(angle strain) which is not ideal; this weakens the C-C bonds in the ring making cyclopropane 
very reactive. As a result, the cyclopropane ring will be susceptible to being cleaved open by 
the Pf GDH in an attempt to relieve the angle strain, thereby, potentially making this analogue 
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an irreversible inhibitor of the Pf GDH enzyme. This is an interesting idea and hopefully it can 
be explored further by future projects. These compounds will then be submitted for anti- 
malarial testing to determine their activity. 
 













5.1 General experimental  
All reactions requiring the use of dry conditions were carried out under an atmosphere of 
nitrogen. Stirring was by internal magnetic follower unless otherwise stated. All reactions were 
monitored by TLC and organic phases extracted were dried with either anhydrous magnesium 
sulfate or sodium sulfate. Thin layer chromatographic analysis was carried out using Merck 
aluminium-backed plates coated with silica gel 60 F254.  Components were visualised using 
ultraviolet light/iodine staining. The compounds that needed further purification were purified 
by flash column chromatography, the silica gel used was Merck 60 (230-400 mesh).  All 
solvents that needed to be dry such as acetonitrile and tetrahydrofuran (THF) were distilled 
from calcium hydride. The chemicals that were used in this project were acquired from Fisher 
Scientific, Sigma-Aldrich, British Oxygen Company (BOC) and Alfa Aesar. The purity of the 
compounds was not determined and thus unknown.  
Infrared spectra were recorded on an Agilent Technologies Cary 630 FT-IR 
spectrophotometer. Elemental analysis was recorded on a Thermo Scientific Flash 2000 
Organic Elemental Analyser. Mass spectra was carried out using Agilent Micromass Q-TOF 
premier Tandem Mass Spectrometer from Micromass utilising electrospray or a Thermo 
Electron Corporation DSQ utilising electron impact. Melting points were determined using 
open glass capillaries on a Stuart Scientific SMP3 apparatus and are uncorrected.  
1H-NMR, 13C-NMR and 31P- NMR were recorded on a Bruker Avance AV500 spectrometer 
operating at 500 MHz for proton, 126 MHz for carbon and 202 MHz for phosphorus. Chemical 
shifts (H and C) are quoted as parts per million downfield from 0. The multiplicity of a 1H-
NMR signal is designated by one of the following abbreviations: s = singlet, d = doublet, t = 
triplet, q = quartet, quin = quintet, sept = septet, br. = broad and m = multiplet. Coupling 




5.2 Synthesis of substituted benzyl-α-hydroxy phosphonates 
 
Figure 5.2.1: Synthesis of substituted benzyl-α-hydroxy  phosphonates general reaction scheme 
To a round bottomed flask, dibenzyl phosphite/diethyl phosphite was added to a solution of a 
substituted benzaldehyde dissolved in dichloromethane (15 cm3). Basic alumina (Al2O3) 10 
molar excess was added to the reaction mixture and the resultant mixture was stirred and left 
to stand for 48 hours. The resultant mixture was washed with dichloromethane (120 cm3) and 
the basic alumina catalyst was removed under reduced pressure. The filtrate was concentrated 
under reduced pressure and the resultant residue was washed with a mixture of hexane/diethyl 
ether (1:1, 20 cm3) four times and dried under reduced pressure for an hour. 
5.2.1 2-Fluorobenzyl-α-hydroxy dibenzyl phosphonate (6) 
 
2-Fluorobenzaldehyde (1.0 cm3, 9.5 mmol), dibenzyl phosphite (2.1 cm3, 9.5 mmol) and 10 M 
basic alumina (Al2O3) (9.70 g, 95.1 mmol). Product; colourless solid (2.51 g, 98%). Rf = 0.64; 
(EtOAc:Hex; 8:2), mp 79-81°C; νmax/cm-1 3238 (O-H), 1212 (P=O), 963 (P-O), 996 (C-F); 
δH(500 MHz, CDCl3) 4.94 – 5.06 (4 H, m, 2 × PhCH2O), 5.52-5.56 (2 H, m, CH-OH, CH-
OH), 6.96- 6.98 (1 H, m ArH), 7.11 (1 H, t, J 7.6, ArH), 7.17-7.18 (2 H, m, 2 × ArH), 7.21-
7.28 (9 H, m, 9 × ArH), 7.71 (1 H, tt, J 5.0, ArH). δC(126 MHz, CDCl3) 63.94 (1 C, dd, J, 
163.5, 2.7,  CH-OH), 68.24 (1 C, d, J 7.3, Ph-CH2), 77.06 (1 C, d, J 6.4, Ph-CH2-), 115.03 (1 
C, dd, J 21.8, 8.8, ArC), 124.26–124.36 (2 C, m, 2 × ArC), 127.73 (4 C, d, J 1.8, 4 × ArC), 
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128.23-128.26 (3 C, m, 3 × ArC), 128.41 (4 C, d, J 3.6, 4 × ArC), 129.08 (1 C, t, J 3.6, ArC), 
129.63 (1 C, dd, J 8.2, 2.7, ArC), 135.99 (1 C, dd, J 5.9, 2.3, ArC), 159.65 (1 C, dd, J 255.78, 
7.3, ArCF). δP(202 MHz, CDCl3) 22.19 (1 P, d, J 6.06). m/z (EI+): 262 ([(PhCH2O)2PO]+, 
34%), 180 ([C6H4CHPO3C]+, 30), 171 ([FC6H4CPO2]+, 73), 122.87 ([FC6H4CO]+, 38), 91 
([C7H7]+, 100).  
5.2.2 3-Cyanobenzyl-α-hydroxy dibenzyl phosphonate (7) 
 
3-Formylbenzonitrile (0.51 g, 3.9 mmol), dibenzyl phosphite (0.86 cm3, 3.9 mmols). Basic 
alumina (Al2O3) (4.0 g, 39.2 mmol). Product; colourless solid (0.57 g, 54%). Rf  = 0.46; 
(EtOAc:Hex; 8:2), mp 81-83 °C; νmax/cm-1  3234 (OH), 2233 (CN), 1220 (P=O), 978 (P-O); 
δH(500 MHz, CDCl3) 4.94-5.05 (4H, m, 2×PhCH2), 5.08 (1 H, dd, J 10.0, 5.0, CH-OH), 5.44 
(1 H, t, J 5.0, CH-OH-), 7.21-7.33 (10 H, m, 10 × ArH), 7.35 (1 H, d, J 10.0, ArH), 7.54 (1 H, 
dd, J 10.0, 5.0, ArH).  7.61 (1 H, d, J 10.0, ArH), 7.64 (1 H, s, ArH). δC(126 MHz, CDCl3) 
68.63 (1 C, d, J 7.6, PhCH2), 69.14 (1 C, d, J 6.3, PhCH2) 70.02 (1 C, d, J 160.02, CH-OH), 
112.24 (1 C, d, J 2.5, ArC), 118.60 (1 C, s, ArCN), 128.04-128.76 (11 C, m, 11× ArC), 128.86 
(1 C, d, J 5.0, ArC), 130.64 (1 C, d, J 5.0, ArC), 131.43 (1 C, d, J 3.8, ArC), 131.51 (1 C, d, J 
2.5, ArC), 135.56 (1 C, t, J 8.8, ArC), 138.12 (1 C, s, ArC).  δP(202 MHz, CDCl3) 21.39 (1 P, 
s). m/z (EI+): 394 ([M]+, 17%), 302 ([M-C7H7]+, 100), 262 ([(PhCH2O)2PO]+, 100), 222 
([CNC6H4CH(OH)PO2(CH)2]+, 5), 196 ([CNC6H4CH(OH)PO2 ]+, 87), 180 
([CNC6H4CH(OH)PO]+, 100), 107 ([C6H4CH(OH)]+, 100), 92 ([C7H7]+, 100). 
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5.2.3 3-Nitrobenzyl-α-hydroxy dibenzyl phosphonate (8) 
 
3-Nitrobenzaldehyde (1.51 g, 10.0 mmol), dibenzyl phosphite (2.2 cm3, 10.0 mmol), basic 
alumina (Al2O3) (10.2 g, 100 mmol). Product; colourless solid (2.64 g, 64%). Rf  = 0.33; 
(EtOAc:Hex; 1:1), mp 115-117 °C; νmax/cm-1  3190 (OH), 1529 (NO2), 1290 (P=O), 1000 (P-
O); δH(500 MHz, CDCl3) 4.78 (1 H, t, J 5.0, CH-OH), 5.02-5.05 (4 H, m, 2 × PhCH2-), 5.15 
(1 H, dd, J 10.0, 5.0, CH-OH), 7.23-7.32 (10 H, m, 10 × ArH), 7.43 (1 H, t, J 7.5, ArH), 7.71 
(1 H, d, J 5.0, ArH), 8.11 (1 H, d, J 10.0, ArH), 8.28 (1 H, d, J 5.0, ArH). δC(126 MHz, CDCl3) 
68.76 (1 C, d, J 7.6, PhCH2), 69.16 (1 C, d, J 7.6, PhCH2) 70.21 (1 C, d, J 158.76, CH-OH), 
122.11 (1 C, d, J 5.0, ArC), 122.93 (1 C, d, J 2.5, ArC), 128.09-128.77 (10 C, m, 10 × ArC), 
129.03, (1 C, d, J 2.5, ArC), 133.03 (1 C, d, J 6.3, ArC), 135.55 (1 C, dd, J 8.8, 2.5, ArC), 
138.51 (1 C, d, J 2.5, ArC), 148.13 (1 C, d, J 2.5, ArC). δP(202 MHz, CDCl3) 21.17 (1 P, s). 
m/z (EI+): 414.11 ([M]+, 10%), 322 ([M-PhCH2]+, 100), 262 ([(PhCH2O)2PO]+, 100),  216 
([NO2C6H4CH(OH)PO2]+, 100),  91 ([C7H7]+, 100). 
5.2.4 2-Nitrobenzyl-α-hydroxy dibenzyl phosphonate (9)  
 
2-Nitrobenzaldehyde (1.51 g, 10.0 mmol) dibenzyl phosphite (2.2 cm3, 10.0 mmol). Basic 
alumina (Al2O3) (10.2 g, 100 mmol). Product; colourless solid (2.68 g, 65%). Rf  = 0.53; 
(EtOAc:Hex; 1:1), mp 108-110 °C; νmax/cm-1 3178 (OH), 1529 (NO2), 1290 (P=O), 985 (P-O);  
δH(500 MHz, CDCl3) 4.63 (1 H, t, J 5.0, CH-OH), 4.94-5.06 (4 H, m, 2×PhCH2), 6.32 (1 H, 
 
140 
dd, J 15.0, 10.0, CH-OH), 7.16-7.31 (10 H m, 10 × ArH), 7.40-7.44 (1 H, m, ArH), 7.61 (1 H, 
t, J 10.0, 5.0, ArH), 7.93 (1 H, d, J 10.0, ArH), 7.96 (1 H, d, J 5.0, ArH). δC (126 MHz, CDCl3) 
66.14 (1 C, d, J 158.76, CH-OH), 68.75 (1 C, d, J 6.3, PhCH2), 69.06 (1 C, d, J 6.3, PhCH2), 
124.88 (1 C, d, 1.3, ArC), 127.91-128.60 (11 C m, 11 × ArC), 128.97 (1 C, d, J 3.8, ArC), 
132.51 (1 C, s, ArC), 133.45 (1 C, d, J 3.8, ArC), 135.70 (1 C, dd, J 5.0, 3.8, ArC), 147.49 (1 
C, d, J 6.3, ArC). δP(202 MHz, CDCl3) 21.59 (1 P, s). m/z (EI+): 414 ([M]+, 4%), 306 ([M-
PhCH2O]+, 3), 262 ([(PhCH2O)2PO]+, 33), 216 (NO2C6H4CH(OH)PO2+, 57), 91 ([C7H7]+, 
100). 
5.2.5 4-Cyanobenzyl-α-hydroxy dibenzyl phosphonate (10). 
 
4-Cyanobenzaldehyde (1.01 g, 7.7 mmol), dibenzyl phosphite (1.7 cm3, 7.7 mmol), Basic 
alumina (Al2O3) (7.9 g, 77.5 mmol). Product; colourless solid (3.15 g, 96%). (data for this 
compound agreed with Pawar, V., et al 2006) Rf = 0.41; (EtOAc:Hex; 1:1), mp 115-117 °C; 
νmax/cm-1  3227 (OH), 2229 (CN), 1223 (P=O), 978 (P-O); δH (500 MHz, CDCl3) 4.89-5.03 (4 
H, m, 2 × PhCH2), 4.18 (1 H, br, CH-OH), 5.10 (1 H, d J 10.0, CH-OH-), 7.20-7.37 (10 H, m, 
10 × ArH), 7.47 (2 H, d, J 10.0, 2 × ArH).  7.54 (2 H, d, J 10.0, 2 × ArH). δC(126 MHz, CDCl3) 
68.69 (1 C, d, J 7.6, PhCH2), 69.04 (1 C, d, J 7.6, PhCH2), 70.49 (1 C, d, J 157.50, CH-OH), 
111.72 (1 C, d, J 2.5, ArC), 118.70 (1 C, s, ArCN), 127.55-128.68 (10 C, m, 10 × ArC), 128.76 
(2 C, d, J 3.8, 2 × ArC), 131.90 (2 C, d, J 2.5, 2 × ArC), 135.55 (1 C, dd, J 5.0, 3.8, ArC), 




5.2.6 4-Nitrobenzyl-α-hydroxy dibenzyl phosphonate (11). 
 
4-Nitrobenzaldehyde (1.51 g, 10.0 mmol), dibenzyl phosphite (2.2 cm3, 10.0 mmol). Basic 
alumina (Al2O3) (10.2 g, 100 mmol). Product; green solid (2.38 g, 58%). (data for this 
compound agreed with Pogatchnik, D., et al 1997). Rf  = 0.33; (EtOAc:Hex; 1:1), mp 105-108 
°C; νmax/cm-1  3275 (OH), 1521 (NO2), 1223 (P=O), 970 (P-O); δH(500 MHz, CDCl3) 4.60 (1 
H, br, CH-OH), 4.92-5.05 (4 H, m, 2 × PhCH2), 5.15 (1 H, dd, J 10.0, 5.0, CH-OH), 7.21-7.34 
(10 H, m, 10 × ArH), 7.52 (2 H, d, J 10.0, 2 × ArH), 8.09 (2 H, d, J 10.0, 2 × ArH). δC(126 
MHz, CDCl3) 68.78 (1 C, d, J 7.6, PhCH2), 69.15 (1 C, d, J 7.6, PhCH2), 70.45 (1 C, d, J 
157.50, CH-OH), 127.69 (1 C, s, ArC), 127.73 (1 C, s, ArC), 128.10-128.70 (8 C, m, 8 × ArC), 
128.78 (1 C, s, ArC), 128.83 (1 C, s, ArC), 135.55 (1 C, t, J 3.9, ArC), 143.45 (1 C, d, J 2.5, 
ArC), 147.58 (1 C, d, J 3.8, ArC). δP(202 MHz, CDCl3) 21.03 (1 P, s). m/z (TOF ES+): 414 
([M+H]+, 18%). 
5.3 Synthesis of substituted benzyl-α-hydroxy diethyl phosphonates 
5.3.1 2-Fluorobenzyl-α-hydroxy diethyl phosphonate (12) 
 
2-Fluorobenzaldehyde (2.0 cm3, 19.2 mmol) diethyl phosphite (2.4 cm3, 18.6 mmol) basic 
alumina Al2O3 (19.38 g, 190 mmol). Product; colourless solid (2.37 g, 47%). Rf  = 0.26; 
(EtOAc:Hex; 8:2), mp 58-61 °C; νmax /cm-1 3216 (OH), 2985 (C-H), 1205 (P=O), 1019 (C-F), 
963 (P-O); δH(500 MHz, CDCl3) 1.22 (3 H, t, J 7.5, CH3), 1.31 (3 H, t, J 7.5, CH3), 4.00-4.16 
(4 H, m, 2 × CH2O-), 4.65 (1 H, t, J 5.0, CH-OH), 5.40 (1 H, dd, J 15.0, 10.0, CH-OH), 7.04 
(1 H, dd, J 10.0, 10.0, ArH), 7.19 (1 H, t, J 7.5, ArH), 7.27-7.30 (1 H, m, ArH), 7.69 (1 H, tt, 
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J 10.0, 5.0, ArH). δC(126 MHz, CDCl3), 16.34-16.37 (2 C, m, 2 × CH3), 63.15 (1 C, d, J 7.6, 
CH2O), 63.59 (1 C, d, J 7.6, CH2O-), 63.87 (1 C, dd, J 162.54, 3.8, CH-OH), 115.02 (1 C, dd, 
J 21.42, 2.5, ArC), 124.26 (1 C, t, 6.3, ArC), 124.41 (1 C, dd, 13.86, 2.5, ArC), 128.87 (1 C, 
t, J 16.4, ArC), 129.62 (1 C, dd, J 8.82, 2.5, ArC), 158.74 (1 C, d, J 7.6, ArC), 160.71 (1 C, 
dd, J 248.22, 7.6, ArC).  δP(202 MHz, CDCl3) 21.35 (1 P, d, J 6.06). m/z (EI+):  262 ([M]+, 
66%), 245 ([M-OH]+, 2), 233 ([M-(CH3)2]+, 9), 217 ([M-OCH2CH3]+, 3) 186 
([FC6H4CHPO(OCH2)]+, 7), 172 ([M-(OCH2CH3)2]+, 2) 153 
([CH(OH)PO(OCH2CH3)(OCH2)]+, 14) 138 ([FC6H4CP]+, 32), 97 ([C6H4F]+, 32) 77 ([C6H4]+, 
25). 
5.3.2 3-Cyanobenzyl-α-hydroxy diethyl phosphonate (13). 
 
3-Cyanobenzaldehyde (0.5 g, 3.8 mmol) diethyl phosphite (0.5 cm3, 3.9 mmol), basic Alumina 
catalyst (Al2O3) (3.99 g, 39.1 mmol). Product; colourless solid (0.84 g, 82%). (data for this 
compound agreed with Pandi. M, et al 2012, 99%). Rf  = 0.15; (EtOAc:Hex; 8:2), mp 68-72 
°C; νmax /cm-1  3208 (OH), 2985 (C-H),  2225 (CN), 1230 (P=O), 963 (P-O); δH(500 MHz, 
CDCl3) 1.26 (3 H, t, J 5.0, CH3), 1.30 (3 H, t, J 5.0, CH3), 4.10- 4.16 (4 H, m, 2 × CH2O-), 
5.09 (1 H, dd, J 10.0, 5.0, CH-OH), 5.55 (1 H, t, J 5.0, CH-OH), 7.47 (1 H, t, J 10.0, ArH), 
7.60 (1 H, dd, J 10.0, ArH), 7.72 (1 H, d, J 10.0, ArH), 7.84 (1 H, s, ArH). δC(126 MHz, 
CDCl3) 16.36-16.43 (2 C, m, 2 × CH3), 63.26 (1 C, d, J 7.6, CH2O), 63.93 (1 C, d, J 7.6, CH2O-
) 69.74 (1 C, d, J 161.28, CH-OH), 112.30 (1 C, s, ArC), 118.76 (1 C, s, ArCN), 128.88 (1 C, 
d, J 2.5, ArC), 130.54 (1 C, d, J 5.0, ArC), 131.41-131.47 (2 C, m, 2 × ArC), 138.71 (1 C, d, 
J 2.5, ArC). δP (202 MHz, CDCl3) 20.56 (1 P, s). m/z (EI+): 269 ([M]+, 10%), 241 ([M-
(CH3CH2)]+, 5), 224 ([M-(OCH2CH3)]+, 8) 180 ([M-(OCH2CH3)2] +, 5), 147 ([CNC6H4CHP]+, 
5), 102 ([C6H4CN]+, 36).  
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5.3.3 4-Cyanobenzyl-α-hydroxy diethyl phosphonate (14).  
 
4-Cyanobenzaldehyde (0.5 g, 3.8 mmol) diethyl phosphite (0.5 cm3, 3.9 mmol) basic alumina 
(3.9 g, 38.2 mmol). Product; colourless solid (0.872 g, 85%). (data for this compound agreed 
with Pandi. M, et al 2012, 99%). Rf  = 0.18, (EtOAc:Hex; 8:2), mp 69-73 °C; νmax /cm-1 3234 
(OH), 2950 (C-H),  2229 (CN), 1255 (P=O), 1030 (P-O); δH(500 MHz, CDCl3) 1.26 (3 H, t, J 
7.5, CH3), 1.28 (3 H, t, J 7.5, CH3), 4.05-4.15 (4 H, m, 2 × CH2O), 5.05-5.08 (1 H, m, CH-
OH), 5.11 (1 H, dd, J 10.0, 5.0, 1 × CH-OH), 7.61 (2 H, d, J 5.0, 2 × ArH), 7.66 (2 H, d, J 
10.0, 2 × ArH). δC(126 MHz, CDCl3) 16.35-16.43 (2 C, m, 2 × CH3), 63.25 (1 C, d, J 7.6, 
CH2O), 63.89 (1 C, d, J 6.3, CH2O-) 70.15 (1 C, d, J 157.5, CH-OH), 111.62 (1 C, d, J 2.5, 
ArC), 118.76 (1 C, d, J 1.3, ArCN), 127.55 (2 C, d, J 5.0, 2 × ArC), 131.92 (2 C, d, J 2.5, 2 × 
ArC). δP(202 MHz, CDCl3) 20.43 (1 P, s). m/z (EI+): 269 ([M]+, 55%), 252. ([M-OH]+, 7), 241 
([M-(CH3CH2)]+, 12), 224 ([M-(OCH2CH3)]+, 57) 180 ([M-(OCH2CH3)2]+, 15), 147 
([CNC6H4CHP+], 3). 
5.3.4 3-Nitrobenzyl-α-hydroxy diethyl phosphonate (15).  
 
3-Nitrobenzaldehyde (1.51 g, 10.0 mmol), diethyl phosphite (1.4 cm3, 10.9 mmol), basic 
alumina (Al2O3) (10.2 g, 100 mmol). Product; colourless solid (2.74 g, 95%). (data for this 
compound agreed with Goldeman. W, et al 2006, 79%). Rf  = 0.17; (EtOAc:Hex; 1:1), mp 76-
79 °C; νmax/cm-1  3234 (OH), 2981 (C-H), 1540 (NO2), 1350 (NO2), 1208 (P=O), 1019 (P-O); 
δH(500 MHz, CDCl3) 1.27 (3 H, t, J 5.0, CH3), 1.31 (3 H, t, J 7.5, CH3), 4.09- 4.17 (4 H, m, 2 
× CH2O-), 5.18 (1 H, dd, J 15.0, 10.0, CH-OH), 5.55 (1 H, t, J 10.0, CH-OH), 7.53 (1 H, t, J 
7.5, ArH), 7.82 (1 H, d, J 10.0, ArH), 8.17 (1 H, d, J 10.0, ArH), 8.43 (1 H, d, J 5.0, ArH). 
δC(126 MHz, CDCl3) 16.36-16.43 (2 C, m, 2 × CH3), 63.33 (1 C, d, J 6.3, CH2O), 63.99 (1 C, 
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d, J 7.6, CH2O-) 69.86 (1 C, d, J 160.02, CH-OH), 122.05 (1 C, d, J 5.0, ArC), 122.81 (1 C, 
d, J 2.5, ArC), 129.01 (1 C, d, J 2.5, ArC), 133.04 (1 C, d, J 5.0, ArC), 139.33 (1 C, d, J 1.3, 
ArC) 148.22 (1 C, d, J 2.5, ArC).  δP(202 MHz, CDCl3) 20.36 (1 P, s). m/z (EI+): 290 ([M]+, 
20%), 272 ([M-(OH)]+, 3), 244 ([M-(OCH2CH3)]+, 3), 152 ([-CHPO(OCH2CH3)2]+, 10), 138 
([-O2NC6H4CH)]+, 100), 77 ([C6H4]+, 42).   
5.3.5 4-Nitrobenzyl-α-hydroxy diethyl phosphonate (16). 
 
4-Nitrobenzaldehyde (1.51 g, 10.0 mmol) diethyl phosphite (1.4 cm3, 10.9 mmol) basic 
alumina (Al2O3) (10.2 g, 100 mmol). Product; brown solid (2.83 g, 98%). (data for this 
compound agreed with Pandi. M, et al 2012, 98%). Rf = 0.17; (EtOAc:Hex; 1:1), mp 75-78 
°C; νmax /cm-1 3231 (OH), 2990 (C-H), 1521 (NO2), 1350 (NO2), 1238 (P=O), 1019 (P-O);  
δH(500 MHz, CDCl3) 1.26-1.31 (6 H, m, 2 × CH3), 4.09-4.15 (4 H, m, 2 × CH2O), 5.18 (1 H, 
d, J 10.0, CH-OH), 5.11 (1 H, br, CH-OH), 7.68 (2 H dd, J 2.5, 2× ArH), 8.23 (2 H, d, J 2.5, 
2× ArH). δC(126 MHz, CDCl3) 16.36-16.45 (2 C, m,  2 × CH3), 63.32 (1 C, d, J 7.6, CH2O-), 
63.99 (1 C, d, J 7.6, CH2O-) 70.11  (1 C, d, J 157.50, CH-OH), 123.33 (2 C, d, J 2.5, 2 × ArC), 
127.66 (2 C, d, J 6.3, 2× ArC), 142.20 (1 C, d, J 2.5, ArC), 147.53 (1 C, d, J 2.5, ArC). δP(202 
MHz, CDCl3) 20.20 (1 P, s). m/z (EI+): 290 ([M]+, 100%), 272 ([M-(OH)]+, 10) 262 ([M-
(CH3CH2)]+, 1), 244 ([M-(OCH2CH3)]+, 13), 228 ([M-O(OCH2CH3)]+, 1), 152 ([-CH-
PO(OCH2CH3)2]+, 6.3), 138 ([-O2NC6H4-CH)]+, 100), 77 ([C6H4]+, 45). 
5.3.6 2-Nitrobenzyl-α-hydroxy diethyl phosphonate (17). 
 
2-Nitrobenzaldehyde (1.51 g, 10.0 mmol), diethyl phosphite (1.3 cm3, 10.1 mmol), basic 
alumina (Al2O3) (10.2 g, 100 mmol). Product; colourless solid (2.16 g, 74%). (data for this 
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compound agreed with Pandi. M, et al 2012, 97%). Rf  = 0.28; (EtOAc:Hex; 1:1), mp 109-111 
°C; νmax /cm-1 3231 (OH), 2985 (C-H), 1532 (NO2), 1350 (NO2), 1205 (P=O), 1015 (P-O); 
δH(500 MHz, CDCl3) 1.21 (3 H, t, J 7.5, 1 × CH3), 1.27 (3 H, t, J 7.5, 1 × CH3), 4.07- 4.16 (4 
H, m, 2 × CH2O), 5.40 (1 H, t, J 7.5, CH-OH), 6.29 (1 H, dd, J 15.0, 10.0, CH-OH), 7.46 (1 
H, t, J 7.5, ArH), 7.69 (1 H, t, J 7.5, ArH), 7.99-8.01 (2 H, m, 2 × ArH). δC(126 MHz, CDCl3) 
16.17 (1 C, d, J 6.3, CH3), 16.27 (1 C, d, J 5.0, CH3), 63.35 (1 C, d, J 7.6, CH2O), 64.10 (1 C, 
d, J 7.6, CH2O-), 65.62 (1 C, d, J 161.28, CH-OH), 124.72 (1 C, d, J 3.8, ArC), 128.40 (1 C, 
d, J 3.8, ArC) 128.87 (1 C, d, J 5.0, ArC), 132.90 (1 C, s, ArC), 133.34 (1 C, d, J 3.8, ArC), 
147.61 (1 C, d, J 6.3, ArC). δP(202 MHz, CDCl3)  20.58 (1 P, s). m/z (ES+): 290 ([M]+, 35%), 
272 ([M-(OH)]+, 3), 244 ([M-(OCH2CH3)]+, 6), 152 ([-CH-PO(OCH2CH3)2]+, 21), 138 ([O2N- 
C6H4-CH)]+, 73), 77 [C6H4]+, 84). 
5.3.7 Attempted synthesis of 2-cyanobenzyl-α-hydroxy diethyl 
phosphonate (18) (data for this compound agreed with Menear. K. 
A, et al 2012, US008247416B2). 
 
2-Cyanobenzaldehyde (1.5g, 11.5 mmol), diethylphosphite (1.5cm3, 11.7 mmol), basic 
Alumina (Al2O3) (11.68 g, 114.5 mmol) (silica gel 70 g, hexane: ethyl acetate, 1:1, 200 cm3, 
2:8, 400 cm3, 1:9, 400 cm3). Product; yellow solid, (0.7990g, 25.84%). (data for this compound 
agreed with Menear. K. A, et al 2012). Rf  = 0.5, (EtOAc:Hex; 9:1), mp 58-61 °C; νmax /cm-1  
2936 (C-H), 1771 (C=O), 1290 (P=O), 1268 (C-O), 996 (P-O); δH(500 MHz, CDCl3) 1.09 (3 
H, t, J 7.5, CH3), 1.41 (3 H, t, J 7.5, CH3), 3.87- 3.88 (1 H, m, CH2O-), 3.99-4.02 (1 H, m, 
CH2O), 4.28- 4.32 (2 H, m, CH2O-), 5.69 (1 H, d, J 15.0, -CH-), 7.60 (1 H, t, J 7.5, ArH-γ-
lactone), 7.75 (1 H, t, J 7.5, ArH-γ-lactone), 7.78 (1 H, d, J 5.0, ArH-γ-lactone), 7.95 (1 H, d, 
J 10.0, ArH-γ-lactone). δC(126 MHz, CDCl3)  16.19 (1 C, d, J 6.3, CH3), 16.46 (1 C, d, J 6.3, 
CH3), 64.01 (1 C, d, J 6.3, CH2O-), 64.30 (1 C, d, J 6.3, CH2O), 75.56 (1 C, d, J 165.06, CH), 
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123.66 (1 C, d, J 2.5, ArC-γ-lactone), 125.33 (1 C, d, J 3.8, ArC-γ-lactone), 125.97 (1 C, d, J 
1.3, ArC-γ-lactone), 129.81 (1 C, d, J 1.3, ArC-γ-lactone), 134.42 (1 C, d, J 2.5, ArC-γ-
lactone), 143.83 (1 C, d, J 3.8, ArC-γ-lactone), 169.77 (1 C, d, J 2.5, C=O-γ-lactone). δP(202 
MHz, CDCl3) 13.80 (1 P, s). m/z (TOF ES+): 271 ([M+H]+, 35%), 243 ([M-CH2CH3]+, 21), 
133 ([C8H5O2]+, 18), 293 ([M+ Na+]+, 100). 
5.4 Conversion of the substituted benzyl-α-hydroxy to the 
substituted benzyl-α-methylene-phosphonates and substituted 
benzyl-dialkyl-phosphates 
 
Figure 5.4.1: Synthesis of substituted benzyl-dialkyl phosphonates general reaction scheme 
To a round bottomed flask containing, substituted benzyl-α-hydroxy- phosphonate and 1, 1 
carbonyl diimidazole were dissolved in dry acetonitrile/ dry tetrahydrofuran (THF) (10 cm3). 
Sodium hydride was added and the reaction mixture stirred for 2 hours at room temperature. 
After which, dichloromethane (70 cm3) and water (30 cm3) were added to the reaction mixture 
and the organic layer was extracted. The organic layer was then washed with dilute 
hydrochloric acid (10 cm3), saturated sodium hydrogen carbonate (NaHCO3) (6.0 cm3), water 
(6.0 cm3), extracted and dried over MgSO4. The crude reaction mixture was concentrated 
under reduced pressure and purified with column chromatography. 
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5.4.1 2-Fluorobenzyl-dibenzyl phosphate (19) 
 
2-Fluorobenzyl-α-hydroxyl-dibenzyl phosphonate (0.70 g, 2.0 mmol), 1,1 carbonyl 
diimidazole (0.29 g, 1.8 mmol), sodium hydride (NaH) (0.25 g, 10.4 mmol) (silica gel; 40 g, 
hexane: ethyl acetate, 1:1, 400 cm3).  Product; oil, (0.18 g, 24%). Rf  = 0.67; (EtOAc: Hex; 
1:1); υmax/cm-1 2925 (C-H), 1272 (P=O), 1000 (P-O); δH(500 MHz, CDCl3) 5.03 (4 H, d, J 
10.0, 2 × PhCH2O-), 5.09 (2 H, d, J 5.0, CH2), 7.04 (1 H, t, J 10.0, ArH), 7.11 (1 H, t, J 7.5, 
ArH), 7.26-7.35 (12 H, m, 12 × ArH). δC(126 MHz, CDCl3) 63.14 (1 C, t, J 5.0, CH2-), 69.34 
(2 C, d, J 6.3, 2 × PhCH2O-), 115.40 (1 C, d, J 20.16, ArC), 124.21 (1 C, d, J 3.8, ArC), 126.98-
127.95 (3 C, m, 3 × ArC), 128.53-128.56 (6 C, m, 6 × ArC), 130.31 (1 C, d, J 3.8, ArC), 130.47 
(1 C, d, J 7.6, ArC), 135.67 (1 C, d, J 7.6, ArC), 160.59 (1 C, d, J 249.48, ArCF). δP(202 MHz, 
CDCl3) -0.51 (1 P, s). m/z (EI+): 387 ([C21H20O4PF]+, 47%), 277 ([M-C6H4FCH2]+, 80%) 199 
([(C6H5CH2O)(OCH2)PO-CH2-]+, 71), 91 ([C6H4CH2]+, 100). 
5.4.2 2-Fluorobenzyl-diethyl phosphate (20)  
 
2-Fluorobenzyl-α-hydroxyl-diethyl phosphonate (0.6 g, 2.4 mmol), 1, 1 carbonyl diimidazole 
(0.37 g, 2.3 mmol), Sodium hydride (NaH) (0.28 g, 11.5 mmol) (silica gel; 40 g, hexane: ethyl 
acetate, 1:1, 400 cm3). Product; oil (0.52 g, 93%). (data for this compound agreed with 
Pallikonda. G, et al 2015, 92%). Rf  = 0.43; (EtOAc:Hex; 1:1); νmax/cm-1 2985 (C-H), 1268 
(P=O), 1011 (C-F), 974 (P-O); δH(500 MHz, CDCl3) 1.32 (6 H, t, J 7.5, 2 × CH3), 4.07-4.15 
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(4 H, m, 2 × CH2O-), 5.14 (2 H, d, 10.0, CH2), 7.08 (1 H, t, J 7.5, ArH), 7.16 (1 H, t, J 7.5, 
ArH), 7.32-7.36 (1 H, m, ArH), 7.47 (1 H, t, J 5.0, ArH). δC (126 MHz, CDCl3) 16.01 (1 C, s, 
CH3), 16.07 (1 C, s, CH3), 62.88 (1 C, t, J 5.0, CH2), 63.88 (1 C, s, CH2O-), 63.93 (1 C, s, 
CH2O), 115.40 (1 C, d, J 21.42, ArC), 123.35 (1 C, dd, J 22.68, 7.6, ArC), 124.23 (1 C, d, J 
3.8, ArC), 130.30 (1 C, d, J 3.8, ArC), 130.44 (1 C, d, J 8.8, ArC), 160.65 (1C, d, J 249.48, 
ArCF). δP(202 MHz, CDCl3) -0.60 (1 P, s). m/z (EI+): 262 ([C11H16PO4F]+, 34%), 233 ([M-
CH3CH2]+, 11%), 214 ([CH2O)(CH3CH2O)-POCH2C6H4]+, 6), 186 ([FC6H4CPO3]+, 30), 109 
([FC6H4CH2]+, 60). 
5.4.3 3-Cyanobenzyl-diethyl phosphate (21)  
 
3-Cyanobenzyl-α-hydroxy diethyl phosphonate (0.55 g, 2.03 mmol), 1:1 carbonyl diimidazole 
(0.36 g, 2.0 mmol), Sodium hydride (NaH) (0.34 g, 14.2 mmol) (silica gel; 50 g, hexane: ethyl 
acetate, 1:1, 400 cm3 and hexane: ethyl acetate, 2:8, 200cm3). Product; oil (0.07 g, 14%). Rf = 
0.14; (EtOAc:Hex; 1:1); νmax/cm-1 2985 (C-H), 2233 (CN), 1458 (CH2), 1268 (P=O), 1022 (P-
O); δH(500 MHz, CDCl3) 1.34 (6 H, t, J 7.5, 2 × CH3), 4.11-4.16 (4 H, m,  2 × CH2O-), 5.09 
(2 H, d, 10.0, CH2), 7.50 (1 H, t, J 7.5, ArH), 7.62-7.64 (2 H, m,  2 × ArH), 7.69 (1 H, d, J 5.0, 
ArH), δC(126 MHz, CDCl3)  16.09 (1 C, s, CH3), 16.14 (1 C, s, CH3), 64.16 (1 C, s, CH2O), 
64.21 (1 C, s, CH2O-), 67.51 (1 C, s, CH2), 112.85 (1 C, s, ArC), 118.42 (1 C, s, ArCN), 129.47 
(1 C, s, ArC), 130.94 (1 C, s, ArC), 131.79 (1 C, s ArC), 132.02 (1C, s, ArC) 137.75 (1C, d, J 
7.6, ArC). δP(202 MHz, CDCl3) -0.49 (1 P, s). m/z (EI+) 270 ([C11H16PO4CN]+, 48%), 256 
([M-CH3]+, 1), 241([M-(CH3CH2)]+, 5), 226 ([M-(CH3)2CH2]+, 1), 213 
([C6H4CH2PO(OCH2)(OCH2CH3)]+, 33), 197 ([C6H4CH2PO(OCH2)2]+, 1), 116 
([CNC6H4CH2]+, 100), 89 ([C7H7]+, 43). 
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5.4.4 4-Cyanobenzyl-diethyl phosphate (22)  
 
4-Cyanobenzyl diethyl phosphonate (0.76 g; 3.0 mmol), 1, 1 carbonyl diimidazole (0.46 g, 3.0 
mmol), sodium hydride (NaH) (0.34 g, 15 mmol) (silica gel; 40 g, hexane: ethyl acetate, 1:1, 
400 cm3).  Product; oil (0.43 g, 59%). Rf  = 0.5; (EtOAc:Hex; 1:1); νmax /cm-1   2985 (C-H), 
2233 (CN), 1264 (P=O), 1019 (P-O); δH(500 MHz, CDCl3) δ/ppm 1.33 (3 H, t, J 7.5, CH3), 
1.34 (3 H, t, J 7.5, CH3), 4.12-4.16 (4 H, m, 2 × CH2O-), 5.13 (2 H, d, 5.0, CH2), 7.51 (2 H, d, 
J 10.0, 2 × ArH), 7.69 (2 H, d, J 5.0, 2 × ArH). δC(126 MHz, CDCl3) 16.10 (1 C, s, CH3), 
16.15 (1 C, s, CH3), 64.16 (1 C, s, CH2O-), 64.21 (1 C, s, CH2O), 67.64 (1 C, d, J 6.3, CH2), 
112.16 (1 C, s, ArC), 118.53 (1 C, s, ArCN), 127.55 (2 C, s, 2 × ArC), 132.41 (2 C, s, 2 × 
ArC), 141.34 (1 C, d, J 7.6, ArC). δP(202 MHz, CDCl3) -0.49 (1 P, s). m/z (EI+): 270 
([C11H16PO4CN]+, 39%), 241 ([M-CH3CH2]+, 4), 228 ([C6H4CH2PO(OCH2CH3)2]+, 24), 213 
([C6H4CH2PO(OCH2)(OCH2CH3)]+, 24), 137 ([PO(OCH2CH3)2]+, 67) 116 ([CNC6H4CH2]+, 
100), 102 ([CNC6H4]+, 29). 
5.4.5 3-Nitrobenzyl-diethyl phosphate (23)  
 
3-Nitrobenzyl-α-hydroxy diethyl phosphonate (1.00 g, 3.7 mmol), 1:1 carbonyldiimidazole 
(0.56 g, 3.5 mmol), sodium hydride (NaH) (0.42 g, 17.4 mmol) (silica gel; 60g, hexane: ethyl 
acetate, 1:1, 400 cm3 and hexane: ethyl acetate, 2:8, 200 cm3). Product; oil (0.44 g, 47%). Rf 
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= 0.19; (EtOAc:Hex; 1:1); νmax/cm-1 2985 (C-H), 1532 (NO2), 1354 (NO2), 1264 (P=O), 1022 
(P-O); δH(500 MHz, CDCl3) 1.34 (3 H, t, J 7.5, CH3), 1.35 (3 H, t, J 7.5, CH3), 4.12-4.18 (4 
H, m, 2 × CH2O), 5.17 (2 H, d, 5.0, CH2), 7.57 (1 H, t, J 7.5, ArH), 7.73 (1 H, d, J 10.0, ArH), 
8.21 (1 H, d, J 5.0, ArH), 8.27 (1 H, s, ArH). δC(126 MHz, CDCl3) 16.10 (1 C, s, CH3), 16.15 
(1 C, s, CH3), 64.17 (1 C, s, CH2O-), 64.21 (1 C, s, CH2O), 67.42 (1 C, d, J 5.0, CH2), 122.36 
(1 C, s, ArC), 123.33 (1 C, s, ArC), 129.66 (1C, s, ArC), 133.36 (1 C, s, ArC), 138.31 (1 C, d, 
J 7.6, ArC), 148.42 (1 C, s, ArC). δP(202MHz, CDCl3) -0.46 (1P, s). m/z (EI+):  290 
([C11H16PO6N]+, 39%), 272 ([O2NC6H4CH2OPO(OCH2CH)(OCH)]+, 57), 244 ([M-
(CH3CH2O)]+, 22), 216 ([O2NC6H4CH2PO(OCH2)]+, 16), 186 ([O2NC6H4CH2PO]+, 12), 153 
([CH2PO(OCH2CH3)2]+, 26) 136 ([O2NC6H4CH2]+, 100), 90 ([C6H4CH2]+, 34).  
5.5 Substituted benzyl- benzyl-α-methylene phosphonates 
 
Figure 5.5.1: Synthesis of substituted benzyl- phosphates general reaction scheme 
5.5.1 4-Nitrobenzyl-α-methylene-dibenzyl phosphonate (24) 
 
4-Nitrobenzyl-α-hydroxy dibenzyl phosphonate (1.00 g, 2.4 mmol), 1:1 carbonyldiimidazole 
(0.39g; 2.42 mmol), NaH (0.30 g, 12.6 mmol). (silica gel; 51 g, hexane: ethyl acetate, 6:4, 400 
cm3). Product; oil (0.24 g, 25%). Rf = 0.70; (EtOAc:Hex; 1:1); Elemental data Anal. Expected. 
C22H20PO3N; C; 63.48%, H; 5.04%, N; 3.53%. Found. C; 63.62%, H; 4.95%, N; 3.61%; 
νmax/cm-1 2925 (C-H), 1514 (NO2), 1346 (NO2), 1246 (P=O), 974 (P-O); δH(500 MHz, CDCl3) 
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3.21 (2 H, d, J 25.0, CH2), 4.89-5.02 (4 H, m, 2 × PhCH2O), 7.25-7.26 (4 H, m, 4 × ArH), 7.28 
(1 H, d, J, 5.0, ArH), 7.30 (1 H, d, J, 5.0, ArH), 7.33-7.34 (6 H, m, 6 × ArH.), 8.06 (1 H, d, J 
10.0, ArH). δC(126 MHz, CDCl3) 34.33 (1 C, d, J 137.34, CH2), 67.97 (1 C, s, 1 × PhCH2O), 
68.02 (1 C, s, PhCH2O-), 123.62 (2 C, d, J 2.5, 2 × ArC), 128.15 (4 C, s, 4 × ArC), 128.65-
128.67 (6 C, m, 6 × ArC), 130.61 (1 C, s, ArC), 130.66 (4 C, s, 4 × ArC), 135.87 (1 C, d, J 
5.0, ArC), 139.09 (1 C, d, J 10.08, ArC), 146.97 (1 C, d, J 3.8, ArC). δP(202 MHz, CDCl3) 
25.85 (1 P, s). m/z (EI+): 398 ([M]+, 1%), 306 ([M-C6H5CH2]+, 80), 260 ([(C6H5CH2O)2 PO)]+, 
1), 180 [(C6H5CH2O)(OCH2)PC]+, 90), 136 ([O2NC6H4CH2]+, 12), 91 [C6H4CH2]+, 100). 
5.5.2 4-Nitrobenzyl-α-methylene-diethyl phosphonate (25). 
 
4-Nitrobenzyl-α-hydroxy diethyl phosphonate (1.00 g, 3.5 mmol), 1:1 carbonyldiimidazole 
(0.56 g, 3.47 mmol), sodium hydride NaH (0.42 g, 17.4 mmol) (silica gel; 60g, hexane: ethyl 
acetate, 1:1, 400 cm3 and hexane: ethyl acetate, 4:6, 200 cm3). Product; oil (0.19 g, 20%). (data 
for this compound agreed with Döpp, D., (2000), (57%). Rf = 0.33; (EtOAc:Hex; 1:1), 
Elemental data Anal. Expected. C12H16PO3N; C; 48.35%, H; 5.86%, N; 5.13%. Found: C; 
48.45%, H; 6.00%, N; 5.27%; νmax/cm-1 2985 (C-H), 1521 (NO2), 1346 (NO2), 1246 (P=O), 
1022 (P-O); δH(500 MHz, CDCl3) 1.27 (6 H, t, J 7.5, 2 × CH3), 3.25 (1 H, d, 20.0, CH2-), 4.03-
4.09 (4 H, m, 2 × CH2O-), 7.47 (1 H, d, J 5.0, ArH), 7.49 (1 H, d, J 5.0, ArH), 8.18 (2 H, d, J 
5.0, 2 × ArH). δC(126 MHz, CDCl3) 16.36 (1 C, s, CH3), 16.40 (1 C, s, CH3), 34.01 (1 C, d, J 
137.34, CH2), 62.44 (1 C, s, CH2O), 62.49 (1 C, s, CH2O-), 123.72 (1 C, d, J 3.8, ArC), 130.61 
(1 C, s, ArC), 130.66 (1 C, s, ArC), 139.73 (2 C, d, J 8.8, 2 × ArC), 147.05 (1 C, s, ArC). 
δP(202 MHz, CDCl3) 24.61 (1 P, s). m/z (EI+): 274 ([M]+, 41%), 246 ([M-CH3CH2]+, 3), 215 
([O2NC6H4CH2PO2CH2]+, 14), 187 ([O2NC6H4CH2PO]+, 16), 153 [CH2PO(OCH2CH3)2]+, 6), 
136 ([O2NC6H4CH2]+, 35), 124 [O2NC6H4]+, 71), 89 ([C6H4CH2]+,76), 78 ([C6H4]+, 31). 
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5.6 Synthesis of substituted benzyl–α-hydroxyl phosphonic acids 
from their diethyl phosphonates precursors. 
 
Figure 5.6.1: Acid hydrolysis of the substituted benzyl-α-hydroxy diethyl phosphonates general reaction 
scheme 
Substituted benzyl-α-hydroxy diethyl phosphonate was dissolved in 6M hydrochloric 
acid/concentrated acetic acid (100 cm3) in a round bottomed flask. The resultant mixture was 
heated under reflux for 30 hours. After which, the resultant mixture was concentrated under 
reduced pressure. The resultant product was then washed three times with diethyl ether (20 
cm3) and dried under reduced pressure for an hour. 
5.7 Synthesis of substituted benzyl–α-hydroxy phosphonic acids 
from their diethyl phosphonates by acid hydrolysis 
5.7.1 3-Carboxy benzyl-α-hydroxy phosphonic acid (26) 
 
3-Cyanobenzyl-α-hydroxy-diethyl phosphonate (0.4g, 1.5mmol), 6 M hydrochloric acid. 
Product; colourless solid (0.3456g, 96.55%). Rf = 0.26; (butanol: H2O:Acetic acid; 4:1:0.5), 
mp 164-167 °C; νmax/cm-1 2963 (C-H), 1699 (C=O), 1246 (P=O); δH(500 MHz, MeOD) 3.62 
(1 H, d, J 280.0, CH-OH), 7.45 (1 H, t, J 10.0, ArH), 7.74 (1 H, d, J 10.0, ArH), 7.94 (1 H, d, 
J 5.0, ArH), 8.20 (1 H, s, ArH). δC(126 MHz, MeOD) 71.87 (1 C, d, J 163.8, CH-OH), 129.16 
(1 C, s, ArC), 129.85 (1 C, d, J 6.3, ArC), 129.98 (1 C, d, J 2.5, ArC), 131.79 (1 C, s, ArC), 
133.17 (1 C, d, J 5.0, ArC) 140.81 (1 C, s, ArC), 169.98 (1 C, s, ArCOOH). δP(202 MHz, 
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MeOD) 20.68 (1 P, s). m/z (TOF ES-): 232 ([M-], 100%), 464 ([2M]-, 212 ([M-H2O], 25), 81 
([PO3H], 8). 
5.7.2 2-Carboxyl benzyl-α- hydroxy phosphonic acid (27) 
 
1,2-Benzyl lactone-2- diethyl phosphonate (0.3g, 1.1 mmol), 6 M hydrochloric acid (100cm3) 
Product; colourless solid (0.037g, 14.35%). Rf  = 0.27; (butanol: H2O: Acetic acid; 4:1:0.5), 
mp 198-201 °C; νmax/cm-1 1701 (C=O), 1285 (P=O); δH(500 MHz, MeOD) 5.80 (1 H, d, J 10.0, 
CH-OH), 7.62 (1 H, t, J 7.5, ArH), 7.78-7.80 (2 H, m, 2 × ArH), 7.90 (1 H, d, J 5.0, ArH). 
δC(126 MHz, MeOD) 78.55 (1 C, d, J 158.8, CH-OH), 124.76 (1 C, s, ArC), 126.43 (1 C, s, 
ArC) 126.54 (1 C, d, J 5.0, ArC), 130.62 (1 C, s, ArC), 135.57 (1 C, s, ArC), 146.88 (1 C, d, 
J 3.8, ArC), 172.48 (1 C, s, ArCOOH). δP(202 MHz, MeOD) 12.86 (1 P, s). m/z (TOF ES-): 
232 ([M-H]-, 2%). 
5.7.3 4-Carboxylbenzyl-α-hydroxy phosphonic acid (28) 
 
4-Cyanobenzyl-α-hydroxyl-diethyl phosphonate (0.8g, 3.0 mmol), concentrated Acetic acid 
(100cm3). Product; yellow solid (0.5879g, 85%); Rf = 0.17; (butanol: H2O: Acetic acid; 
4:1:0.5), mp 184-186 °C; νmax/cm-1 3460 (O-H), 1647 (C=O), 1261 (P=O); δH(500 MHz, D2O 
SUPPRESSED), 4.77 (1 H, d, J 15.0, CH-OH), 7.51 (2 H, d, J 10.0, 2 × ArH), 7.82 (2 H, d, J 
10.0, 2 × ArH). δC(126 MHz, D2O) 76.70 (1 C, d, J 139.86, CH-OH), 129.56 (1 C, s, ArC), 
129.60 (1 C, s, ArC), 131.22 (1 C, s, ArC), 137.31 (1 C, s, ArC), 147.71 (1 C, s, ArC), 163.70 
(1 C, s, ArC), 178.70 (1 C, s, ArCOOH). δP(202 MHz, D2O) 15.11 (1 P, s). m/z (TOF ES-): 
231 ([M-], 100%), 463 ([2M-], 1), 253 ([M+Na+]-, 1), 213 ([M-H2O]-, 1), 81 ([PO3H]+, 3). 
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5.8 Synthesis of substituted benzyl–α-hydroxy phosphonic acids by 
dealkylation of the substituted benzyl–α-hydroxy diethyl 
phosphonate precursors with bromotrimethylsilane 
 
Figure 5.8.1: Reaction scheme for the dealkylation of the substituted benzyl-α-hydroxy diethyl 
phosphonates by TMSiBr 
Substituted benzyl-α-hydroxy diethyl phosphonate and 2 molar equivalents of sodium iodide 
(NaI) were dissolved in dry acetonitrile (20 cm3) in a round bottomed flask. 
Chlorotrimethylsilane (TMSiCl)/bromotrimethylsilane (TMSiBr) 1.5 molar equivalent was 
added and the resultant mixture was left to stir for 48 hours at 50 °C. After which, the filtrate 
was concentrated under reduced pressure at 40 °C to give an oily residue. 1 M sodium 
hydroxide (1.0 cm3) was dissolved in methanol (5 cm3) and added to the oily residue and the 
resultant mixture was stirred for 24 hours at room temperature. After which, the resultant 
product was filtered under reduced pressure, washed three times with diethyl ether (20 cm3) 
and dried under reduced pressure overnight.  
5.8.1 2-Fluorobenzyl–α-hydroxy phosphonic acid (29). 
 
2-Fluorobenzyl-α-hydroxyl diethyl phosphonate (0.5 g, 1.9 mmol), sodium iodide (NaI) (0.58 
g, 3.8 mmol), chlorotrimethylsilane (TMSiCl) (0.4 cm3, 2.9 mmol) 1 M sodium hydroxide (1.0 
cm3). Product colourless solid (0.083 g, 19.80%). (data for this compound agreed with Murai. 
K, et al 2016). Rf  = 0.27; (butanol: H2O: Acetic acid; 4:1:0.5), mp >300 °C; νmax/cm-1 3238 
(O-H), 1228 (P=O); δH(500 MHz, MeOD) 5.13 (1 H, d, J 10, CH-OH), 6.98 (1 H, t, J 5.0, 
ArH), 7.12 (1 H, t, J 7.5, ArH), 7.14-7.23 (1 H, m, ArH), 7.74 (1 H, tt, J, 10.0, 5.0, ArH). 
δC(126 MHz, MeOD) 66.52 (1 C, d, J 152.5, CH-OH), 115.48 (1 C, s, ArC), 115.66 (1 C, s, 
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ArC), 124.79 (1 C, m, ArC), 129.36 (1 C, dd, J 10.80, 2.5, ArC), 129.86 (1 C, d, J 12.6, ArC), 
130.75 (1 C, t, J 3.8, ArC). δH(202 MHz, MeOD) 16.55 (1 P, d, J 6.06). m/z (TOF ES+): 413 
([2M+], 84%), 191 ([M-OH]+, 3), 229 ([M+Na+]+, 14), 127 ([FC6H4CH(OH)]+, 4), 85 ([-
PO(OH)2]+, 5). 
5.8.2 2-Nitrobenzyl–α-hydroxy phosphonic acid (30). 
 
2-Nitrobenzyl-α-hydroxyl diethyl phosphonate (0.4 g, 1.3 mmol), sodium iodide (NaI) (0.58 
g, 3.5 mmol), chlorotrimethylsilane (TMSiCl) (0.5 cm3, 3.5 mmol). Product; yellow solid 
(0.2208 g, 68.35%). (data for this compound agreed with Uhlmann. E, et al 2000). Rf = 0.18; 
(butanol:H2O:Acetic acid; 4:1:0.5), mp 155-158 °C; νmax/cm-1 3238 (O-H), 2842 (P-OH), 1513 
(NO2), 1347 (NO2), 1174 (P=O); δH(500 MHz, MeOD) 5.76 (1 H, d, J 15, CH-OH), 7.34 (1 
H, t, J  10.0, ArH), 7.57 (1 H, t, J  10, ArH), 7.83 (1 H, d, J 10.0, ArH), 8.03 (1 H, d, J 10, 
ArH). δC(126 MHz, MeOD) 69.05 (1 C, d, J 142.38, CH-OH), 125.00 (1 C, s, ArC), 127.82 (1 
C, s, ArC), 130.48 (1 C, d, J 3.8, ArC),  133.39 (1 C, s, ArC), 139.14 (1 C, s, ArC), 150.06 (1 




5.9 Synthesis of substituted benzyl-α-amino phosphonic acids  
 
Figure 5.9.1: Synthesis of substituted benzyl-α-amino phosphonic acid reaction scheme 
Equimolar amounts of triphenylphosphite, substituted benzylaldehyde and benzyl carbamate 
were dissolved in glacial acetic acid (80 cm3) in a round bottomed flask at room temperature. 
Boron trifluoride in diethyl ether (BF3.OET2) (2.5%v/v) in toluene (50 cm3) was added to the 
reaction mixture and the resultant mixture was left to stir for 30 minutes at room temperature 
and then heated under reflux for 4 hours. The resultant solution was concentrated under 
reduced pressure and then refluxed for a further 4 hours in concentrated hydrochloric acid 
(HCl) (100 cm3). The aqueous layer was extracted and washed with toluene (50 cm3). The 
resultant mixture was concentrated under reduced pressure and triturated 3 times with diethyl 
ether (30 cm3). The resultant reaction mixture was dissolved in methanol (4 cm3) and added to 
a round bottomed flask containing chloroform (400 cm3) dropwise, stirred and left to settle 
overnight.  The solid product was filtered out under reduced pressure, washed three times with 
dichloromethane (20 cm3) and dried under reduced pressure for 24 hours. 
5.9.1 2-Fluorobenzyl-α- amino phosphonic acids (34)  
 
Triphenylphosphite (2.6 cm3; 10mmols), 2-fluorobenzylaldehyde (1.2 cm3; 10 mmols) and 
benzyl carbamate (1.52 g; 10 mmols). Product; colourless solid (0.73 g 35.60%,). Rf = 0.5; 
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(EtOAc: methanol; 6:4), mp 232-235 °C; νmax/cm-1 3126 (OH), 2828 (NH2), 2616 (P-OH), 
1235 (P=O); δH(500 MHz, NaOD, D2O) 4.13 (1 H, d, J 20.0, CH-NH2), 7.12-7.14 (1 H, m, 
ArH), 7.22-7.24 (1 H, m, ArH), 7.30-7.31 (1 H, m, ArH), 7.46 (1 H, tt, J 10.0, 5.0, ArH). 
δC(126 MHz, D2O, NaOD) 51.00 (1 C, d, J 132.30, CH-NH2), 117.60 (1 C, d, J 22.68, ArC), 
126.67 (1 C, s, ArC), 130.39 (1 C, dd, J 6.30, 1.30, ArC), 131.55 (1 C, s, ArC), 132.36 (1C, s, 
ArC), 162.54 (1 C, d, J 243.18, ArC). δP(202 MHz, D2O, NaOD) 18.20 (1 P, s). m/z (EI+): 109 
([FC6H4CH]+, 56%), 83 ([PO3H3]+, 11).  
5.10 Protocols and procedures for the antimalarial evaluations 
5.10.1 P. falciparum drug assay method 
Parasites (Pf 3D7 and Pf Dd2 strains) were propagated as previously described (Trager W, 
Jensen JB, Science 1976, PMID: 781840) in RPMI-1640 that was supplemented with 50 mg/l 
hypoxanthine, 0.25 % sodium bicarbonate, 0.5 % Albumax II, 25 mM HEPES and GlutaMAX 
at 1x concentration. To assay their antimalarial activity, a two-fold serial dilution of 
compounds was performed in duplicate, in 96-well flat bottom plates. Parasites at 
predominantly ring-stage were added at 1% parasitemia, with a final haematocrit of 1% red 
blood cells (RBCs). No-drug wells (i.e. maximum growth) and RBC only wells were also 
included. Plates were incubated at 37 °C for 72 hours before measurement of parasite growth 
using SYBR green stain. Cells were re-suspended in SYBR lysis buffer (final concentration 
1xSYBR green stain in 5 mM Tris-HCl, 1.5 mM EDTA, 0.05% w/v saponin, 0.5% v/v Triton 
X-100), incubated at 37 °C for 30 minutes, and fluorescence signal measured on a FLUOstar 
Omega (BMG Biotech, ex. 485 nm, em. 535 nm). 
5.11 Protocols and procedures for the testing against other parasites, 
(T. brucei, T. cruzi, L. major and HeLa). 
5.11.1 Cell lines and cell culture  
Bloodstream form (BSF) Trypanosoma. brucei strain 427, hereafter referred to as ‘wild-type’.  
BSF T. brucei were grown in either HMI-11 media supplemented with 10% foetal bovine 
serum (Gibco) and 2.5 μg/mL G418 (Calbiochem) at 37°C with 5% v/v CO2 as described 
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elsewhere (Hirumi et al, 1989). Cells were routinely grown in 10 mL media in 75 cm2 vented 
flasks and passaged three times per week to maintain cells in mid-log phase (i.e. below 2 
x106/mL).   
Epimastigote Trypanosoma cruzi CL Brener strain expressing pLEW13, hereafter referred to 
as ‘wild-type’ were grown at 28°C in RTH media (RPMI 1640 medium (Sigma) supplemented 
with 20 mM HEPES pH 7.2 (Sigma), 4.9 mg/mL tryptone (Sigma), PGAB (2 mM sodium 
glutamate, 2 mM sodium pyruvate, 100 μg/mL streptomycin and 100 U/mL penicillin, all 
Sigma), 20 μg/mL haemin and 10% HI-FBS).  Cells were routinely grown in 10 mL media in 
75 cm2 flasks and passaged three times per week by splitting cultures 1 in 10 to maintain 
cultures in log phase between 1 x106/mL and 1 x107/mL.   
Promastigote L. major MHOM/IL/80/Friedlin were grown at 28°C in M199 media (Sigma) 
pH 7.4, supplemented with 40 mM HEPES pH 7.4, 100 μM adenosine, 5 μg/mL haemin and 
10% HI-FBS. Cells were routinely grown in 10 mL media in 75 cm2 non-vented flasks 
(MANU) and passaged three times per week to maintain cells in mid-log phase, below 1 
x107/mL.   
HeLa cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma) 
supplemented with 10% HI-FBS and grown at 37°C in 5% CO2 atmosphere.  Cells were grown 
in 75 cm2 vented flasks and passaged twice per week by trypsinization when monolayers 
reached ~90% confluency.  All media was removed, the monolayer washed in PBS, and 
trypsinized with 2 mL Trypsin-EDTA, incubated at 37°C until the monolayer detached, 
following which 8 mL fresh media was added to neutralize the trypsin.  Cell culture was then 
split at a 1 in 5 ratio in fresh media.  
5.11.2 Cytotoxicity EC50 assay 
The EC50 of the compounds (in DMSO) was determined using two-fold serial dilutions of 
compound in media, these were carried out in a 96-well plate in quadruplicate.  Cells were 
counted using CASY TT Cell Counter and seeded as specified below.  For Alamar Blue assays, 
cell viability was quantified using an FLx 800 plate reader (BioTek) with excitation 
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wavelength 540/35nm and emission wavelength at 590/10nm using Gen5 Reader Control 2.0 
Software (BioTek).  EC50 values were determined using a 4-parameter logistic regression 
equation using GraFit 5.0 (Erithacus Software).   
Bloodstream form T. brucei were seeded in 96-well plates at 1 x103 cells/well in HMI-11 with 
serial dilutions of test compound and incubated at 37 °C 5% CO2 for 72 hours, after which 20 
μL Alamar Blue (0.125 mg/mL resazurin salt in PBS) was added to all wells and incubated for 
a further 6 hours.   
For HeLa cell assays, monolayer cells were detached, diluted in DMEM with 10% HI-FBS 
and seeded at 4 x103 cells per well.  Plates were incubated at 37°C with 5% CO2 for 24 hours 
to allow attachment, after which media was removed and replaced with fresh media containing 
serial dilutions of the compound. Drug diluted in media was added and plates were incubated 
for 72 hours, after which 10 μL Alamar Blue was added to all wells and incubated for a further 
2 hours.   
Mid-log L. major promastigotes were diluted in media and seeded at 2 x105 per well.  Negative 
controls of DMSO and positive controls of pentamidine were included.  Plates were incubated 
at 28 °C for 72 hours, after which 20 μL Alamar Blue was added to all wells and incubated for 
a further 6 hours. After 72 hours’ incubation at 37°C with 5% CO2 cell viability was 
determined using 20 μL Alamar Blue for 6 hours. 
Mid-log T. cruzi epimastigotes were diluted in RTH media and seeded at 5 x105 per well.  
Negative controls of DMSO only and positive control of nifurtimox were included.  Plates 
were incubated at 28 °C for 72 hours, after which 10 μL Alamar Blue was added to all wells 
and incubated for a further 6 hours. 
All plates were read at 570 nm and EC50 values were determined using a 4-parameter logistic 
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